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ABBREVIATIONS 
Ab antibody 
AFM atomic force microscope 
APC antigen-presenting cell 
APN  aminopeptidase N 
BMDC bone marrow-derived dendritic cells 
BSA bovine serum albumin 
CARD caspase recruit domain 
CCP complement control protein 
CD cluster of differentiation 
cDNA complementary deoxyribonucleic acid 
CLR C-type lectin receptor 
Cq quantification cycle 
CR3 complement receptor 3 
CRD carbohydrate recognition domain 
CSR class-switch recombination 
CT  cholera toxin 
CTL cytotoxic T lymphocyte 
DC dendritic cell 
dmLT double mutant heat-labile enterotoxin 
DMP dimethyl pimelimidate  
DMSO dimethylsulfoxide  
DP  degree of polymerisation 
ECL enhanced chemiluminescence 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EGF epidermal growth factor  
ERK extracellular signal regulated kinase 
ETEC enterotoxigenic Escherichia coli  
FAE follicle-associated epithelium 
FAK focal adhesion kinase  
FCS fetal calf serum 
FDC follicular dendritic cell 
GALT gut-associated lymphoid tissue 
GC germinal center 
GIT gastrointestinal tract 
GM-CSF granulocyte macrophage colony-stimulating factor 
GP β-glucan microparticle 
HBSS Hanks' balanced salt solution 
ICAM intercellular adhesion molecule-1 
IFN interferon 
Ig immunoglobulin 
IKK inhibitor of κB kinase 
IL interleukin 
IPEC intestinal porcine epithelial cells 
ISCOM immune stimulating complex 
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PEI polyethylenimine 
PI propidium iodide 
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PWD post-weaning diarrhoea 
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SCFA short-chain fatty acids 
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siRNA small interfering RNA 
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SSC side scatter 
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Tm melting temperature  
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PREFACE 
Enterotoxigenic Escherichia coli (ETEC) infections are a major cause of morbidity and mortality among 
both humans and pigs. Human ETEC strains affect mainly children and are also a source of traveler’s 
diarrhoea in regions where ETEC is endemic. Porcine ETEC cause diarrhoea in neonatal and newly 
weaned piglets.1-3 Pathogenicity of these bacteria is associated with fimbrial adhesins that mediate 
their colonisation to the microvilli of the intestinal epithelial cells in the small intestine. Porcine ETEC 
strains express five different fimbriae, namely the F4, F5, F6, F18 and F41 fimbriae, of which F18 and 
F4 fimbriae are most frequently associated with post-weaning disease in pigs.4 Once colonised, ETEC 
strains will secrete heat-labile enterotoxins (LT) or heat-stable enterotoxins (STa or STb). These 
enterotoxins will disrupt the water and electrolyte balance in the intestine which will cause severe 
watery diarrhoea.5 
In neonatal and recently weaned piglets, ETEC infections results in severe economic losses due to 
growth retardation, increased drug use and elevated mortality.6 Most neonatal infections can be 
prevented by a passive lactogenic immunity obtained by vaccination of the sow. These maternal 
vaccines are mainly applied parenterally in the pregnant sow and contain inactivated ETEC bacteria 
with fimbriae or purified fimbriae with or without LT.7 However, this passive protection disappears at 
the moment of weaning.8 For the control of post-weaning diarrhoea (PWD), antibiotics are 
commonly used.9, 10 Besides their prophylactic usage, antibiotics were also applied for improving 
growth and production. The long term and extensive use of antibiotics has resulted in the 
development of antibiotic resistance. Therefore, since 1 January 2006 all commonly-used 
antimicrobial growth promoters have been banned in the EU member states. However, this caused a 
reduced performance and increased morbidity in post-weaning pigs and consequently, the 
development of alternative strategies is required.11 
A wide variety of immunomodulating substances used as in-feed additives have been proposed to 
help post-weaning piglets to cope with feed transition and stress during this period.12, 13 The aim of 
these dietary substances is to help piglets develop an ‘appropriate’ innate and acquired immunity at 
the intestinal mucosal surface to support a microenvironment for protection against enteric 
infections, including ETEC.11 Among these substances, a variety of non-digestible carbohydrates are 
extensively studied, such as β-glucans.14 The beneficial effects of dietary β-glucans have already been 
demonstrated. Indeed, these polysaccharides display immunomodulatory effects upon oral 
administration and are also known to improve growth and general performance of the individual.15-20 
Although numerous articles have tried to unravel these immunostimulatory effects, there is no 
consensus about their mechanism of action. Understanding β-glucan-mediated effects by elucidating 
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the main β-glucan receptor and its signalling pathway in immune cells is important to use these 
powerful modulating properties in the protection of newly-weaned piglets against enteropathogens.  
Another strategy to prevent ETEC infections in post-weaning piglets consist of inducing an active 
mucosal immune response by oral vaccination of piglets. Thereby, it would be interesting to use the 
immunostimulatory potential of β-glucans. Interestingly, β-glucan microparticles (GPs) were recently 
described as promising antigen vehicle systems with inherent adjuvant capacity owing to their β-
glucans. Moreover, these particles are known for their high antigen encapsulation, efficiency and 
safety.21-32 Unfortunately, developing oral subunit vaccines has been challenging due to numerous 
potential obstacles, such as the hostile environment of the gastro-intestinal tract, oral tolerance and 
the epithelial barrier.33-37 Many approaches have been described to overcome these limitations, 
including enteric coating, encapsulation in immune-stimulating antigen delivery systems and 
targeting to endocytotic receptors, located at the apical surface of intestinal epithelial cells.38 
Chapter one will provide background information about β-glucans, their receptor usage and 
signalling, while the second chapter is focused on oral vaccination strategies and the potential role of 
β-glucans as both mucosal adjuvants and antigen vehicle system. Different methods for targeting 
particles to endocytotic receptors are discussed in the second chapter as well. 
   
  PART 
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1 CHAPTER 1: β-glucans 
1.1 Molecular structure of β-glucans 
β-glucans are carbohydrate polymers consisting of long linear chains of glucose and are classified by 
their intrachain linkages (α- or β-linked),39 their stereoisomer of glucose (D- or L-glucose), different 
types of glycosidic bonds (β-1,3/1,4- or -1,6-glucans) and their constitution (homoglucans or 
heteroglucans).40  
These glucose polymers can be derived from several sources, such as fungi, yeast, some bacteria, 
seaweeds, algae and cereals (Table 1).41 In seaweeds and algae, β-glucans serve as storage 
carbohydrates, while in bacteria, fungi, yeast and cereals, they play a role as structural frame and 
define cellular shape and rigidity.42 The molecular structure of β-glucans, such as linkages, 
ramification and molecular weights, depends not only on the cited source, but also on the isolation 
and purification procedure. β-glucans purified from yeast, fungi, seaweed and some algae consist of 
a β-1,3-linked glucose backbone with small numbers of β-1,6-linked branches, while β-glucans from 
bacterial origin and some algae are unbranched β-1,3-linked glucose residues (Figure 1A).43, 44 In 
contrast, β-glucans derived from cereals contain single β-1,3-linkages of cellotriosyl and 
cellotetraosyl units together with regions that have a more cellulose-like structure, with two to four 
consecutive β-1,4-linked glucose residues (Figure 1B).45  
 
A         B 
 
 
 
 
 
 
 
 
 
Figure 1. Basic structure of β-1,3/1,6-glucans and β-1,3/1,4-glucans.  
(A) The main chain consists of 1,3-linked β-D-glucose units along with 1,6-linked β-D-glucose side chains. (B) β-
glucans with semi-random alternating β-1,3- and β-1,4-linkages. 
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Table 1. Overview of the origin, solubility, structure and molecular weight (MW) of β-glucans derived from 
different sources. 
Origin β-glucan name Solubility Structure MW References 
SEAWEED 
  
β-1,3 with some β-1,6-branching (30:1).  
The β-1,6 side chains are composed of 2 
glucose units 
 
46-48 Laminaria 
digitata 
Laminarin Soluble 7.7 
YEAST      
Saccharomyces 
cerevisiae  
Macrogard® Particulate β-1,3/1,6-branched (10:1 or 20:1). The 
β-1,6 side chains are composed of 2 or 3 
glucose-units 
unknown 20, 49 
 Zymosan Particulate Crude extract with β-glucans, mannan 
and proteins; non-uniform branches 
and backbone units. β-1,3/1,6-
branched 
<200 50-52 
 Glucans from 
Saccharomyces 
cerevisiae 
Particulate β-1,3/1,6-branched (30:1) 200 53 
ALGAE      
Euglena 
gracilis 
Glucans from 
Euglena gracilis 
Particulate β-1,3-unbranched 500 53, 54 
FUNGI   β-1,3/1,6-branched (6:1). The β-1,6 side 
chains are composed of 2 glucose units 
  
Sclerotium 
rolfsii 
Scleroglucan Soluble 1020 53, 54 
CEREALS      
Avena sativa Glucans from oat Soluble β-1,3-branched, mixed with two to four 
β-1,4-glucose units 
50-
3000 
45 
BACTERIA      
Alcaligenes 
faecalis 
Curdlan Particulate β-1,3-unbranched 100 55, 56 
 
Most of the β-1,3-linked-glucans exist in a stiff, triple stranded helical structure, where hydrogen 
bonds hold the individual polymer chains together.57 When the strength of these bonds decreases 
below a critical limit, insoluble polysaccharides can be denatured into single helixes or random coil 
structures.58-63 Denaturation of β-1,3-D-glucan triplexes occurs by increasing the temperature above 
the triple-helix melting temperature (Tm = 135°C), by dissolving the molecules in strongly alkaline 
solutions (1 M NaOH) or in dimethylsulfoxide (DMSO; water weight fraction WH < 0.13).
57 When 
exposed to high temperatures, the thermal energy of the β-glucan strands leads to helix 
destabilisation. Molecular separation by alkaline solutions occurs by repulsion between the ionised 
groups, and leads to disruption of the ordered structure and causes dissolution, while dissolving β-
glucans in DMSO destabilises the polysaccharide hydroxyl groups by the formation of hydrogen 
bonds. Interestingly, β-1,3-glucans with a high degree of polymerisation are insoluble in water, as 
their conformation allows stronger cooperative interactions and associations between chains than 
between the chains and water molecules.64 However, the degree of branching influences the 
solubility as well;65 many β-1,6-glucans side chains render the glucans more soluble.66 Thus, the 
physical organisation and structure influences the solubility of β-glucans. Moreover, these factors 
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contribute to the biological activity of β-glucans as well. Indeed, studies revealed that primary 
structure, solubility, degree of branching (DB) and molecular weight (MW), as well as the charge of 
their polymers and structure in aqueous media, are important parameters in the biological activity of 
β-glucans.67 The relation between the β-glucan structure and acitivity is already extensively reviewed 
by Soltanian et al.68 The most active β-glucans are particulate with a triple helical configuration and 
consist of many branches, a large main chain and have a high molecular weight.64, 69 For example, 
scleroglucan has a linear triple helical arrangement and triggers cytokine secretion by monocytes, 
however, denaturation abolished this ability.58  
Although the structure and immune-modulating character of β-glucans are well known, how these 
polysaccharides exhibit their biological activity is largely unclear. Numerous discrepancies are found 
in the literature concerning the effect of β-glucans on innate and adaptive immunity, since different 
β-glucan preparations were used during studies, and this is often inappropriately extrapolated to all 
β-glucans. These inconsistencies stems from the use of β-glucans which vary in origin, purity and 
molecular structure (particulated vs soluble) as well as the use of different cell types and model 
systems to study these β-glucans.   
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1.2 β-glucan receptors and signalling 
As β-glucans are not found in animals, they are considered to be classic microbe-associated 
molecular patterns (MAMPs).70 These polysaccharides are recognised as MAMPs by immune cells via 
several pattern recognition receptors (PRRs), including dectin-1,71 complement receptor 3 (CR3),72 
scavenger receptors73 and lactosylceramide.74 As cells can express several β-glucan receptors and 
engagement of these receptors results in different biological outcomes, it is interesting to know 
which intracellular pathways are activated upon engagement of the different β-glucan receptors. 
 
1.2.1 Dectin-1 
Dectin-1 has been recognised as the most important receptor for β-glucans in mice and consequently 
most studies have focused on the function of dectin-1 in the immunomodulating effect of β-
glucans.71, 75 Dectin-1 is highly specific for β-glucans with a pure β-1,3-linked backbone structure with 
β-1,6-branches.76 This receptor was originally thought to be a dendritic cell (DC)-specific receptor, 
hence its name ‘dendritic-cell-associated C-type lectin-1’.77 However, dectin-1 is also expressed by 
neutrophils, monocytes, macrophages and human intestinal and pulmonary epithelial cells.78-85 
Dectin-1 consists of an extracellular, transmembrane and cytoplasmic domain. The extracellular 
domain contains a stalk regions and one c-type lectin domain (carbohydrate binding domain). The 
cytoplasmic region contains an immunoreceptor tyrosine-based activation motif (ITAM)-like 
signalling motif.86 The full-length dectin-1 is encoded by the C-type lectin domain family 7 member A 
(CLEC7A) gene,87 which contains of six exons (Figure 2). Exon 1 encodes the N-terminal cytoplasmic 
tail (Cyto). This tail varies in length and commonly contains internalisation motifs or binding sites for 
cytosolic proteins. The transmembrane region (TM) is encoded by exon 2. The extracellular variable 
length-neck (stalk) region and C-terminal carbohydrate recognition domain (CRD) are encoded by 
exon 3 and exons 4-6, respectively.77, 81 
Interestingly, alternative splicing of dectin-1 generates species-specific transcripts. In mice, at least 
two major isoforms exist. The first isoform is the full-length dectin-1A, containing all six exons, while 
the second dectin-1B isoform lacks the stalk region between the CRD and transmembrane region.88 
Human dectin-1 is alternatively spliced into two major (A-B) and six minor isoforms (C-H), however, 
only the two major isoforms are able to bind β-glucans.81, 82, 89 The minor isoforms consist of 
variations of the major isoforms, some with deletions in the CRD-encoding (isoform C and D) or the 
transmembrane and stalk region (isoform E and F), while two isoforms (G and H) possess small 
insertions.81 In pigs, two major isoforms, which differ by the presence of the stalk region, and one 
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minor isoform were identified. The minor isoform is a variation of the major isoform with a deletion 
in the transmembrane and stalk region (Figure 2).83 
 
 
 
 
 
 
 
 
Figure 2. Schematic illustration of the dectin-1 gene, splice variants and structure of dectin-1. 
The N-terminal cytoplasmic tail (Cyto) is encoded by exon 1, the transmembrane region (TM; exon 2), stalk 
region (exon 3), and the carbohydrate recognition domain (CRD; exon 4–6) are illustrated. In pigs, dectin-1 is 
alternatively spliced in two major isoforms, with (blue) or without (purple) the stalk region, and one minor 
isoform (red) with a deletion in the TM and stalk region. 
Activation of dectin-1 results in numerous cellular responses including phagocytosis, autophagy, 
respiratory burst and the production of inflammatory lipids, cytokines and chemokines.90 Different 
signalling pathways triggered by dectin-1, which result in these cellular responses, will be outlined 
below. 
After ligand engagement, the intracellular hemi-ITAM domain of dectin-1 is phosphorylated (P) by 
sarcoma (Src) family kinases on its tyrosine (Y) residue, which serves as docking site for spleen 
tyrosine kinase (Syk).91 Tyrosine phosphatase containing Src homology 2 domain (SHP2) is required to 
facilitate the recruitment of Syk to dectin-1.92 The immunoreceptor tyrosine-based activation motif 
(ITAM) consists of two tyrosine (YxxL/I) motifs (Y =tyrosine, x = amino acid residues, L = leucine or I= 
isoleucine) separated by a defined interval of 6-8 amino acids.93-95 In contrast, the hemi-ITAMs have 
only a single tyrosine-based motif (YxxL), suggesting that activation of dectin-1 requires receptor 
clustering into a phagocytic synapse to properly activate its signalling molecule Syk. Indeed, Syk 
possess tandem SH2 (Src Homology 2) domains and each of these domains can bind to a 
phosphorylated tyrosine residue (YxxL) by bridging two dectin-1 molecules (Figure 3).96-100 
Recruitment of Syk further activates phospholipase-Cy2 (PLCy2), resulting in the engagement of the 
caspase recruit domain (CARD)-containing protein (CARD9), which together with Bcl10 and MALT1, 
signals for activation of NF-κβ (canonical pathway). NF-κβ is a master transcription factor, regulating 
the expression of many inflammatory genes. In mammals, the NF-κβ family is composed of five 
related transcription factors: p50, p52, RelA (p65), c-Rel and RelB.101 The canonical pathway activates 
NF-κβ dimers comprising RelA, c-Rel, RelB and p50. The non-canonical pathway however activates 
p52/RelB complexes.101, 102 Dectin-1 is the first PRR for which activation of NF-κβ via the non-
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canonical pathway utilising NF-κβ-inducing kinase (NIK) through Syk activation has been described 
(Figure 3).103 There is also evidence of another Syk-dependent, CARD9-independent signalling 
pathway. Ligation of dectin-1 can activate the transcription factor nuclear factor of activated T cells 
(NFAT) through Syk activation of PLCγ2 (Figure 3).103 The functions of NFAT in myeloid cells include 
modulation of cytokine production, survival, induction of cell fusion and differentiation into 
osteoclasts.104 
Besides these Syk-dependent pathways, dectin-1 ligation triggers a Syk-independent pathway as well 
(Figure 3). Indeed, dectin-1 ligation also activates the serine-threonine kinase Raf-1, which promotes 
the activation of canonical NF-κβ.90, 97 This dectin-1/Raf-1 pathway activated by β-glucans also 
triggers trained innate immunity by epigenetic reprogramming of monocytes.90, 105 Thus, dectin-1 
activates two independent signalling pathways, one through Syk and one through Raf-1, to trigger 
immunity.106 Which signalling pathway is activated by dectin-1 depends on the cell type, state of 
activation and encountered ligand.106 
 
Figure 3. Schematic illustration of dectin-1 
signalling. 
Yeast cells can bind dectin-1 into a phagocytic 
synapse, which results in the phosphorylation of 
hemi-ITAMs by Src kinases. Syk is recruited to 
these phosphorylated ITAMs, facilitated by SHP2, 
resulting in the activation of PLCy2, which in turn 
will activate the CBM complex (CARD9, Bcl10 and 
MALT1). This complex then activates canonical 
NF-κβ. Dectin-1 can also activate NFAT and non-
canonical NF-κβ in a Syk-dependent, CARD-9-
independent manner. Dectin-1 ligation triggers a 
Syk-independent pathway by activation of Raf-1, 
which results in the activation of canonical NF-κβ. 
Figure adapted from Marakalala et al. (2011).
91
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1.2.2 Complement receptor 3 
Complement receptor 3 (CR3, CD11b/CD18, otM/32, Mac-l, Mol) is typically known as a mediator of 
leukocyte adhesion to activated endothelium and as the phagocytic receptor for iC3b opsonised 
particles.107, 108 However, CR3 has also been reported to recognise β-glucans.72, 109-112 β-glucan 
recognition by CR3 can induce anti-tumor effects by priming the complement receptor 3 to clear 
iC3b-opsonised tumor cells.113-118 
Since complement function is associated with immunity, CR3 is highly expressed on leukocytes. 
Complement receptor 3 belongs to the β2-integrin family, consisting of an α-chain (CD11b) 
noncovalently associated with the β-chain (CD18).119 The CD11b subunit has a unique structure 
consisting of two distinct domains: the I- or A-domain is an essential binding site for a diverse array 
of ligands, such as ICAM-1 and iC3b,119, 120 and the spatially separated carbohydrate-binding domain, 
located C-terminal to the I-domain. This lectin domain binds with highest affinity to β-1,3-glucans 
with β-1,6-linked branches.72, 110, 119, 121-123 
In pigs, complement receptor 3 is expressed on immune cells as well, including granulocytes and 
peripheral blood mononuclear cells. The α subunit (CD11b) of CR3 is not yet identified, but two 
candidate molecules, namely CD11R1 and CD11R3, have been described. Both CD11R1 and CD11R3 
dimerise with the β-chain CD18, but their role in complement or β-glucan recognition is still unclear. 
CD11R1 and CD11R3 differ in their expression pattern and molecular weight. CD11R1 is present on 
approximately 50% of all porcine neutrophils, whereas CD11R3 is expressed on all neutrophils and 
monocytes. Although the expression pattern of CD11R3 correlates with human CD11b, CD11R3 is not 
recognised by human CD11b monoclonal antibodies (mAbs). In contrast, human CD11b mAbs cross-
react with CD11R1, which has the same molecular weight as its human counterpart.124  
In the absence of exposure to inflammatory stimuli, such as chemokines and cytokines, CR3 binds 
poorly to ligands. Exposure to these stimuli increases the avidity of CR3 through inside-out signalling 
(Figure 4A).122 This tight regulation serves to avoid systemic inflammation. Indeed, only after binding 
of specific cytokine or chemokine receptors, CR3 undergoes a conformational change from a non-
adhesive to an adhesive state, which recognises CR3 ligands (such as iC3b and the components of the 
extracellular matrix) (Figure 4B).122 Intriguingly, binding of β-glucans to the lectin domain directly 
induces conformational changes of the A-domain and activates CD11b, without the need for inside-
out signalling.118, 122 
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A       C 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic illustration of inside-out signalling and outside-in signalling of CR3 and integrin signalling. 
(A) Inside-out signalling: inflammatory stimuli can occupy specific cytokine/chemokine receptors on immune 
cells, which results in the conformational changes of the A-domain of CD11b. (B) Outside-in signalling: CR3, in 
its active state, can bind specific integrin ligands such as iC3b. This leads to an intracellular signalling pathway 
(Figure adapted from Li et al. (2011)
125
). (C) Clustering of integrins activates focal adhesion kinase (FAK), which 
will autophosphorylate its Y397 residue. This leads to the FAK-Src kinase complex, which further 
phosphorylates FAK at additional sites (Y576, Y577). Interaction of Paxillin and Talin with FAK results in actin 
polymerisation and cytoskeleton rearrangements. Furthermore, the mutually activated FAK/Src complex 
triggers several signalling pathways (e.g. ERK and PI3K/Akt) that result in cell survival, proliferation and 
migration. Ligation of β2-integrins can also induce phosphorylation of ITAM-containing adaptor molecules, such 
as DAP12 and FcRγ, by Src kinases. This results in docking sites for Syk kinases, which will activate FAK as well. 
Figure adapted from Bolos et al. (2010) and Pentassuglia et al. (2013).
126, 127
 
The signalling pathways of complement receptor 3 have not yet been fully identified, only the 
involvement of the Src kinases Hck, Fgr and Lyn have been reported to be essential for CD11b/CD18-
mediated cellular responses, such as the production of reactive oxygen species (ROS).122, 128 On the 
contrary, much more is known about the signalling pathway triggered by β2-integrins (Figure 4C).  
Two nonreceptor intracellular tyrosine kinases are associated with integrin activation, namely focal 
adhesion kinase (FAK) and sarcoma kinase (Src). FAK associates to the cytoplasmic tail of the integrin 
and autophosphorylates its tyrosine residue at position 397 (Y397).126 This phosphorylated tyrosine 
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provides a docking site for the SH2 domains of Src family kinases, which leads to the creation of a 
transient FAK-Src kinase signalling complex. This complex further phosphorylates FAK on additional 
sites (resulting in further increased activity of FAK), which amplifies the recruitment and activation of 
multiple downstream signalling proteins, including Paxillin, Talin, PI3K and ERK, that eventually leads 
to different cellular responses (cell survival, proliferation and migration) (Figure 4C).126, 129 
Interestingly, β2-integrins can associate with adaptor proteins, such as DAP12 or FcRy, in order to 
initiate its signalling pathway. Typically, DAP12 and FcRγ are coupled to immunoreceptors through 
charged amino acid interactions within the transmembrane region of each protein. Although 
integrins lack such charged residues in their transmembrane segment, after integrin ligation the 
ITAM-bearing adaptor molecules DAP12 and FcRγ become phosphorylated by Src family kinases. This 
creates docking sites for Syk,130-132 which also contributes to activation of FAK (Figure 4C).130 
 
1.2.3 Other putative β-glucan receptors 
1.2.3.1 Scavenger receptors 
Scavenger receptors (SR) have been reported as potential receptors for β-glucans.73 These receptors 
constitute a diverse family of pattern recognition receptors (PRRs) and have a range of cellular 
functions, being involved in the pathogenesis of chronic inflammatory conditions, such as 
atherosclerosis and Alzheimer’s disease, and in the host response to some bacterial pathogens.133, 134 
Scavenger receptors are integral membrane proteins consisting of at least eight different subclasses 
(Class A to Class H),135 which bind to a range of ligands, including modified lipoproteins, selected 
polyanionic molecules and a number of microbial structures.133, 136 Most scavenger receptors are 
expressed on myeloid and certain endothelial cells (Class E and F), although some scavenger 
receptors are also present on epithelial cells.133, 134  
Several studies have reported that these receptors are implicated in β-glucan recognition.73, 134, 137-139 
The basic β-(1,3)-glucan structure is probably recognised by these receptors, however, the affinity of 
these interactions can be influenced by the polymer charge (polyanionic) as well as other structural 
characteristics that remain undefined.137 Until today, only the scavenger receptors class A, B, C and F 
have been associated with β-glucan recognition (Figure 5). For example, the scavenger receptor 
collectin placenta 1 (CL-P1) (belonging to class A) is involved in nonopsonic zymosan uptake in human 
endothelial cells.135 Furthermore, it has been demonstrated that CD5, expressed on lymphocytes, is 
able to bind and aggregate several fungal species by recognition of β-glucans.139 In addition, two 
conserved members of the scavenger receptor family, SCARF1 and CD36, also recognise β-glucans 
and have an essential function in antifungal immunity and host defence against the pathogenic yeast 
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Candida neoformans.134 Although vertebrate β-glucan recognition mechanisms differ from those of 
invertebrates, a Drosophila melanogaster scavenger receptor (dSR-CI) has been shown to recognise 
these carbohydrates as well, indicating a functional conservation in the evolution of these 
receptors.140  
 
1.2.3.2 Lactosylceramide 
Lactosylceramide (LacCer, CDw17 or Galβ4Glcβ1Cer) is a neutral glycosphingolipid PRR found in the 
plasma membrane of many cells, including neutrophils, macrophages and lung epithelial cells. This 
receptor consists of a hydrophobic ceramide lipid and a hydrophilic sugar moiety (Figure 5).141-143 
Lactosylceramide has been shown to bind macromolecular β-1,3-glucans74 and this interaction has 
been reported to induce a number of cellular responses in vitro;144-146 such as evoking inflammatory 
cytokine responses in alveolar epithelial cells144, 145 and chemotactic activities for human lung 
neutrophils.146 
 
 
 
 
 
 
 
 
 
 
Figure 5. Overview of the other putative β-glucan cell surface receptors. 
The structural diversity of the different scavenger receptors classes and lactosylceramide (LacCer) are shown. 
Scavenger receptor class A have a collagen-like domain. Class B scavenger receptors, such as CD36 and CD5, 
have an extracellular loop structure. dSR-C1 has two complement control protein (CCP) domains at the 
extracellular N-terminus (yellow), followed by an extracellular domain of the meprin A5 antigen and receptor 
protein tyrosine phosphatase µ (MAM) family (black). SCARF1 contains multiple N-terminal extracellular 
epidermal growth factor (EGF)-like repeats (purple and blue), a transmembrane domain and a long cytoplasmic 
tail. Lactosylceramide is composed of lactose (hexagon), incorporated in a ceramide. Figure adapted from 
Wilkinson et al. (2012) and Pluddemann et al. (2007).
133, 147
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1.2.4 Contribution of dectin-1 and CR3 in β-glucan recognition and -signalling 
Since the discovery of dectin-1 as a β-glucan receptor in 2001,71 several studies in mice have 
established that this receptor is the most important β-glucan receptor on immune cells,75, 81, 125, 148, 149 
while the role of CR3 in the recognition of β-glucans became neglected. However, recent articles 
have convincingly demonstrated that CR3 is pivotal in β-glucan recognition and -signalling, although 
the contribution of this receptor seems to be cell type and species-dependent. 
Neutrophils are usually the first cells to arrive at infection sites early in antifungal immunity and are 
therefore interesting cell types to unravel the mechanism of β-glucan recognition and -signalling. In 
human neutrophils, it has been demonstrated that CR3 is the major receptor involved in the binding 
of zymosan and S. cerevisiae yeasts as well as the ROS production triggered by these stimuli, while 
dectin-1 was demonstrated to be dispensable for these responses.150 In addition, NET (neutrophil 
extracellular trap) release for the response towards Candida albicans is solely dependent on β-glucan 
recognition by complement receptor 3 in human neutrophils.151 NETosis is a process where 
neutrophils release chromatin fibrils (NETs) outside the cells to kill invading pathogens.152 During this 
process, neutrophils lose their viability by destruction of the intracellular and plasma membranes.151, 
152 
In contrast to human studies, dectin-1 seems to play a more important role in mice. The absence of 
dectin-1 resulted in loss of β-glucan (zymosan) recognition in murine neutrophils.148 Moreover, 
dectin-1 is important for the recruitment of neutrophils after intraperitoneal injection of zymosan in 
mice.153 Interestingly, it has been demonstrated in mice that the cooperation of dectin-1 and CR3 is 
necessary for neutrophil responses towards zymosan and β-glucans. This mechanism requires the 
inside-out activation of CR3 by dectin-1-mediated recognition of β-glucans. Indeed, engagement of 
dectin-1 by β-glucans leads to phosphorylation of its ITAMs by Src kinases and recruitment of Syk. 
This results in vav activation and Ca2+ release, which induce a conformational change of CR3, enabling 
CR3 to bind β-glucans. As such, complement receptor 3 contributes to the signalling pathways 
initiated by dectin-1, resulting in the activation of downstream targets including Pyk2, PAK and ERK 
(Figure 6).125 These results are however in contrast with previous observations,118, 154 where it was 
shown that CR3 did not need inside-out signalling for β-glucan recognition in neutrophils. A possible 
explanation for these discrepancies is the use of different species. Indeed, experiments were 
conducted with murine125 or human neutrophils,118, 154 indicating a species-dependent receptor usage 
for β-glucan recognition in neutrophils.  
Interestingly, in both human and mice, complement receptor 3 seems to play a major role in 
recognising β-glucans, however, only after opsonisation with complement. Indeed, Bose et al. (2013) 
demonstrated that antibodies blocking CD11b and CD18 significantly inhibited binding of soluble 
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serum-opsonised β-glucans to human neutrophils, establishing CR3 as the key receptor recognising 
soluble β-glucans through serum iC3b.155 In mice as well, a minor role was observed for dectin-1 in 
the response towards opsonised β-glucans rather than non-opsonised β-glucans.148, 153 
Figure 6. Species-dependent β-glucan receptor 
usage in neutrophils. 
In humans (red), particulate or soluble β-glucans 
bind CR3, which results in phosphorylation of the 
Src kinases Lyn, followed by ROS production, 
phagocytosis of β-glucans and/or NETosis. In mice 
(black), binding of β-glucans to dectin-1 stimulates 
CR3 to recognise β-glucans via vav-proteins 
(inside-out signalling). These steps result in CR3 
activation, which is now able to bind β-glucans. β-
glucan-bound CR3 will phosphorylate Pyk2, which 
results in the phagocytosis of β-glucans and the β-
glucan-mediated radical oxygen production. 
Serum-opsonised β-glucans will bind complement 
receptor 3 through iC3b. 
 
 
Many controversies are found in the literature about the contribution of dectin-1 and CR3 in β-glucan 
recognition and -signalling by monocytes/macrophages. Different studies indicate a structure-
dependent β-glucan recognition in murine and human monocytes. It has been demonstrated in 
human monocytes that the responses to soluble β-glucans requires CR3-mediated detection,155, 156 
while β-glucan particles require dectin-1-mediated recognition.156 Likewise, the results from the 
Marakalala’s and Goodridge’s studies suggest that productive intracellular signalling from dectin-1 
can only occur following recognition of large β-glucan complexes, which cluster the receptor in 
synapse-like structures, indicating that soluble β-glucans are unable to activate dectin-1.157, 158 
Furthermore, binding of particulate β-glucans to dectin-1 on monocytes/macrophages induces Syk-
dependent and -independent pathways (see above),75, 98, 105, 156, 159, 160 while binding of soluble β-
glucans to complement receptor 3 phosphorylates FAK/Pyk2. This results in the activation of Src, Syk, 
PI3K/Akt, PLC/PKC and MAPK kinases (Figure 7).156 
Besides the demonstration of dectin-1 as the most important receptor for (particulate) β-glucans in 
mice and man,75, 125, 158, 161-163 several studies showed a redundant role for dectin-1 in particulate β-
glucan-mediated signalling.23, 157, 164 Huang and coworkers demonstrated in mice that phagocytosis of 
yeast-derived β-glucans by peritoneal macrophages was comparable in wild-type and dectin-1-/- 
mice.165 Another group could not detect an involvement of dectin-1 in inducing inflammatory 
responses towards zymosan in mice.157 Data from a recent study have demonstrated that blocking 
dectin-1 or the downstream Syk/Raf-1 pathways in human mononuclear cells only marginally 
reduced particulate β-glucan-induced IL-1 receptor antagonist (IL-1Ra) production.164 
Part I: Review of the literature 
 
23 
 
Furthermore, different studies highlight that other receptors than dectin-1 are involved in promoting 
β-glucan-mediated intracellular signalling and that they may contribute to β-glucan recognition in 
monocytes/macrophages lacking dectin-1.148, 157, 161, 164 Indeed, the importance of heterogeneity of 
receptor expression across myeloid cell subsets in protective immune responses towards fungal 
particles was recently demonstrated.153 Inflammatory monocyte recruitment seems to be dependent 
on dectin-1 when low doses of zymosan are administered to mice, while this effect was lost in the 
higher dose studies, indicating that other receptors could substitute for dectin-1.153 In addition, no 
role for dectin-1 or CR3 was detected in the recognition of soluble β-glucans by murine 
macrophages161 and in the particulate β-glucan-induced IL-1Ra production,164 indicating the presence 
of a diverse receptor array in eliciting protective immunity towards fungal particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Contribution of dectin-1 and CR3 in β-glucan recognition and signalling in monocytes/macrophages. 
Particulate β-glucans activate the Src-family kinases (Src) by binding dectin-1. Syk is recruited to these 
phosphorylated ITAMs, facilitated by SHP2, which results in ROS production. This ROS production can be 
induced in a Syk-independent pathway as well by activating PI3K/Akt. On the other hand, β-glucans will bind 
dectin-1, which lead to the activation of the Raf-1 pathway, resulting in canonical NF-kβ activation. Soluble β-
glucans get recognised by complement receptor 3 (CR3), which induces FAK/Pyk2 phosphorylation. Activation 
of FAK results in activation of Src, Syk, PI3K/Akt, PLC/PKC and MAPK kinases. CR3 or other receptors can bind 
particulate and/or soluble β-glucans in the absence of dectin-1, which induces the activation of different 
signalling pathways. 
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Taken together, there is no consensus on the cell-type and species-specific contribution of dectin-1 
or CR3 to recognise β-glucans. In human neutrophils, CR3 seems to play a major role in β-glucan 
recognition, however, dectin-1 is more important in murine neutrophils. In monocytes/macrophages, 
the β-glucan structure seems to be important for receptor binding. Particulate β-glucans are more 
likely to engage dectin-1, while soluble β-glucans preferentially bind to complement receptor 3. 
However, it is feasible that multiple receptors are used for β-glucan recognition in monocytes, where 
one receptor can dominate over the other. In addition, overlapping signalling pathways between the 
different β-glucan receptors and species-specific differences limit the identification of one major 
receptor in this cell type.  
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1.3 Biological activities of β-glucans  
1.3.1 Interaction with the immune system 
The first indication for biological activity of β-glucans appeared when zymosan was observed to 
generate hyperplasia and hyperfunctionality in macrophages.166 Compositional analyses revealed 
that zymosan preparations contained β-glucans, mannans, proteins, and fat in addition to small 
amounts of glucosamine, phosphorus, and magnesium.167 Subsequently, β-glucans were identified as 
the immunostimulating component168 and classified as biological response modifiers.169 Since this 
discovery, β-glucans have been recognised to be capable of modulating the immune system of 
various living organisms from insects170-173 to mammals43, 64, 174-179 through specific interactions with 
different immune cells.180 Interaction of β-glucans with receptors located on innate immune cells is 
crucial for their activity. Binding to these β-glucan receptors will induce phagocytosis, permitting 
their destruction by lytic enzymes in the acidic environment of the phagolysosome.181 The 
phagosome is also the site of assembly of the phagocyte oxidase complex, which is responsible for 
the production of reactive oxygen species (ROS) upon detection and internalisation of β-glucans.98, 
100, 182 In addition, internalisation of β-glucans by antigen-presenting cells (dendritic cells, 
macrophages) can stimulate secretion of pro-inflammatory cytokines64, 183-187 and chemokines,187 
which in turn can activate adaptive immunity. It has been demonstrated that large amounts of IL-23 
are secreted after stimulation of dendritic cells with purified particulate β-glucans, which direct the 
subsequent polarisation of naïve CD4+ T cells to Th17 effector cells.32, 181, 188, 189 However, TNFα and 
IL12 is also secreted by β-glucan-stimulated murine macrophages skewing towards a Th1 immune 
response.189-191 It is hypothesised that IL-17 is important for early steps in immunity involving the 
recruitment of efficient numbers of neutrophils to deal with the β-glucan bearing pathogen, and that 
subsequent IFN-γ produced by Th1 cells is important for activation of these neutrophils and other 
phagocytes to kill the pathogen.181 
Besides activating macrophages, β-glucans are able to epigenetically reprogram monocytes, which 
can create innate immune memory.192 Although establishing immunological memory is often 
attributed to T and B cell function, it was recently proposed that the enhanced and sustained innate 
immune responses following initial infection or vaccination may also afford protection against 
reinfection/revaccination.193 This phenomenon has been named “trained immunity”.192 Quintin and 
coworkers have shown that mice lacking functional T and B lymphocytes are protected against 
reinfection with Candida albicans in a monocyte-dependent manner.193 The molecular mechanism of 
this protection is mediated by the dectin-1/Raf-1 pathway activated by β-glucans on the cell wall of 
C. albicans.192-194 Reprogramming of these monocytes was maintained for at least a week and is 
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associated with specific trimethylation of histones, which suggests the involvement of epigenetic 
mechanisms in this phenomenon.193, 195 
 
1.3.2 Therapeutic application of β-glucans 
β-glucans, derived from yeast, could have numerous applications in curing patients by improving 
their immune system. The most attractive therapeutic properties of β-glucans are their anti-tumor 
effect and cholesterol-lowering potential.196 
 
1.3.2.1 Anti-tumor effect  
Since 1980, many studies have pointed out the positive effects of β-glucans in tumor therapy.196-199  
Under normal conditions, the immune system is able to overcome the invasion of cancer cells, 
however, unfavourable factors, such as stress, UV-radiation and an unbalanced diet may, impair the 
immune functions of the body. Thus, when the immune system is compromised, β-glucans as 
immunomodulators can compensate for such factors and help the immune cells. β-glucans can bind 
macrophages and natural killer (NK) cells and trigger their activation. As a result, activated killer cells 
circulate in the body and destroy their targets.196, 200 Indeed, experiments in mice demonstrated that 
intravenous injection of soluble and particulate β-1,3-glucans from yeast inhibits tumor growth of 
the syngenic anaplastic mammary carcinoma and melanoma B-16.201 This study indicated that β-
glucans, if used therapeutically, could inhibit either hepatic metastases or primary tumor growth and 
result in enhanced survival.64 
In addition, the effectiveness of β-glucans in combination with antitumor monoclonal antibodies has 
been demonstrated in several studies. β-1,3/1,6-glucans in combination with anti-tumor mAbs 
improved tumor regression and long-term survival to a greater degree than monoclonal antibodies 
alone. This β-glucan action is mediated via complement receptor 3 (CR3), which is found on NK-cells, 
neutrophils, monocytes and lymphocytes. First antitumor monoclonal antibodies will activate the 
complement system, by which tumor cells will be opsonised with the complement fragment iC3b. β-
glucans will then prime the granulocyte receptor CR3 to clear the iC3b-opsonised tumor cells.113-118 
 
1.3.2.2 Cholesterol-lowering effect 
Oral administration of specific particulate β-glucans is well-tolerated and has received the Generally 
Recognised as Safe status (GRAS).167 Additionally, β-glucans from various sources have effective 
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cholesterol and lipid lowering properties. Worldwide studies have demonstrated that uptake of β-
glucan is a safe, powerful and inexpensive way to lower blood cholesterol and high lipid levels in 
humans and laboratory animals with high cholesterol.196, 202, 203 Clinical trials proved the benefical 
effect of dietary pure β-glucans and cereals on hypercholesterolemia.204 The hypocholesterolemic 
mechanisms of β-glucans include (a) reducing the intestinal absorption of cholesterol and bile acids 
by sequestration to β-glucans, (b) shifting the liver from cholesterol synthesis to bile acid production, 
(c) fermentation of β-glucans by intestinal bacteria to short-chain fatty acids, which are absorbed and 
inhibit hepatic cholesterol synthesis.205 
 
1.3.3 Health-promoting and immunostimulatory effects upon oral administration 
The health-promoting and immunomodulatory effects of β-glucans can be exerted upon parenteral 
and enteral administration.206 The strongest immunomodulatory β-glucans are particulate, since they 
can directly activate leukocytes, triggering phagocytosis and antimicrobial activities.43 However, due 
to the particulate nature of the glucan preparation, it is difficult to administer these via a parenteral 
route. Moreover, intravenous administration of particulate β-glucans results in a number of side 
effects, such as development of pulmonary granulomatous vasculitis, splenomegaly and 
inflammation. These adverse side effects have made particulate β-glucans useless in clinical medicine 
when administrated parenterally.64 In contrast, oral administration of particulate β-glucans are well-
tolerated and are approved as novel food ingredients by the European Food Safety Authority.167  
Besides their cholesterol-lowering effect, dietary β-glucans have multiple other beneficial effects on 
the health and well-being of the individual attributed to the interaction with the microbiota and/or 
the immune system.207 Indeed, since vertebrates lack the appropriate glucanases that are necessary 
to metabolise the β-glycosidic bonds of these polysaccharides, complex β-glucans will reach the 
terminal gut, where they interact with the intestinal microbiota (prebiotic effect).208 The intestinal 
microbial flora is known to ferment β-glucans, derived from oat and barley, into short-chain fatty 
acids (SCFA),209-211 with the strongest relative effect on butyrate.212 Butyrate plays an important role 
in promoting and maintaining colonic health.213, 214 Furthermore, SCFA are known to regulate several 
leukocyte functions including production of cytokines and chemokines.215 β-glucans are also known 
to alter the composition of microbiota as shown by the higher abundance of Lactobacillus and 
Bifidobacterium, together with the lower abundance of the Bacteroides fragilis group in the 
caecum.214 These β-glucan-mediated effects make them attractive functional feed ingredients.216 
Besides these prebiotic effects, β-glucans can directly bind to specific receptors on immune cells, 
resulting in a microbial independent immunomodulatory effect.207 Indeed, orally administered yeast 
β-1,3-glucans can be taken up by murine mononuclear phagocytes via β-glucan receptors and are 
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subsequently transported to the spleen, lymph nodes, and bone marrow.113 However, although 
numerous articles have tried to unravel β-glucan receptor binding and their signalling pathways in 
vitro, their mechanism of action upon oral administration is still unknown. Nevertheless, because of 
their known health-promoting and immunomodulatory effects, β-glucans have been proposed as 
alternative for antibiotics to improve health, growth and general performance of post-weaning 
piglets and protect them against enteric infections.180 Indeed, β-glucans can balance their pro-
inflammatory response by inducing IL-1 receptor antagonist production, resulting in higher feed 
intake and growth performance.217, 218 Other reports have shown the health-promoting and 
immunomodulatory effects of β-glucans after oral administration as well. In human studies, orally 
administered β-1,3/1,6-glucans derived from yeast significantly reduced the incidence of upper 
respiratory tract infections in persons susceptible to upper respiratory tract infections.167, 219 In pigs, 
oral administration of β-glucans derived from Saccharomyces cerevisiae reduced the replication of 
swine influenza virus.15 Furthermore, our lab demonstrated the priming effect of β-glucans on the 
immune system in pigs and dogs. In weaned piglets, oral administration of Macrogard or Sclerotium 
rolfsii β-glucans as feed additive resulted in a lower susceptibility to F4+ ETEC infections in weaned 
piglets, evidenced by a reduction in the faecal excretion of the bacteria as well as a reduced F4-
specific serum antibody response.20 In dogs, oral administration of Macrogard influenced the 
systemic humoral immune response by temporarily decreasing the total IgA response, while the total 
IgM response increased.220 Significant systemic immunomodulating effects in terms of humoral and 
cellular immune responses were demonstrated in rats as well.208 In conclusion, orally delivered β-
glucans appear to elicit diverse immunomodulatory effects in different species.  
In summary, based on animal experiments, orally administered particulate β-glucans enter the 
proximal small intestine rapidly where β-glucans can be taken up by immune cells or will transit 
further to the lower intestinal tract to be fermented by the intestinal microflora. As a result, β-
glucans improve the health status of the individual and boost mucosal immunity. Thereby, it would 
be interesting to use this immunostimulatory potential of β-glucans in oral vaccine design. 
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2 CHAPTER 2: Oral vaccination for protection against enteropathogens 
2.1 Introduction 
Since the development of the first vaccine against smallpox in the 18th century by Edward Jenner, 
vaccines have become crucial in the control of many human and veterinary diseases.38 The majority 
of vaccines used today are parenteral vaccines, which can be administered intradermally, 
subcutaneously or intramuscularly. However, most of the pathogens initiate their infections at 
mucosal surfaces and parenteral vaccines only induce humoral immune protection without 
pathogen-specific mucosal immunity. Although experiments conducted in ruminants have 
demonstrated mucosal immunity upon parenteral immunisation.221 Therefore, mucosal vaccination is 
highly advantageous for infectious diseases that are inhaled, ingested or sexually transmitted.222 
Mucosal vaccination can be achieved by oral, intranasal, sublingual, pulmonary, rectal or vaginal 
administration.223 To prevent gastrointestinal infections, the oral route seems to be the most 
favourable way, since it induces an immune response at the site of pathogen entry and it obviates 
the need for needles and trained medical personnel. Furthermore, for veterinary purposes, the oral 
route is also the most practical.224-226 
Enteropathogens, such as pathogenic E. coli, Vibrio cholera and rotavirus, can cause infectious 
diarrhoea, which is a significant global health challenge. For example, the global disease burden of 
enterotoxigenic Escherichia coli (ETEC) is estimated at over 210 million human cases and 380 000 
deaths annually.38 Moreover, in neonatal and recently weaned piglets this infection causes huge 
economic losses due to growth retardation, increased drug use and elevated mortality.6 Therefore, 
the development of effective oral vaccines for these pathogens is very desirable.38 However, only a 
very limited number of oral vaccines is approved for human use (Table 2), such as vaccines against 
polio (OPV), Salmonella, Vibrio cholerae and rotavirus.33, 38, 227, 228 In pigs, oral vaccines against 
Lawsonia intracellularis, rotavirus, Erysipelothrix rhusiopathiae and Salmonellla have been 
commercialised (Table 2). However, all these vaccines are composed of live-attenuated or whole 
killed bacteria, which are often genetically unstable or not immunogenic enough.229 Recombinant 
subunit vaccines use only a part of the pathogen to provoke an immune response and thus are much 
safer. Until today, although recombinant strategies are dominating the development of modern 
vaccines, recombinant non-living oral vaccines are not available.230 Designing an oral subunit vaccine 
platform remains a major challenge as oral vaccines face many hurdles posed by the gastro-intestinal 
tract. Vaccine antigens have to survive the harsh conditions in the gastro-intestinal tract, cross the 
epithelial barrier and avoid the induction of tolerance. Indeed, oral administration of antigens 
generally results in a state of immunological hyporesponsiveness or oral tolerance.231, 232 When 
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developing an oral subunit vaccine platform, all these limiting factors have to be taken into 
consideration in order to combat these challenges. Therefore, it is necessary to design antigen 
delivery systems which protect the pathogen antigens and aid them in the induction of an effective 
mucosal immune response. Before designing an oral vaccine, understanding the complexity of the 
intestinal immune system is essential. 
 
Table 2. Overview of the globally licensed oral vaccines in humans and pigs. Adapted from Davitt et al. (2015).
38
 
Pathogen Species Commercial name oral vaccine 
(manufacturer) 
Components (dosing) 
Poliovirus Human OPV (many) Trivalent, bivalent and monovalent live-
attenuated poliovirus strains (3 doses) 
Rotavirus Human RotaTeq (Merck) Pentavalent live-attenuated rotavirus (3 
doses) 
 Human Rotarix (GSK) Live-attenuated human rotavirus RIX4414 
strain (2 doses) 
 Pig ProSystem® Rota (Merck) Bivalent live-attenuated rotavirus (1 oral 
dose and 1 IM dose) 
Salmonella Human Vivotif (Crucell) Live-attenuated S. typhi Ty21a (3-4 doses) 
 Pig Argus® SC/ST with Diluent (Intervet) Live-attenuated S. choleraesuis (single dose) 
 Pig Nitro-Sal FD (Arko Laboratories) Live-attenuated S. choleraesuis (single dose) 
 Pig Enterisol SC-54 (Boehringer Ingelheim 
Vetmedica) 
Live-attenuated S. choleraesuis (single dose, 
oral or intranasal) 
 Pig Salmo Shield Live (Novartis Animal 
Health US) 
Live-attenuated S. choleraesuis (single dose, 
oral or intranasal) 
 Pig Salmoporc (IDT Biologika) Live-attenuated S.choleraesuis (single dose) 
Vibrio cholerae Human Dukoral (Crucell) Whole killed V.cholerae (O1 strains) and 
recombinant CTB (2-3 doses) 
 Human Orochol (Crucell) Bivalent live recombinant V. cholera (O1 
and O139 strains) (mutant lacking CTA) 
(single dose) 
 Human mORC-Vax (VaBiotech) Whole killed V.cholerae (O1 and O139 
strains) (2-3 doses) 
 Human Shanchol (Shantha biotechnics) Whole killed V.cholerae (O1 and O139 
strains) (two doses) 
Enterotoxigenic 
E.coli  
Pig Coliprotec F4 (Prevtec microbial) 
 
Live non-pathogenic (not attenuated) 
E.coli O8:K87 (single dose) 
 Pig Entero Vac (Arko Laboratories) Live-attenuated (K88 E.coli, single dose) 
 Pig Edema Vac (Arko Laboratories) Live-attenuated (F18 E.coli, single dose) 
 Pig Porcine Ecolizer 3+C (Novartis Animal 
health) 
Antiserum against K88, K99 and 987P E. Coli 
and C. Perfringens type C. 
Lawsonia 
intracellularis 
Pig Enterisol Ileitis (Boehringer Ingelheim 
Vetmedica) 
Live-attenuated Lawsonia intracellularis 
(single dose) 
Erysipelothrix 
rhusiopathiae 
Pig Ery Vac (Arko Laboratories) Live-attenuated Erysipelothrix rhusiopathiae 
(single dose) 
 Pig Nitro-Ery ALC (Arko Laboratories) Live-attenuated Erysipelothrix rhusiopathiae 
(single dose) 
 Pig Ingelvac ERY-ALC (Boehringer Ingelheim 
Vetmedica) 
Live-attenuated Erysipelothrix rhusiopathiae 
(single dose) 
 Pig Suvaxyn E-Oral (Zoetis) Live-attenuated Erysipelothrix rhusiopathiae 
(2 doses) 
Adenovirus Human (military 
personnel) 
Oral adenovirus vaccine (Barr 
Pharmaceuticals) 
Live (not attenuated) adenovirus type 4 and 
type 7 (single dose, two tablets) 
Clostridium 
perfringens 
Pig Clostratox (Novartis Animal health) Clostridium Perfringens Type C antitoxin 
(single dose) 
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2.2 The gastrointestinal mucosal immune system 
2.2.1 Structure of the small intestine and gut-associated lymphoid tissue 
The gastrointestinal tract consists of the mucosa, submucosa, muscularis externa and serosa (Figure 
8A). The submucosa, muscularis externa and serosa consist mainly of muscular layers and connective 
tissue with large blood vessels and lymphatics in order to supply immune cells to the mucosa. The 
mucosa is the inner layer surrounding the lumen, consisting of the epithelium, the lamina propria 
and the muscularis mucosae. The epithelium is constituted of a monolayer of epithelial cells, which 
are continuously renewed from stem cells present at the crypt base. These multipotent stem cells 
give rise to four major epithelial cells: enterocytes, paneth cells, enteroendocrine cells and goblet 
cells (Figure 8A). The enterocytes, goblet and enteroendocrine cells migrate upwards to the villous 
tip, while paneth cells differentiate during a downward migration to the crypt base. The enterocytes 
form the basis of the integrity of the epithelium and are held together by tight junctions. These tight 
junctions form a seal against the external environment and thus regulate the paracellular transport 
of antigens.233 The paneth cells establish a protective environment as well by secreting large dense 
core granules from the apical membrane, which are rich in antimicrobial proteins and peptides 
(defensins, lysozyme) as well as potent proinflammatory mediators.233-235 At the crypt base, paneth 
cells also synthesize and secrete factors that are capable of influencing proliferation and migration of 
intestinal stem cells, including epidermal growth factor (EGF).236 Enteroendocrine cells are essential 
for normal life. They are sensory epithelial cells that coordinate nutrient sensing with metabolic and 
behavioural functions, like insulin secretion and the regulation of food intake. Such fine coordination 
is achieved through the secretion of a broad range of neuropeptides.237, 238 The last epithelial cell 
type, the goblet cells, are specialised in the synthesis and secretion of mucus.239 The mucus of the 
small intestine is a complex viscous matrix and can be divided in two different layers: the loosely 
attached external (mucus layer) and internal (glycocalyx) layer. The mucus provides an effective 
chemical and physical barrier to foreign materials, such as bacteria.240, 241 The major component of 
the mucus are the mucins, which are carbohydrate-modified proteins. There are two different types 
of mucins: the classical gel-forming mucins, which form extremely large polymers (mucus layer) and 
the transmembrane mucins, which cover the apical surface of the enterocytes (glycocalyx).242  
The glycocalyx is much thinner at certain places, particularly above the gut-associated lymphoid 
tissue (GALT). The GALT is located in the intestinal mucosa and is a component of the mucosa-
associated lymphoid tissue (MALT), in which approximately 70 percent of the body’s immune cells 
are found and is therefore described as the largest and most complex part of the immune system.243, 
244 The lymphoid tissue of the small intestine, the Peyer’s patches (PPs), is composed of a specialised 
follicle associated epithelium (FAE), a subepithelial dome (SED) containing numerous immune cells, B 
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cell follicles containing germinal centers (GCs) and intrafollicular regions (IFR) containing mostly T 
cells (Figure 8B).226, 243 The FAE differs from the villus epithelium because of the presence of 
Microfold cells (M cells), while goblet and enteroendocrine cells are largely absent.245 M cells are 
characterised by irregular shaped microvilli, the absence of an extensive mucus layer, a thin 
glycocalyx and a reduced enzymatic activity. In addition, the basolateral membrane is invaginated, 
forming an intraepithelial pocket, which contains lymphocytes and antigen presenting cells (APCs) 
(Figure 9B).246 Hence, M cells can transport macromolecules and bacteria through the epithelial 
barrier to deliver them to antigen presenting cells (APCs) in the subepithelial dome (SED) (Figure 
8b).245 
 
A        
 
 
 
 
 
 
 
 
B     
 
 
 
 
           
 
 
 
 
 
Figure 8. Schematic representation of the small intestine and the intestinal mucosa.  
(A) Schematic illustration of the intestine. The intestine is composed of the mucosa, submucosa, muscularis 
externa and serosa. The mucosa consists of the epithelium and the lamina propria. The epithelium is 
constituted by enterocytes, goblet cells, paneth cells and enteroendocrine cells and is covered by mucus. The 
lamina propria contains immune cells, such as dendritic cells and lymphocytes. (B) Schematic illustration of the 
GALT. The FAE consists of enterocytes and M cells. This epithelium overlies the SED, which contains immune 
cells, such as dendritic cells (DCs). The Peyer’s patches also contain B-cell follicles with germinal centers (GCs) 
and intrafollicular regions (IFR) containing mostly T cells. Figures adapted from Fagarasan et al. (2003).
247
 
  Part I: Review of the literature 
 
33 
 
M cells are present in varying proportions in the FAE of a wide variety of species such as laboratory, 
domestic and farm animals and man.204, 248-250 Interestingly, the occurrence of other GALT-like 
structures is species-dependent, such as lymphocyte-filled villi (rat and human), cryptopatches 
(mouse) and lympho-glandular complexes (pig).251 In pigs, Peyer’s patches are found sporadically in 
the jejunum (JPP) and continuously in the ileum (IPP). Intriguingly, porcine IPP are not primary 
lymphoid organs252 as they are neither required to maintain the systemic B cell pool nor are they a 
site of B cell lymphogenesis.253 Similar to dolphins, elephants, rhinoceros, hippopotamus and 
warthog, porcine peripheral and mucosa-associated lymph nodes are inverted:254 the lymph nodes 
are preferentially composed of cortical areas and paracortex and lack a larger medullary area.255, 256  
 
2.2.2 Antigen uptake in the small intestine 
Understanding the mechanisms of antigen uptake in the intestine is important to develop oral 
vaccines, since transcytosis of antigens is crucial for inducing intestinal immune responses. Uptake of 
antigens in the small intestine can occur by four main mechanisms. 
The first mechanism involves M cells. These cells located in the Peyer’s patches play a decisive role in 
the uptake and transcytosis of both soluble and particulate matter to the underlying lymphoid 
follicles.245 Antigens can also be taken up by lysozyme expressing antigen presenting cells (APCs) 
present in the M-cell pocket. These cells can extend transcellular dendrites through pores in the M 
cell membrane to sample the lumen and take up bacteria.257 M cells are generally considered as the 
preferred route to trigger intestinal immune reactions, however, the importance of villous 
enterocytes should not be disregarded.258, 259 
Receptor-mediated endocytosis is another mechanism for antigen sampling in the intestinal lumen. 
At the villous epithelium, luminal antigens are shuttled through the epithelial layer to the intestinal 
tissues via epithelial transcytotic receptors, such as FcRn, dectin-1 and aminopeptidase N.260-262 FcRn 
binds the Fc domain of IgG in a pH-dependent manner and is capable of bidirectional transport of 
immunoglobulin G (IgG) across the intestinal barrier.263 Immunoglobulin G (IgG) binds the receptor at 
the basolateral side, which is then transported into the lumen across the epithelial barrier, where the 
IgG can bind cognate antigens. Subsequently, FcRn recycles the IgG-antigen complex back across the 
intestinal barrier into the lamina propria for processing by immune cells.263 Moreover, recent data 
indicate that FcRn mediates uptake of Fc-conjugated particles as well.264 FcRn is expressed by adult 
enterocytes in humans265 and in pigs.266 Furthermore, It has been demonstrated that intestinal 
secretory IgA (SIgA) antibodies in complex with its antigens are taken up by M cells via dectin-1.261 
Carbohydrate residues on the antibodies are involved in this M-cell-mediated transcytosis. Since 
SIgA-antigen complexes can be taken back up by the intestinal epithelium, binding to dectin-1 can 
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promote the uptake and delivery of antigens from the intestinal lumen to the underlying immune 
cells.261 Besides immunoglobulin-mediated transcytosis of antigens across the epithelial barrier, 
antigens can bind different transcytotic receptors located at the apical surface of enterocytes. For 
example, porcine aminopeptidase N has been identified as an endocytotic receptor for F4 fimbriae in 
the epithelial barrier, the adhesin of F4+ enterotoxigenic Escherischia coli (ETEC).260 
A third route of antigen uptake in the lamina propria of the small intestine involves phagocytes. It 
seems that CX3CR1+ mononuclear phagocytes extend transepithelial dendrites (TEDS) to sample 
luminal content.267, 268 269, 270 Therefore, they extend their dendrites through the intestinal epithelium 
in the gut lumen.247, 268 The integrity of the epithelial barrier is not disturbed as the immune cells 
express tight junction proteins, such as occludin, claudin and zonula occludens.268 After antigen 
uptake, CX3CR1+ cells transfer their antigens to CD103+ DCs, which will migrate to the mesenteric 
lymph nodes (MLN) and present the bacterial antigens to T cells and B cells, which can induce IgA 
class-switching and differentiation.247, 269, 270 
Finally, recent data indicate that goblet cells can transport small soluble molecules to underlying 
tolerogenic APCs via goblet cell-associated antigen passages (GAPs).271 
How each uptake mechanism contributes and interplays in tolerance or protective immunity is 
however still a matter of debate, although targeting to apical receptors to enhance bioavailability at 
subepithelial tissues might be necessary to design an efficient oral vaccine. 
 
2.2.3 Intestinal immune reaction against enteric pathogens 
Mucosal surfaces are continuously exposed to the external environment and therefore represent the 
largest lymphoid organ of the body.226 The key element in intestinal mucosal immunity is the local 
production of pathogen-specific secretory IgA (SIgA) molecules at the infection site.272 
The intestinal immune system can be subdivided into distinct functional compartments. These are 
classified as the inductive site, considered as sites of initiation of lymphocyte education, and the 
effector site, where lymphocytes neutralise foreign antigens.273 Luminal antigens are taken up by the 
different mechanisms described above into the immune inductive site, resulting in the activation of 
antigen presenting cells (APCs). Once activated by foreign antigens, the antigen-loaded cells migrate 
into the mesenteric lymph nodes, where they can present the antigens to naïve CD4+ T cells. It is 
believed that differentiation of naïve CD4+ T cells continues within the mesenteric lymph node 
(MLNs) that drain the gastrointestinal mucosal tissue.273 Alternatively, antigen-loaded APCs can 
migrate through the lymph vessels towards the draining mesenteric lymph nodes where they 
stimulate CD4+ T cells.274 Primed T cells will activate B cells, which will then migrate into B cell follicles 
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to form a germinal center together with follicular dendritic cells (FDC).275 These germinal centers (GC) 
play a crucial role in the development of class-switched antibodies and the formation of B cell 
memory.247, 276, 277 GCs contain mainly rapidly dividing B cells (dark zone) and resting B cells (light 
zone). B cells expand in the dark zone, mutate their immunoglobulin genes (somatic hypermutation), 
and those that acquire mutations that maintain or improve the affinity of the B cell receptor (BCR) 
for the foreign antigen are rescued from programmed cell death.278 B cells, which have acquired 
affinity-increasing mutations, will be able to interact with germinal center T cells (CD40/CD40 ligand 
interaction) and follicular dendritic cells (FDCs) in the light zone. Selected germinal center B cells 
undergo repeated rounds of proliferation, mutation and selection278 and will further undergo IgA 
class-switch recombination (CSR).273 These activated IgA-producing B lymphocytes migrate to 
mesenteric lymph nodes and pass into the blood stream via efferent vessels (ductus thoracicus). 
Subsequently, the IgA effector B cells travel to their mucosal effector sites (lamina propria or 
epithelium)251, 277 where they differentiate into plasma cells. Finally, at their effector sites, dimeric IgA 
is secreted and transported across the epithelium by binding to the polymeric Ig receptor (pIgR) 
expressed on the basolateral surface of mucosal epithelial cells.247 The secretory IgA (SIgA) in the 
intestinal lumen is composed of dimeric IgA molecules and the secretory component (SC), which is 
derived from the pIgR.279 These secretory IgA (SIgA) complexes play multiple protective 
roles.280 Indeed, SIgA forms a critical part of the intestinal immune system both in protection from 
harmful pathogens and in homeostasis38 by promoting immune exclusion via entrapping dietary 
antigens and microorganisms in the mucus and by downmodulating the expression of 
proinflammatory bacterial epitopes on commensal bacteria.280 On the other hand, as described 
above, SIgA-antigen complexes can also facilitate antigen sampling by binding to M cells, leading to 
inflammatory responses.261 Furthermore, IgA dimers, locally released by plasma cells, remove 
microorganisms that passed the epithelial barrier in two ways: by transporting them back into the 
lumen through the pIgR and by promoting their clearance via FcαRI (also known as CD89), an IgA 
receptor expressed by dendritic cells (DCs), neutrophils, and other phagocytes (Figure 9).280 
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Figure 9. Schematic representation of the intestinal mucosal immune system. 
Foreign antigens are taken up from the lumen to the subepithelial dome (SED) by M cells located in the follicle 
associated epithelium (FAE) of the GALT. The SED contains antigen-presenting cells, such as dendritic cells 
(DCs), which capture the antigens and present them to naïve CD4
+
 T cells. These primed T cells within the 
mesenteric lymph node (MLNs) will activate B cells, which will then migrate into B cell follicles to form a 
germinal center. After clonal expansion and somatic hypermutation in the dark zone, B cells with acquired 
affinity-increasing mutations are selected and will interact with primed CD4
+
 T cells and follicular DCs (FDC) in 
the light zone. Here, class switching into IgA-producing cells occur. IgA
+
 B cells leave the PP through efferent 
lymph and migrate first to the mesenteric lymph node and then to the blood. These cells migrate to effector 
sites such as the intestinal lamina propria and differentiate into plasma cells. Plasma cells secrete dimeric IgA 
antibodies that are transcytosed by polymeric Ig receptors (pIgRs) located in the mucosal epithelial cells. Figure 
adapted from Lamichhane et al. (2014).
226  
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2.3 Oral vaccine design strategies 
2.3.1 Challenges of oral subunit vaccines 
The current licensed oral vaccines are composed of inactivated or live-attenuated pathogens (Table 
2). Unfortunately, inactivated vaccines are often not immunogenic, while the use of live-attenuated 
micro-organisms could have devastating consequences when transmitted to immunocompromised 
individuals or infants, who lack a mature immune system, and as such are less able to cope with the 
attenuated pathogens.229 Indeed, the previously available oral live rotavirus vaccine (RotaShield) was 
withdrawn after a short time on the market because of potential serious adverse reactions 
(intussusception).281, 282 Due to the safety risks associated with live-attenuated vaccines there is a 
shift toward the development of safer subunit vaccines that are composed of purified native or 
recombinant proteins of the target pathogen.283 
Unfortunately, oral delivery of soluble recombinant proteins have to overcome at least three 
challenges to induce efficient mucosal immune responses. First, the luminal environment in the 
gastrointestinal tract is hostile to antigens, degrading most antigenic epitopes delivered in soluble 
form.284 Second, the epithelial barrier with its mucus secreting epithelium limits the antigen 
absorption from mucosal surfaces. Third, mucosal tolerance protects against unwanted immune 
responses to dietary and commensal bacterial antigens.133, 285, 286 The mechanism of this oral 
tolerance has not been fully elucidated. The combination of commensals, regulatory T cells and 
CD103+ DCs are probably involved in the creation of a tolerogenic environment in the gut.286-288 
In this regard, designing oral vaccines is rather a difficult task. To overcome these challenges, several 
solutions are available such as an enteric coating for protecting the antigens against the harsh 
environment of the gastro-intestinal tract. Furthermore, potent mucosal adjuvants and/or special 
delivery systems are often required for successful oral vaccination as well (Figure 10).282  
 
Figure 10. Schematic representation of the 
different strategies for oral vaccine subunit 
design.  
Soluble antigens can be protected from physical 
elimination and enzymatic digestion via an enteric  
coating. A mucosal adjuvant can be added to 
soluble antigens to generate long lasting 
immunological memory. Finally, soluble antigens 
can be encapsulated in nano- or microparticles. 
The combination of all three strategies is 
illustrated. 
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2.3.2 Enteric coating 
Enteric coating protects soluble antigen-based vaccines against the harsh, acidic condition of the 
stomach289 by using pH-sensitive polymers, (e.g. methacrylic acid, hydroxypropyl methylcellulose 
phthalate).290 These polymers remain impermeable at the low gastric pH but dissolve in the slightly 
basic pH in the intestinal fluid.291 Eudragit is the brand name for a diverse range of poly(methacrylic 
acid-co-ethylacrylate) copolymers and are commonly used to coat tablets and to prepare controlled 
release formulations.292, 293 Several types of Eudragits are available, which dissolve at different pHs. 
Eudragit L100-55 contains an anionic copolymer, which dissolves when the pH is higher than 5.5.294 
Combinations of Eudragit L100-55 with other polymers have been shown to improve the oral 
bioavailability and the controlled release of drugs.290 Our lab used Eudragit L30 D-55 to coat F4ac 
fimbriae pellets to be used as solid formulation, mixable with creep feed. This enteric coating 
protected the F4 fimbriae against the acid environment in the stomach as well as against 
neutralisation by maternal milk. Oral administration of these pellets in pigs followed by virulent F4+ 
enterotoxigenic Escherichia coli (ETEC) challenge resulted in a significant reduction in F4+ Escherichia 
coli excretion compared to F4 fimbriae in solution.295 
 
2.3.3 Mucosal adjuvants 
Mucosal adjuvants are used to prevent oral tolerance and to induce a protective immune response. 
These adjuvants can be divided into two different groups: the immunopotentiators and the antigen 
delivery systems (i.e. nano- and microparticles). For oral subunit vaccines, the combination of 
immunopotentiators and delivery systems is probably required to elicit optimal immune 
responses.296 
Mucosal immunopotentiators can improve the effectiveness of soluble antigen-based vaccines by 
enhancing the immunogenicity of the vaccine.296 It is important that these mucosal adjuvants induce 
protective immune responses both in the mucosal and systemic immune compartments, stimulate 
local antibody production (SIgA), trigger CD4+/CD8+ T cell responses and long-term B and T cell 
memory.223, 297 Classical adjuvants, e.g. aluminium salts and water-in-oil emulsions, are unable to 
enhance cell-mediated responses.298 Therefore novel mucosal adjuvant formulations, such as 
bacterial toxins, cytokines, TLR ligands and β-glucans have been developed.  
The most powerful mucosal adjuvants are the enterotoxins secreted by V. cholerae and E. coli, 
cholera toxin (CT) and E. coli heat-labile (LT) enterotoxin, respectively.299-301 These enterotoxins are 
structure-related proteins: both toxins are composed of an A subunit and a pentameric B subunit. 
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The A subunit possesses strong ADP-ribosyltransferase activity, while the B subunit binds to its 
receptor, GM1 gangliosides.302, 303 However, these mucosal adjuvants have a high level of toxicity 
limiting their use for human vaccine formulations. Therefore, several genetically modified forms have 
been engineered to detoxify these enterotoxines by mutagenesis of the A subunit and are currently 
under clinical evaluation.300, 301, 304, 305 For example, administration of a single oral dose of 100 µg of 
the double mutant heat-labile enterotoxin (dmLT) was found to be safe, well tolerated and 
reasonably immunogenic in a clinical trial.304  
Furthermore, immunomodulatory cytokines, Toll-like receptor (TLR) agoinsts and β-glucans can be 
used as mucosal adjuvants as well. Cytokines such as IL-12 and granuloyte/macrophage colony-
stimulating factor (GM-CSF) have shown adjuvant activity when administered mucosally together 
with soluble antigens.300, 306 TLR ligands including CpG-containing oligonucleotide, flagellin and 
bacterial porins elicit the secretion of proinflammatory cytokines and chemokines.300, 307-309 β-glucans, 
co-administered with bacterial, fungal, protozoal or viral antigens, display adjuvant effects when 
administered parenterally310-312 and orally.20, 32 In addition, as described above, β-glucans are used as 
immunoadjuvant therapy for cancer.199 
 
2.3.4 Encapsulation in nano- or microparticles  
2.3.4.1 Particle design 
The encapsulation of soluble antigens in particles effectively protects them against degradation in 
the gastrointestinal tract, enhances the immunogenicity of the antigens, can have a dose-sparing 
effect and mimics pathogen dimensions.313-315 Indeed, soluble antigens preferential induce oral 
tolerance in the absence of adjuvants, while particulate antigens are more effective in stimulating 
protective immunity and cross-presentation by antigen presenting cells (APCs).241, 290, 316 When 
designing these oral particle systems, many factors should be taken into consideration such as 
particle size, hydrophobicity and surface charge. 
Determining the optimal particle size seems to be very important for their uptake in the gastro-
intestinal tract.317 M cells, located in Peyer’s patches, have been mostly implicated in the process of 
particle uptake318, however, nanoparticles can gain access to the mucosa through normal villous 
epithelial cells as well.319, 320 Particulate vaccines within the 0.1-10 µm range are efficiently 
internalised by M cells and antigen presenting cells (APCs), probably due to resembling the 
dimensions of common bacteria and viruses.290 In contrast, the particle size for receptor-mediated 
uptake by villous enterocytes is much smaller, since the mucin network forms an exclusion filter for 
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larger particles.321 Particles up to 200 nm are able to migrate through the physical mucin pore, 
however, at certain circumstances native mucin fibres can create larger pores allowing larger 
particles to transit.240, 241 The size of a particle also plays a critical role in determining antigen and 
adjuvant loading and release: nanoparticles exhibit a large surface area, which accelerates carrier 
dissolution and antigen release, while microparticles allow higher antigen encapsulation and slower 
antigen release.290 
Hydrophobicity and charge of the particles is important for designing oral vaccines as well, as the 
mucus is negatively charged and has hydrophobic domains.321 To increase the bioavailability of oral 
vaccine delivery systems, it is important that they rapidly penetrate mucus to avoid being shed.322 
Mucus-penetrating particles possess near neutrally charged surfaces and lack of hydrophobic 
regions, in order to reduce the hydrophobic or electrostatic interaction with mucus.322, 323 To achieve 
such mucus-penetrating surface properties, PEGylation of particles has been used as a strategy, since 
polyethylene glycol (PEG) is a hydrophilic, uncharged and biocompatible polymer. Coating particles 
with a dense layer of low MW PEG (between 2-5 kDa) effectively reduces hydrophobic interaction 
and hydrogen bonding with the mucus.321, 322  
 
2.3.4.2 Oral particulate delivery systems 
A wide variety of delivery systems for the oral route has been developed, including lipid based 
delivery systems (micelles, liposomes and immune stimulating complexes (ISCOMs)), virus-like 
particles and synthetic or natural particle-based strategies (for example poly(lactic-co-glycolic acid) 
(PLGA) and β-glucan microparticles).26, 38, 324-328 
Micelles are composed of lipid monolayers, while liposomes are characterised by a single or 
collection of multiple phospholipid bilayers. The natural hydrophobicity of these delivery systems, 
especially when they are positively charged, allows them to fuse with cell membranes. As such, 
antigens are directly delivered into the cytosol and will traffic to the MHC class I presentation 
machinery. However, their use in oral vaccines is more limited, since micelles and liposomes are 
susceptible to degradation in the gastrointestinal tract (GIT) through acidic pH, lipases and bile salts. 
Bile salts are secreted into the GIT to digest lipids making it unlikely that lipid based delivery systems 
would retain their structural integrity in such an environment, thus compromising their ability to 
protect antigens.38 In addition, liposomes typically have a poor antigen encapsulation efficiency for 
hydrophilic molecules.326 Immune-stimulating complexes (ISCOMs) are related to liposomes, but 
form icosahedral pentagons due to the inclusion of cholesterol and saponins in the membrane. 
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Despite the fact that the incorporation of these additional components confers intrinsic adjuvant 
properties, oral vaccines based on ISCOMs probably require the addition of an immune stimulatory 
component to potentiate their oral efficacy.38, 329 The incorporation of antigens into ISCOMs occurs 
via hydrophobic interactions, which potentially limits the utility of this particle system for soluble 
protein antigens.330 Another major drawback of these ISCOMs is the inability to incorporate 
negatively charged antigens. The development of PLUSCOMS and PosintroTM has been successful in 
altering the surface charge of the particle, making it possible to load positively charged antigens as 
well.38 Moreover, these modifications allow the loading of higher amounts of unmodified protein, 
thus retaining the natural conformation and immunogenicity of the antigen, while ISCOMs have poor 
incorporation of either native or derivitized proteins.331 However, the production process of these 
cationic ISCOMs is very complex and requires at least a 3-day reaction.332 
Virus-like particles (VLPs) and virosomes are multiprotein structures that mimic the organisation and 
3D conformation of authentic native viruses but lack the viral genome, potentially yielding safer 
vaccine candidates.333 VLPs are able to incorporate vaccine antigen, either produced by 
recombination (genetically inserting genes into the recombinant viral genome) or chemically 
coupling antigens to the VLP.334 As such, virus-like particles can also be engineered to incorporate 
proteins with a variety of beneficial functions, including targeting and immunostimulatory activity. 
The advantages of VLPs and virosomes for oral delivery are their small size and the variable 
composition of their surface chemistry. However, virus-like particles and virosomes both suffer from 
challenges in formulation and scaling up. The production process of these particles is also very 
extensive, which adds to manufacturing costs. In addition, VLPs require the addition of adjuvants in 
order to elicit enhanced immune responses.38 For example, oral administration of non-replicating 
rotavirus-like particles, expressing VP2 and VP6 proteins, are only effective as booster vaccine, after 
priming the pigs with live-attenuated viruses.335 
Synthetic or natural-based particles are one of the most versatile oral delivery systems. Vaccine 
antigens can be admixed together with the particles, encapsulated in or conjugated to particles. 
Their size can be controlled, ranging from 30 nm up to mm.38 Both synthetic and naturally occurring 
polymeric particulate delivery systems can be engineered to have a specific particle size, surface 
chemistry and 3D architecture in order to protect the payload from degradation, overcome mucosal 
barriers, interact with specific cell types and exert desired immunomodulatory functions.38 Synthetic 
nanoparticles using the copolymer poly(lactic-co-glycolic acid) (PLGA) are most widely used as a 
results of its biodegradability and biocompatibility.334 In addition, PLGA has been approved for 
human use in sutures, bone implants, and screws as well as in implants for sustained drug delivery by 
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the FDA.334 Despite these attractive features, application of PLGA-based oral vaccines has many 
challenges, such as the relatively high cost of producing these delivery systems, the unknown toxicity 
of the used organic solvents and reagents, low antigen encapsulation efficiency and the use of 
rigorous processes to develop these particles which may be damaging to the recombinant 
antigens.336 Apart from PLGA, other polymers have also been used for vaccination purposes, such as 
β-glucan microparticles (GPs), alginate and chitosan. In this thesis, the use of β-glucan microparticles 
is extensively discussed. 
β-glucan microparticles (GPs) are emerging as an oral delivery system. These particles display a high 
antigen encapsulation efficiency (> 90%) and an intrinsic immunomodulatory capacity owing to the β-
glucan cell wall.21-32 Furthermore, GPs have been generally recognised as safe by the Food and Drug 
Administration.38 These promising antigen-carriers are highly purified, hollow and porous biomimetic 
3-4 µm particles derived from the cell wall of Saccharomyces cerevisiae (Baker’s yeast) and are 
composed of >85% β-1,3-D-glucan polymers (β-glucans), ~2% chitin and <1% lipids and proteins, with 
the rest being mostly ash and moisture.26 β-glucan particles were initially engineered for DNA 
delivery. Encapsulation of DNA in these microparticulate delivery systems was based on the in situ 
layer-by-layer synthesis. Polyethyleneimine (PEI) and carrier tRNA were sequentially adsorped inside 
the particles in order to obtain a positively charged gel matrix within the hollow β-glucan particles, 
whereafter DNA was captured inside the particles via electrostatic interactions.26 Huang and 
coworkers were the first to demonstrate the capture of soluble antigens inside these β-glucan 
particles.25 This technique used hydration and lyophilisation steps to load the antigen inside the 
particles, thus eliminating the use of the cytotoxic PEI,25 rendering them more suitable for oral 
immunisation.  
β-glucans possess immunomodulating capacities and are also recognised by specific β-glucan 
receptors on immune cells, indicating that these particles have a great potential to be exploited as an 
antigen delivery vehicle. Indeed, many reports have demonstrated the immunostimulatory activity of 
these DNA or protein loaded β-glucan particles in vitro and in preclinical animal models.21, 25, 26, 29-31, 165 
It has been demonstrated that incubation of mouse bone marrow derived dendritic cells (BMDCs) 
with ovalbumin (OVA) loaded GPs resulted in phagocytosis, upregulation of maturation markers, 
rapid proteolysis of ovalbumin and proliferation of OVA-reactive transgenic CD8+ OT-I and CD4+ OT-II 
T cells.25 Furthermore, subcutaneous immunisation of GP-OVA induced strong humoral and Th1- and 
Th17-biased CD4+ T cell responses in mice.25 Oral administration of silencing RNA (siRNA)-loaded 
particles in mice was investigated as well. siRNA-mediated gene silencing occurred by internalisation 
of the particles by GALT mononuclear phagocytes. These cells then migrated to spleen, liver and 
lung.21 
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Only two articles have evaluated the capacity of these β-glucan microparticles as particulate antigen 
vehicle for oral vaccination.28, 32 The first study by Berner et al. (2008) demonstrated that BSA-
conjugated GPs were able to initiate an enhanced systemic IgG response against BSA after 
intradermal and oral immunisation in mice.28 However, BSA was conjugated to the particles surface, 
losing the advantage of antigen protection. De Smet and coworkers, on the other hand, have loaded 
ovalbumin inside the GPs using the same technique as described by Huang et al. (2010). Oral 
administration of these GP-OVA particles in mice resulted in a Th17-biased response and the 
production of OVA-specific IgA, secretory IgA (SIgA) and secretory component antibodies.32 This local 
immune response is obtained via the transepithelial transport of GPs by Peyer’s patch M cells,22, 32 
resulting in the accumulation of GPs in CD11c+ mononuclear phagocytes situated in the Peyer’s patch 
sub-epithelial dome (SED) regions.22 However, because of the small number of M cells present in the 
intestinal tract, a huge amount of particles is probably necessary to induce protective immune 
responses against intestinal pathogens. Since villous enterocytes outnumber M cells and possess a 
transcytotic capability for macromolecules and inert particles, specific targeting of particles to 
enterocytes could enhance particle absorption in the gastro-intestinal tract.337 
Taken together, a suitable delivery system in combination with powerful mucosal adjuvants and an 
enteric coating have been demonstrated to greatly enhance the efficacy and efficiency of oral 
vaccines, however, many oral route-specific challenges that must be overcome remain. Targeting 
these immunostimulating particulate vehicle systems to epithelial transcytotic receptors is a 
promising technological adaptation that can be made in order to enhance the efficacy of the oral 
vaccine.  
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2.4 Targeting 
2.4.1 Bioadhesion and delivery 
Although encapsulation of antigens in nano- or microparticles is a promising approach for oral 
vaccination, the uptake of particles by epithelial cells remains poor due to the rapid transit time in 
the intestinal tract and the limited availability of M cells.241 As a consequence, high and multiple oral 
doses of these antigen carriers are often required to elicit sufficient immune responses against the 
antigen of interest. Decorating these particles with bioadhesive molecules can increase the 
bioavailability of the particles by increasing the residence time of the vaccines within the gut.338 The 
pivotal role played by M cells in the uptake of intestinal antigens has made them a key target for oral 
vaccine delivery. However, directing vaccine towards mucosal DCs or enterocytes should not be 
disregarded.38 A combination of antigen encapsulation in nano- or microparticles and the 
functionalisation of these particles with bioadhesive molecules is an advanced concept for oral 
vaccine design and holds much promise (Figure 11). The most common used bioadhesins are lectins, 
bacterial adhesins or specific antibodies targeting transcytotic receptors. 
 
 
 
Figure 11. Schematic representation of a promising functionalised particulate oral antigen delivery vehicle.  
Soluble antigens together with a mucosal adjuvant can be encapsulated in nano- or microparticles. These 
particles can be coated with bioadhesive molecules in order to increase the residence time in the 
gastrointestinal tract. 
Lectins are naturally occurring proteins, which bind specifically to carbohydrates.339 These lectins can 
bind to membrane anchored glycoconjugates present on intestinal epithelial cells.241 Since these 
intestinal epithelial cells exhibit regional and even cell-type specific differences in their carbohydrate 
composition, the use of lectins may permit targeting to specific locations within the intestinal 
tract.337, 340 The most investigated lectin is Ulex europaeus agglutinin 1 (UEA-1), specific for α-L-fucose 
residues expressed on the apical surface of M cells, goblet and Paneth cells in mice.337, 341 Other 
lectins that have demonstrated an ability to both target and enhance Peyer’s patches uptake when 
associated to nanocarriers are: wheat germ agglutinin, peanut agglutinin, asparagus pea lectin and 
Aleuria aurantia lectin.241 However, once coated on the surface of particles, these plant lectins are 
susceptible to proteolytic degradation in the gastrointestinal tract.342 Moreover, lectins as targeting 
ligand for oral vaccine delivery are toxic, resulting in anti-nutritional properties.343 To overcome these 
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limitations, recombinant lectins or peptides/molecules which mimic the function of lectins can be 
produced. However, using lectins in vaccine delivery should be restricted since the glycosylation 
pattern in the intestine differs between enterocytes and M cells at different intestinal locations 
(presumably influenced by the local microflora) with age and between species.337, 338, 340 Moreover, 
the interaction of these lectins with the mucus layer could lead to immobilised particles in the mucus 
layer. As a consequence, when the mucus is renewed, these lectin-conjugated particles will be 
cleared.241, 344 
The use of microbial adhesins to functionalise particles is an interesting approach, since these 
adhesins are relatively resistant to intestinal degradation, may exhibit mucus-permeating properties 
and can have an important effect as immunomodulators (adjuvants). In this biomimetic approach 
different ligands have been proposed including the use of flagellin, LPS, F4 fimbriae or FimH.241, 345 
Several enterotoxigenic E. coli (ETEC) strains express fimbriae on their surface allowing adhesion to 
the intestinal epithelium. Conjugation of these fimbriae to antigens has been shown to enhance 
mucosal antigen-specific antibody responses upon oral administration.346 However, although 
bacterial adhesins are potent immunogens, immune responses directed against the adhesin itself 
could be generated, thereby decreasing the endocytosis of the vaccine delivery systems and the 
efficient induction of immune responses.337 
Due to the drawbacks that lectins and microbial adhesins entail, research has recently focused on 
fusing particles to antibodies to target antigen sampling routes at the mucosal surfaces.320, 337 
Mimicking the invasive strategies from enteric pathogens, mediated by specific pathogen-host 
interactions, is a promising approach to increase the endocytosis of particulate vaccine antigens. 
Indeed, it has already been demonstrated that targeting of antigen-loaded microspheres to ligands of 
pathogenic adhesins can enhance oral vaccine delivery.337 For example, antibody-mediated targeting 
to porcine aminopeptidase N (APN or ANPEP), expressed on intestinal epithelial cells, results in a 
strong IgA, IgG and IgM immune response.260 Porcine aminopeptidase N (APN) serves as an uptake 
receptor for bacteria and viruses, such as group I coronaviruses,347 transmissible gastroenteritis virus 
(TGEV)348 and F4+ enterotoxigenic E. coli.260 Our lab has demonstrated that F4 fimbriae interact with 
APN in a sialic acid-dependent manner and this interaction results in F4 endocytosis.260 Moreover, 
APN serves as a transcytotic receptor for antibodies as well, indicating that APN may represent a 
promising target for oral delivery of antigens across the epithelial barrier.260 Aminopeptidase N or 
CD13349 is expressed by many tissues, including on myeloid cells of the intestine.350, 351 It has been 
demonstrated that crosslinking CD13 on immune cells positively modulates phagocytosis,352 making 
APN an attractive target for both transcytosis and immune stimulation.  
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2.4.2 Strategies to conjugate antibodies to particles 
A great challenge in the development of oral delivery systems is providing target specificity to the 
particles.353 Targeting oral delivery systems to intestinal transcytotic receptors allows the particles to 
cross epithelial particles in order to maximally reach the mucosal immune cells, thereby reducing 
vaccination doses and any potential side effects.264, 354 One classical approach for active targeting is 
mediated by antibodies specific for the target.355 Conjugation of antibodies to particles offers great 
opportunities: they have the ability to bind to their target with high affinity and can improve cell 
penetration.353, 356 Decoration of particles with antibodies has already been demonstrated as a 
feasible approach for an increased internalisation of particles by intestinal epithelial cells264, 354 and 
by M cells.357-359 Antibody conjugation methods for the formation of targeted particles should be 
efficient, reproducible, stable and non-toxic, yielding an oriented antibody binding. Here, we 
describe different strategies to conjugate antibodies (Abs) to nano- or microparticles. 
 A              B       C    
      1       2                3         1               2       3 
 
 
 
 
Figure 12. Schematic representation of different strategies for functionalisation of particles with antibodies. 
A) Electrostatic adsorption of antibodies to negatively charged particles. B1) Carbodiimide coupling method: 
covalent binding via primary amines on the antibodies and carboxylgroup on the particles. B2) AminoLink 
method: covalent binding via carbohydrate groups on the antibodies. B3) Thiolation of antibodies: reduction of 
disulfide groups in the hinge region of the antibodies. These sulfhydryl groups will react with thiol reactive 
groups on the particles. C) Use of adapter biomolecules: streptavidin-biotin (1), his-tag (2) and protein G (3). 
The first method to conjugate antibodies to particles is by physical adsorption. Physical adsorption is 
generally based on hydrophobic, electrostatic, hydrogen bonding and van der Waals attractive forces 
between the antibody and the surface of the particle (Figure 12A). However, decoration of 
antibodies to particles by physical adsorption results in a weak, unstable and/or pH-dependent 
attachment.355, 360 
Attachment of antibodies via covalent coupling is more attractive than physical adsorption due to its 
strong binding. However, this coupling method is more complex, since the conjugation requires the 
introduction of functional groups on the particle surface, use of chemical linkers and/or chemical 
modification of the antibodies.355 Most covalent coupling methods use one of the following targets: 
1) primary amines (NH2), 2) carbohydrates or 3) sulfhydryl groups (-SH) on the antibody. 
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The first techniques (carbodiimide method) allows the direct reaction of the particles (containing 
amino-reactive groups) with primary amines (NH2) available on the antibody surface (Figure 12B1). 
However, this coupling method results in randomly oriented Abs on the particle surface. Moreover, 
the high reactivity of all the aminebinding linkers makes them very unstable at alkaline pH values, 
thus the coupling reaction must be carried out under mild pH values. The most reactive amino group 
on the antibody under mild pH conditions is the terminal amino group, which is near to the antigen 
recognition place. Consequently, most of the Ab molecules would adopt “head-on” and “sideways-
on” spatial orientations. This causes the loss of antigen binding capacity due to direct binding of the 
antigen-binding site or steric hindrance by the particle surface.355, 361 
Using the carbohydrates of the Abs to covalently conjugate them to particles results in an oriented 
immobilisation (Figure 12B2). Therefore, the carbohydrate chains of the antibodies (located in the Fc 
fragment) are mildly oxidated using sodium periodate to create reactive aldehydes for coupling. 
Then, these aldehyde groups form stable secondary amine bonds with primary amines (-NH2) present 
on the particles, followed by stabilisation of these bonds with a mild reductant.355 However, some 
antibodies are not glycosylated (like hybridoma’s) or are glycosylated near the antigen binding 
area.361 In addition, the highly toxic sodium cyanoborohydride is routinely used for the reduction of 
the Schiff’s base to a covalent bond, making this method unfavourable as a standard process for 
targeted oral vaccines. 
Another common reactive group on antibodies are the thiol residues (carbon-bonded sulhydryl (-SH) 
group, derived from the amino acid cystine and cysteine) (Figure 12B3). Unfortunately, in antibodies 
these sulfhydryl groups (-SH) are oxidised as disulfide bonds (S-S), which covalently connect the 
heavy and light chains and the two antibody halves at the hinge region.355 Since only free sulfhydryls 
(-SH) can be conjugated directly with thiol-reactive groups, these groups have to be created 
(thiolation reagent system) or generated (reduction of disulfide groups). Reduction of these disulfide 
bonds with a reagent such as dithiothreitol (DTT) or 2-mercaptoethylamine is a common method to 
generate free thiol groups. Disulfides in the hinge region are the most susceptible to reduction, 
which will split the chain linkage of these antibodies into two monovalent immunoglobulin fragments 
without altering the 3D structure and antigen-binding site.355, 362 Now, the antibody fragments can be 
crosslinked to particles with thiol reactive groups on their surface (such as maleimide and 
iodoacetyl).361 
Conjugation of antibodies to particles can also be accomplished using adapter biomolecules. These 
molecules are directly coupled to the particle surface. There are several options described in the 
literature: biotin binding proteins (avidin, streptavidin), genetically engineered Abs with terminal 
linker-peptide residues, proteins that specifically bind to the Fc region (Protein A or G) and nucleic 
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acid-mediated hybridisation.355 For oral administration, conjugation of antibodies to particles via 
nucleic acids is unsuitable, since high levels of DNase I are present in the digestive tissue.363, 364 When 
using the adaptor molecules avidin or streptavidin, the antibodies first need to be modified with 
biotin and the surface of the particles need to be functionalised with (strept)avidin (Figure 12C1). 
This technique is among the most rapid and strongest non-covalent interactions known, making the 
(strept)avidin-biotin complex very resistant to a wide range of pH values, elevated temperatures, and 
harsh chemical conditions. However, biotinylation of antibodies is required, which only can be 
obtained by covalent coupling.355 Likewise, modification of antibodies is also required when using 
terminal linker-peptide residues, such as his-tags (Figure 12C2). The antibodies first have to be 
genetically engineered with these additional peptide residues, before conjugation to 
microspheres.355 In contrast, the antibodies do not require any modification when using Fc-binding 
proteins to conjugate antibodies to particles. Only the particles need to be modified with Fc-binding 
proteins (Figure 12C2). Since these proteins contain several IgG binding sites per molecule, randomly 
covalent binding of Fc-binding proteins to the particles does not represent a problem.355 Protein A 
and G are bacterial cell wall proteins that specifically bind the Fc region of the immunoglobulin and 
therefore provide proper orientation of the bound antibody.355, 365 These proteins bind exclusively 
the IgG class of the antibodies, but differ in IgG subclasses specificity and are species-dependent. 
Protein A is generally preferred for rabbit, pig, dog and cat IgG, while protein G shows a broader 
binding activity to Abs of different species as well as to different isotypes.355 Nowadays, recombinant 
forms of these proteins, which lack the albumin and cell surface binding domains, which are present 
in their native forms, are commonly used.355 
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AIMS OF THE STUDY   
Enterotoxigenic E. coli (ETEC) are an important cause of neonatal and post-weaning diarrhoea in 
piglets, resulting in severe economic losses in swine husbandry.3 Antibiotics are commonly used to 
control these diseases instead of prevention with immunomodulators or vaccination.9, 10 The ongoing 
debate on the use of antibiotics has increased the search for alternatives, especially natural bioactive 
materials capable of maintaining animal health and improving growth performance.180 One of the 
promising alternatives for antibotics are β-glucans. Despite the fact that orally administered β-
glucans are already used as immunomodulatory agents in humans and animals, their mechanism of 
action is still unclear.14 Recognition of β-glucans is mediated by specific cell surface receptors, 
however, many discrepancies are found in the literature about the most important β-glucan receptor 
and signalling molecules involved in their biological activities. In this dissertation, we examined the 
involvement of the β-glucan receptors dectin-1 and complement receptor 3 (CR3) and their signalling 
pathways in the β-glucan-mediated activation of porcine innate immune cells. 
Besides the use of immunomodulators, active oral vaccination against these ETEC infections is an 
appealing approach to prevent an outbreak. Commercial oral vaccines mainly use live-attenuated 
microorganisms, however, the identification of adverse risks associated with the use of these 
vaccines has intensified the search for recombinant oral subunit vaccines. Unfortunately, these types 
of vaccines have to combat a number of obstacles to induce immunity after oral delivery, such as the 
harsh environment in the gastrointestinal tract, oral tolerance and the epithelial barrier. 
Encapsulation of antigens in immune-stimulating particles combined with targeting to apical 
endocytotic receptors located on intestinal epithelial cells seems to be an attractive approach to 
successfully design oral vaccines. The aim of this part of the thesis was to investigate if β-glucan 
particles could be used as an antigen delivery vehicle, without impeding their immunomodulating 
character. In addition, we determined if APN could be used as target for delivery of antigens to the 
gut-associated immune system. 
The following questions were addressed: 
1. Which is the most important β-glucan receptor in porcine neutrophils and macrophages? 
Which signalling molecules are involved in β-glucan-mediated ROS production and cytokine 
production? 
2. Could the adhesin of F18 fimbriae (FedF) be loaded efficiently and intact inside the β-glucan 
microparticles? Do these loaded particles still possess immunostimulatory effects? Which 
receptor is involved in the particle-mediated ROS production in porcine neutrophils? 
3. Could β-glucan microparticles be efficiently decorated with monoclonal antibodies? Does 
APN-targeting result in an increased transcytosis through the epithelial barrier? Does APN-
targeting trigger an elevated immune response in porcine dendritic cells and in pigs in vivo? 
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3.1 Abstract 
β-glucans exert receptor-mediated immunomodulating activities, including oxidative burst activity 
and cytokine secretion. The role of the β-glucan receptors dectin-1 and complement receptor 3 (CR3) 
in the response of immune cells towards β-glucans is still unresolved. Dectin-1 is considered as the 
main β-glucan receptor in mice, while recent studies in man show that CR3 is more important in β-
glucan-mediated responses. This incited us to elucidate which receptor contributes to the response 
of innate immune cells towards particulate β-glucans in pigs as the latter might serve as a better 
model for man. Our results show an important role of CR3 in β-glucan recognition, as blocking this 
receptor strongly reduced the phagocytosis of β-glucans and the β-glucan-induced ROS production 
by porcine neutrophils. Conversely, dectin-1 does not seem to play a major role in β-glucan 
recognition in neutrophils. However, recognition of β-glucans appeared cell type-specific as both 
dectin-1 and CR3 are involved in the β-glucan-mediated responses in pig macrophages. Moreover, 
CR3 signalling through focal adhesion kinase (FAK) was indispensable for β-glucan-mediated ROS 
production and cytokine production in neutrophils and macrophages, while the Syk-dependent 
pathway was only partly involved in these responses. We may conclude that CR3 plays a cardinal role 
in β-glucan signalling in porcine neutrophils, while macrophages use a more diverse receptor array to 
detect and respond towards β-glucans. Nonetheless, FAK acts as a master switch that regulates β-
glucan-mediated responses in neutrophils as well as macrophages. 
 
3.2 Introduction 
β-glucans exert immunomodulatory effects upon oral and i.v. administration.366, 367 These glucose 
polymers can be derived from several sources, such as fungi, yeast, some bacteria, seaweeds and 
cereals.41 In seaweeds, they serve as storage carbohydrates, while in bacteria, fungi, yeast and 
cereals, such as oat and barley, they play a role as structural frame and define cellular shape and 
rigidity.42 The oat and barley cell walls contain unbranched β-glucans with 1,3- and 1,4-β-linked 
glucopyranosyl residues, whereas β-glucans from bacterial origin and some algae are unbranched 
1,3-β-linked glucopyranosyl residues.43, 368 In contrast, cell wall β-glucans of yeast, fungi and β-
glucans produced by some algae consist of 1,3-β-linked glucopyranosyl residues with small numbers 
of 1,6-β-linked branches. Both the frequency and length of these branches differ depending on the 
source. 
β-glucans are recognised as microorganism-associated molecular patterns (MAMPs) by immune cells 
via several pattern recognition receptors, including dectin-1, complement receptor 3 (CR3), 
lactosylceramide and scavenger receptors.369 Receptor activation results in an enhanced production 
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of pro-inflammatory cytokines, chemokines and reactive oxygen species by innate immune cells in 
several species.74, 75, 137, 183, 187, 370 Dectin-1 has been recognised as the most important receptor for β-
glucans in mice and consequently most studies have focused on the function of dectin-1 in the 
immunomodulating effect of β-glucans.75 This receptor is expressed by dendritic cells (DCs), 
neutrophils, monocytes and macrophages.79-82, 371 The intracellular domain of this receptor contains a 
hemi-immunoreceptor tyrosine-based activation motif (hemITAM), probably indicating the need for 
receptor dimerisation to properly activate signalling pathways. Dually phoshorylated ITAMs serve as 
docking site for spleen tyrosine kinase (Syk), a key player in the activation of immune cells.96-98 
Recently, several studies have questioned the role of dectin-1 in β-glucan recognition.157, 161 Indeed, 
dectin-1 was not involved in triggering inflammatory responses to zymosan in mice.157 Likewise, 
although neutrophils in man express dectin-1, phagocytosis of β-glucans and β-glucan-mediated ROS 
production is here completely dependent on CR3.372 Interestingly, Bose et al.156 demonstrated that 
human monocytes use distinct receptors (dectin-1 and CR3) for oxidative burst in response to 
different physical forms of β-glucans. CR3, a β2-integrin, is usually associated with complement 
function, but recognises an array of various ligands. The ability of CR3 to bind diverse ligands is 
mainly attributed to a consensus binding site within its CD11b subunit.373 The carbohydrate binding 
domain is however spatially separated from this consensus binding domain.374-377 Upon ligand 
recognition, the cytoplasmic domain of CR3 interacts with kinases, such as focal adhesion kinase 
(FAK), regulating the interaction between cells and the extracellular matrix and controlling several 
integrin-dependent processes.129, 378, 379 In pigs, dectin-1 and CR3 are expressed on immune cells, 
including neutrophils, monocytes, macrophages and DCs.83 The α subunit (CD11b) of CR3 is not yet 
identified, but two candidate molecules, namely CD11R1 and CD11R3, have been described.124 Both 
CD11R1 and CD11R3 dimerise with the β2 chain CD18, but their role in complement or β-glucan 
recognition is still unclear.124 
The involvement of dectin-1 and CR3 in mediating the biological activities of particulate β-glucans 
remains largely unresolved, but seems to be cell type-specific, structure-related and species-
dependent.76, 156, 161, 165, 372 Here, we investigate the role of these receptors in immunomodulating 
innate immune cells by different particulate β-glucans in order to elucidate the mechanism of β-
glucan recognition and signalling in pigs.  
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3.3 Materials and Methods 
3.3.1 β-glucans 
Six different β-glucans were used to stimulate porcine innate immune cells (Table 1). Curdlan, 
zymosan and β-glucans purified from Saccharomyces cerevisiae and Euglena gracilis were purchased 
from Sigma (Diegem, Belgium). Scleroglucan and Macrogard were kindly provided by INVE 
(Dendermonde, Belgium) and Biotec Pharmacon ASA (Tromsø, Norway), respectively. A description 
and comparison of the carbohydrate structures as well as the preparation and storage of these β-
glucans was previously published.380 The endotoxin concentration present in each β-glucan 
preparation was determined by the Chromogenic Limulus Amebocyte Lysate (LAL) test (Cambrex Bio 
Science Walkersville, Inc., Wiesbaden, Germany) and with exception of curdlan (47 endotoxin 
units/µg β-glucan), these levels were consistently lower than 0.5 endotoxin units/µg β-glucan. 
Laminarin was kindly provided by INVE (Dendermonde, Belgium). Depleted zymosan was purchased 
from Invivogen (Toulouse, France). 
 
Table 1. Overview of the origin, solubility, structure and molecular weight (MW) of different β-glucans. 
Origin β-glucan name Solubility Structure MW References 
Laminaria 
digitata 
Laminarin Soluble β-1,3 with some β-1,6-branching (30:1).  
The β-1,6 side chains are composed of 2 
glucose units 
7.7  
46-48
 
    
Saccharomyces 
cerevisiae  
Macrogard® Particulate β-1,3/1,6-branched (10:1 or 20:1). The β-1,6 
side chains are composed of 2 or 3 glucose-
units 
unknown 20, 49 
 Zymosan Particulate Crude extract with β-glucans, mannan and 
proteins; non-uniform branches and 
backbone units. β-1,3/1,6-branched 
<200 50-52 
 Glucans from 
Saccharomyces 
cerevisiae 
Particulate β-1,3/1,6-branched (30:1) 200 53 
Euglena 
gracilis 
Glucans from 
Euglena gracilis 
Particulate β-1,3-unbranched 500 53, 54 
   
β-1,3/1,6-branched (6:1). The β-1,6 side 
chains are composed of 2 glucose units 
  
Sclerotium 
rolfsii 
Scleroglucan Soluble 1020 53, 54 
      
Alcaligenes 
faecalis 
Curdlan Particulate β-1,3-unbranched 100 55, 56 
 
3.3.2 Isolation of porcine PBMCs and neutrophils  
Pigs (between 4 and 23 weeks old) were housed under standard conditions as blood donors. All 
animal experiments were approved by the animal care and ethics committee of the Faculty of 
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Veterinary Medicine, Ghent University (grant nr: EC2008/79). Peripheral blood (10 ml) was collected 
on heparin (100 µl) from the jugular vein. Subsequently, peripheral blood monomorphonuclear cells 
(PBMCs) and neutrophils were isolated as previously described by density gradient centrifugation on 
Lymphoprep (NYCOMED Pharma AS, Life Technologies, Merelbeke, Belgium) or a discontinuous 
Percoll gradient (68% and 75%) (GE healthcare, Diegem, Belgium), respectively.380 
 
3.3.3 Generation of monocyte-derived macrophages  
Monocyte-derived macrophages (MDM) were generated from blood-derived monocytes, which were 
enriched from the PBMC fraction to a purity of >95% by positive immunomagnetic bead selection 
(MACS; Miltenyi Biotec, Leiden, The Netherlands) using the CD172a-specific monoclonal antibody 
(clone 74-12-15a). These cells were seeded in a 96-well plate at a density of 2 x 105 cells/well in MDM 
medium (DMEM (Gibco, Merelbeke, Belgium) supplemented with 10% (v/v) fetal calf serum (FCS, 
Greiner, Wemmel, Belgium), 100 IU/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco) and 
recombinant human M-CSF (3 ng/ml; R&D systems, Abingdon, UK). After three days incubation (37°C, 
90% humidity, 5% CO2) fresh MDM medium was added to obtain monocyte-derived macrophages at 
day 7-8. 
 
3.3.4 β-glucan-induced PBMC proliferation 
To examine if dectin-1 is involved in the β-glucan-induced PBMC proliferation in pigs, PBMCs were 
seeded in a 96-well plate at 5.0 x 105 cells/well (100 µl/well) in leukocyte medium (RPMI-1640 
containing FCS (10%), non-essential amino acids (1%), sodium-pyruvate (100 µg/ml), L-glutamine 
(292 µg/ml), penicillin (100 IU/ml), streptomycin (100 µg/ml) and kanamycin (100 µg/ml)) 
supplemented with β-mercapto-ethanol (50 µM). To block dectin-1, laminarin (1 mg/ml) was added 
to the cells (1h). Subsequently, different concentrations of the six β-glucans (800, 200, 50 and 5 
µg/ml) were added. As a positive control the cells were treated with 1 µg/ml concanavalin A (ConA, 
Sigma-Aldrich, Diegem, Belgium), while medium served as a negative control. The cells were 
incubated for 72h at 37°C in a humidified atmosphere with 5% CO2. Next, the cells were pulse-
labeled with 1 µCi of [H3]-methyl-thymidine (Amersham ICN, Bucks, UK) per well for 18h at 37°C and 
5% CO2, harvested onto glass fiber filters and measured incorporated radioactivity with a β 
scintillation counter (PerkinElmer, Life Science, Merelbeke, Belgium). Each stimulation was 
performed in duplicate and the results are presented as counts per minute (cpm). 
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3.3.5 β-glucan receptor inhibitors  
To inhibit dectin-1 or CR3, cells were pre-incubated with the inhibitors in the CO2 incubator at 37°C 
before exposure to the β-glucans. To inhibit dectin-1, laminarin was added to the cells. To inhibit 
CR3-mediated responses, monoclonal antibodies (mAbs; mouse IgG1 isotypes) against CD18, CD11R1 
and CD11R3 (AbD Serotec, Kidlington, UK) were added. These antibodies were dialysed against PBS 
to remove sodium azide. An isotype-matched mAb control (IgG1) was added to the cells to measure 
background inhibition.  
 
3.3.6 Signalling pathway inhibitors  
To inhibit the signalling pathway of dectin-1 or CR3, cells were pre-incubated with the inhibitors 
before exposure to the β-glucans. Dectin-1-mediated responses (Syk) were blocked with R406 
(Selleckchem, Huissen, The Netherlands), whereas PF 573228 (Tocris Biosciences, Bristol, UK) should 
disrupt the CR3 signalling pathway (FAK). The efficacy of the Syk signalling pathway inhibitor (R406) 
in pigs was investigated by stimulating neutrophils with plate-bound IgG to activate FcγR signalling. 
Briefly, F4 fimbriae (5 µg/ml) were coated on a 96-well plate (2h at 37°C), unbound sites were 
blocked by 3% BSA in PBS and F4 fimbriae-specific porcine IgG antibodies (10 µg/ml) were added to 
the F4 fimbriae for 1h at 37°C. Subsequently, neutrophils (2 x 105 cells/well) pre-incubated with 
different concentrations of R406 (0, 0.1, 1, 5, 10, 50, 100 or 200 µM) were added to this plate-bound 
IgG, and the production of reactive oxygen species (ROS) was measured. 
 
3.3.7 Oxidative burst assay 
To analyse the role of dectin-1 and CR3 in the β-glucan-induced oxidative burst by porcine 
neutrophils, monocytes or monocyte-derived macrophages, ROS was measured using a 
chemiluminescence assay as described by Donne et al.381 with some modifications. Neutrophils or 
monocyte-derived macrophages were seeded in a 96-well plate at 2.0 x 105 cells/well, while PBMCs 
were seeded at a concentration of 2.0 x 106 cells/well. The plates were incubated at 37°C for 2h in a 
humidified atmosphere with 5% CO2 to allow the cells to adhere to the plastic surface. Then, the cells 
were pre-treated with the β-glucan receptor inhibitors (3.3.5) or signalling pathway inhibitors (3.3.6) 
for 1 hour at 37°C. Subsequently, luminol was added to the cells (0.5 mM diluted in HBSS + Ca2+ Mg2+) 
and, after 5 minutes of background measurement at 37°C, 25 µl of the β-glucan preparations were 
added. Stimulation of the cells with phorbol myristate acetate (PMA; 50 µg/ml) was used as a 
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positive control. ROS production was then measured during 120 min in the integration mode. Each 
stimulation was performed in duplicate. ROS production is expressed as relative light units (RLU). 
 
3.3.8 Phagocytosis assay 
Neutrophils or monocyte-derived macrophages were seeded in a 96-well plate or 24-well plate (2.0 x 
105 cells/well), respectively, and incubated at 37°C in a humidified atmosphere with 5% CO2. To 
investigate which receptor plays a role in the phagocytosis of β-glucans by neutrophils or 
macrophages, the cells were pre-treated with the β-glucan receptor inhibitors (3.3.5) for 30 minutes 
at 37°C to allow binding of laminarin or the mAbs to their specific receptor. Subsequently, Alexa Fluor 
488-conjugated zymosan particles (Invitrogen, Gent, Belgium) were added for 1 hour to the cells. 
Excess particles were removed by repeated washing in cold PBS. Adherent cells were recovered by 
treatment with Accutase (Invitrogen) for 15 min at 37°C. The number of cells demonstrating green 
fluorescence was determined on a FACSCanto (BD Biosciences, Erembodegem, Belgium) and FACS 
analysis was performed on 10,000 events with FACSDiva software 6.1.3 (doublet discrimination). 
 
3.3.9 Isolation of CD11R1 positive and negative populations 
In pigs, CD18 dimerises with either CD11R1 or CD11R3, which differ in their expression pattern and 
molecular weight.124 CD11R1 is present on approximately 50% of all porcine neutrophils and not on 
monocytes and macrophages, whereas CD11R3 is expressed on all neutrophils, monocytes and 
macrophages. Although the expression pattern of CD11R3 correlates with the human CD11b, CD11R3 
is not recognised by human CD11b mAbs. In contrast, human CD11b mAbs cross-react with CD11R1, 
which has the same molecular weight as CD11b.124, 382 To investigate whether CD11R1 is important in 
β-glucan recognition by neutrophils, and thus serves as the α subunit of CR3, CD11R1+ and CD11R1- 
cells were FACS-sorted (FACSAria III Cell sorter; BD Biosciences; purity CD11R1+: = 99.3% ± 0.5 and 
CD11R1- = 98.7% ± 1.07) and stimulated with β-glucans for ROS production. 
 
3.3.10 Cytokine ELISA 
Neutrophils or monocyte-derived macrophages were seeded in a 96-well plate (2.0 x 105 cells/well) 
in leukocyte or MDM medium, respectively, and incubated at 37°C in a humidified atmosphere with 
5% CO2. First, different β-glucan receptor inhibitors (3.3.5) or signalling pathway inhibitors (3.3.6) at 
the indicated concentrations were added to the cells for 1h, followed by stimulation with 200 µg/ml 
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zymosan, Macrogard or Euglena gracilis for another 16h. Thereafter, culture supernatant was 
collected and the TNFα, IL-8 and IL-1β cytokine concentrations were determined in porcine-specific 
ELISAs (R&D systems). The viability of the cells was examined by propidium iodide (PI) staining and 
measured by flow cytometry (FACSCanto).  
 
3.3.11 siRNA-mediated dectin-1 silencing in monocyte-derived macrophages 
Monocyte-derived macrophages were seeded in a 96-well plate (2 x 105 cells/well) and incubated at 
37°C. The culture medium was replaced 60 minutes before transfection. Dectin-1 was knocked down 
by a mix of two siRNAs (Sigma); the sequence of the target site for siRNA1 is 5’-
GCATGTGTCTTCCCAACCT-3’ and for siRNA3 5’-CTAACTGGATCACACATGA-3’ (Figure 1). Macrophages 
were transfected with siRNA (50 nM) using the GenMute siRNA transfection Reagent for Primary 
Macrophages (Signagen, Kampenhout, Belgium) according to the manufacturer's instructions. Gene 
silencing was measured 48 hours post transfection by qPCR. Briefly, total RNA was isolated from the 
cells using TRIzol (Invitrogen) and was reverse transcribed into cDNA using the iScript cDNA synthesis 
kit (Biorad, Temse, Belgium). The resulting cDNA served as a template for the qPCR assay 
(StepOnePlusTM system, Applied Biosystems). The primers (IDT) used for detection of dectin-1 
(accession number: FJ386383) were 5’-TGCTCTCAACTGGGTTCTTATC-3’ (sense) and 5’-
CTTCAGTCTGGCTGTGAGAAA-3’ (antisense). The qPCR reaction mix consisted of the SYBR Green PCR 
Master Mix (Applied Biosystems), 0.5 µM of each sense and antisense primer and cDNA. The cycle 
conditions were 1 cycle of 10 min at 95°C and 40 cycles of 15s at 95°C, 30s at the annealing 
temperature (60°C), and 30s at 72°C. Relative expression levels (Rq) were determined from the 
quantification cycle (Cq) values applying the qBase+ software from Biogazelle. Eight reference genes 
(ACTB, GAPDH, RPL19, CYPA, B2M, HPRT1, YWHAZ and SDHA; Table 2) were investigated on 12 
samples of porcine macrophages. Based on geNorm analysis, two most stable reference genes (CYPA 
and RPL19) were identified and used for normalisation of qPCR data. Subsequently, the transfected 
cells were stimulated with β-glucans and after 16h the cytokine secretion (TNFα and IL-1β) was 
determined by porcine-specific ELISAs (R&D systems). The viability of the cells and CR3 expression 
was examined by flow cytometry (FACSCanto). 
Figure 1: Schematic illustration of the dectin-1 gene.  
Dectin-1 consist of an N-terminal cytoplasmatic tail 
(Cyto), encoded by exon 1, a transmembrane region 
(TM; exon 2), a stalk region (exon 3), and the 
carbohydrate recognition domain (CRD; exon 4–6). 
Dectin-1 is silenced by adding siRNA 1 and 3 to the 
cells. Silencing efficiency (60.74% ± 6.03 dectin-1 
reduction) was determined by qPCR. The primers 
locations are indicated. 
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Table 2. Primer sequences, amplicons length, annealing temperature, concentration and reference GenBank 
accession numbers of investigated porcine genes. 
 
3.3.12 Statistics 
Data are presented as the mean ± SEM. Data were analysed with GraphPad Prism 5 using a Friedman 
test (Post hoc: Dunn) to compare conditions with or without laminarin and each inhibitor with its 
isotype-matched control or control cells. Data were considered significant at p < 0.05. 
 
  
Gene 
symbol 
 
Gene name 
Primer sequence  (5’            3’) 
 
Amplicon 
length 
(bp) 
Annealing 
tempera-
ture 
(°C) 
Concen-
tration 
(µM) 
GenBank: 
accession  
number 
Refe-
rence 
ACTB β-actin 
F：TCA TCA CCA TCG GCA ACG 
R：TTC CTG ATG TCC ACG TCG C 
133 60 
 
0.3 
 
DQ178122 383 
GAPDH 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
F：GGG CAT GAA CCA TGA GAA GT 
R：AAG CAG GGA TGA TGT TCT GG 
230 60 
 
0.2 
 
DQ178124 
384
 
RPL19 
 
Ribosomal protein 
L19 
 
F：AAC TCC CGT CAG CAG ATC C 
R：AGT ACC CTT CCG CTT ACC G 
 
147 60 
 
0.2 
 
XM_0031315
09 
 
385
 
CYPA 
 
Cyclophilin A 
F：TAA CCC CAC CGT CTT CTT 
R：TGC CAT CCA ACC ACT CAG 
 
368 57 
 
0.2  
 
JX523419 
 
384
 
B2M 
 
β-microglobulin 
F： AAA CGG AAA GCC AAA TTA CC 
R： ATC CAC AGC GTT AGG AGT GA 
 
178 60 
 
0.1  
 
DQ178123 386 
HPRT1 
Hypoxantine 
phosphoribosyl-
transferase I 
F： CCG AGG ATT TGG AAA AGG T 
R： CTA TTT CTG TTC AGT GCT TTG ATG T 
181 60 
 
0.1 
 
DQ178126 
386
 
YWHAZ 
Tyrosine 3-
monooxygenase/ 
tryptophan 5-
monooxygenase 
activation protein 
F： ATG CAA CCA ACA CAT CCT ATC 
R： GCA TTA TTA GCG TGC TGT CTT 
 
178 60 
 
0.1  
 
DQ178130 
386
 
SDHA 
Succinate 
dehydrogenase 
complex, subunit A 
F： GAA CCG AAG ATG GCA AGA 
R： CAG GAG ATC CAA GGC AAA 
191 58 
 
0.1 
 
DQ178128 
386
 
 
 
Dectin-1 
 
 
Dendritic cell-
associated C-type 
lectin 1 
F： TGC TCT CAA CTG GGT TCT TAT C 
R： CTT CAG TCT GGC TGT GAG AAA  
127 60 
 
0.5 
 
FJ386383 
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3.4 Results 
3.4.1 β-glucan-induced PBMC proliferation and ROS production is not solely dependent on 
dectin-1 
Previously, we observed a dose-dependent β-glucan-induced PBMC proliferation.380 Moreover, the 
extent of this proliferation seemed to be dependent on the β-glucan structure. In an effort to study if 
dectin-1 is involved in β-glucan signalling, we added six different β-glucans to PBMCs upon blocking 
dectin-1 via laminarin. The β-glucan-induced PBMC proliferation was not significantly different 
between laminarin pretreated and control cells (Figure 2). However, in the presence of laminarin the 
lymphocyte proliferation induced by scleroglucan, curdlan and zymosan at all assayed concentrations 
was decreased. In addition, at 200 µg/ml laminarin also reduced the lymphocyte proliferation upon 
stimulation with all β-glucan preparations. Together this implies that dectin-1 is only partially 
involved in the β-glucan-induced lymphocyte proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Dectin-1 is not involved in the β-glucan-induced PBMC proliferation.  
PBMCs (5 x 10
5
 cells) were incubated simultaneously with laminarin (1 mg/ml) and different concentrations of 
the indicated β-glucans. Data are shown as the mean counts per minute (cpm) ± SEM of four pigs.  
 
To investigate the potential role of dectin-1 in the β-glucan-induced ROS production by porcine 
innate immune cells, monocytes and neutrophils were incubated with laminarin to block dectin-1 
800 µg/ml 200 µg/ml 
50 µg/ml 5 µg/ml 
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prior to β-glucans stimulation. Remarkably, scleroglucan and curdlan were unable to trigger ROS 
production by monocytes and neutrophils as opposed to the other β-glucans, which elicited a dose-
dependent oxidative burst response (Figure 3). Dectin-1 blocking with laminarin failed to inhibit the 
β-glucan-induced ROS production even at a 4-fold lower β-glucan concentration, implying that 
dectin-1 is not involved in the respiratory burst response of neutrophils and monocytes to different 
β-glucans.  
 
 A 
 
 
B 
 
 
 
Figure 3. Dectin-1 is not involved in the β-glucan-induced ROS production by porcine neutrophils and 
monocytes.  
Neutrophils (2 x 10
5
 cells) (A) or monocytes (2 x 10
6
 cells) (B) were pre-incubated with laminarin (1 mg/ml), 
after which the cells were stimulated with 400 and 100 µg/ml of the indicated β-glucan preparations. ROS 
production was determined via chemiluminescence. Data are shown as the mean relative light units (RLU) ± 
SEM of four pigs. 
 
3.4.2 Receptor usage in zymosan phagocytosis is cell type-specific 
Surprisingly, we could not establish a clear role for dectin-1 in the recognition of β-glucans by porcine 
innate immune cells. This motivated us to investigate if other β-glucan receptors, such as CR3, are 
involved in the phagocytosis of β-glucans by porcine monocytes and neutrophils. To examine which 
receptor is involved in the phagocytosis of β-glucans, dectin-1 and CR3 were blocked. In the presence 
of laminarin zymosan is still phagocytosed by neutrophils (Figure 4A), while the uptake of zymosan by 
macrophages was inhibited with 48.5% ± 11.4 by laminarin (Figure 4B). Interestingly, the 
phagocytosis of zymosan by neutrophils is diminished upon blocking the CR3 subunits CD18 and 
CD11R3, while blocking CR3 on macrophages had no influence on the phagocytosis of this β-glucan 
400 µg/ml 100 µg/ml 
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(Figure 4). Thus, neutrophils (CR3) and macrophages (dectin-1) use different receptors to 
phagocytose zymosan.  
A     B 
 
 
 
 
Figure 4. CR3 is involved in the phagocytosis of zymosan in porcine neutrophils, while dectin-1 is involved in 
the phagocytosis of zymosan in porcine macrophages.  
(A) Neutrophils (2 x 10
5
 cells) were incubated with 200 µg laminarin, 1.45 µg aCD18, 0.15 µg aCD11R1, 5 µg 
aCD11R3 or 5 µg isotype control (IgG1). Subsequently, the cells were stimulated with fluorescent 200 µg/ml 
zymosan. Phagocytosis was determined via flow cytometry. Data are shown as the phagocytic index (% of mock 
or isotype control) of the mean fluorescence intensity ± SEM of six pigs. (B) Macrophages (2 x 10
5
 cells) were 
incubated with 200 µg laminarin, 1.45 µg aCD18, 5 µg aCD11R3 or 5 µg isotype control (IgG1). Subsequently, 
the cells were stimulated with fluorescent 5 µg/ml zymosan. Phagocytosis was determined via flow cytometry. 
Data are shown as the phagocytic index (% of mock or isotype control) of the mean fluorescence intensity ± 
SEM of four pigs. *: p < 0.05. 
 
3.4.3 CR3 is critically involved in the β-glucan-induced ROS production by neutrophils  
The results from the phagocytosis assay imply a role for CR3 in the β-glucan recognition by porcine 
neutrophils. Interestingly, blocking CD11R1 could not influence the phagocytosis of zymosan, while 
blocking CD11R3 diminished the uptake of zymosan by neutrophils (Figure 4A). This implies that 
CD11R3 has a carbohydrate binding domain, similar to its human CD11b counterpart, while CD11R1 
is not involved in the recognition of β-glucans. To further explore this hypothesis, the role of CD11R1 
in β-glucan signalling was examined. As CD11R1 is only present on 50% of porcine neutrophils, 
CD11R1+ and CD11R1- neutrophils were FACS-purified. Subsequently, these neutrophil populations 
were stimulated with three different β-glucans (200 µg/ml zymosan, Macrogard and Euglena 
gracilis), since these particular β-glucans displayed high responses (Figure 2 and 3). The ROS 
production upon β-glucan stimulation did not differ between these neutrophil subsets (Figure 5A), 
confirming that CD11R1 is not involved in the response of porcine neutrophils towards β-glucans.  
Figure 5A. CD11R1 is not involved in the recognition of β-
glucans by neutrophils 
Neutrophils were FACS-purified into CD11R1-positive 
(purity: 99.3% ± 0.5) and CD11R1-negative (purity: 98.7% ± 
1.07) populations. Subsequently, the cells (2 x 10
5
 cells) 
were stimulated with 200 µg/ml of the indicated β-glucan 
preparations. ROS production was determined via 
chemiluminescence. Data are shown as the mean relative 
light units (RLU) ± SEM of three pigs. 
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We further investigated whether CD11R3 is involved in the β-glucan-induced activation of porcine 
neutrophils. As shown in Figure 5B, the zymosan-induced ROS production by neutrophils was 
completely inhibited in the presence of anti-CD11R3 as compared to its isotype-matched control. 
Likewise, antibodies against CD18 decreased the ROS production, albeit not significantly. In contrast 
to CR3, the respiratory burst towards all three β-glucans was only slightly affected by inhibiting 
dectin-1, confirming our previous results. For the β-glucans Macrogard and Euglena gracilis, the 
ability of CD18-specific mAbs to block ROS production by porcine neutrophils was negligible, while 
blocking CD11R3 induced a reduction in this oxidative burst response.  
 
 
 
 
Figure 5B. CR3 is critically involved in the recognition of β-glucans by neutrophils.  
Neutrophils (2 x 10
5
 cells) were incubated with laminarin (1 mg/ml), aCD18 (5 µg/ml), aCD11R3 (15 µg/ml) or 
isotype control (IgG1; 15 µg/ml). Subsequently, the cells were stimulated with 200 µg/ml of the indicated β-
glucan preparations. ROS production was determined via chemiluminescence. Values shown are mean relative 
light units (RLU) ± SEM of four pigs. Values of the negative control have been subtracted from the values 
represented on the graph.*: p < 0.05; **: p < 0.01.  
 
3.4.4 Role of dectin-1 and CR3 in the β-glucan-induced cytokine secretion  
Besides their anti-microbial activity, innate immune cells secrete danger signals, such as pro-
inflammatory cytokines, in response to pathogens to alert the adaptive immune system. Although 
blocking of CR3 abrogated ROS production, the secretion of TNFα, IL-1β and IL-8 by β-glucan 
stimulated neutrophils was unaffected by CR3 blocking (Figure 6A). In both neutrophils and 
macrophages, blocking of dectin-1 by laminarin failed to diminish the cytokine secretion (Figure 6A 
and B). However, blocking CD11R3 results in a decreased cytokine production upon stimulation with 
zymosan and Macrogard in porcine macrophages, indicating that CR3 is significantly involved in the 
β-glucan-mediated cytokine secretion (Figure 6B). The isotype control, CD11R3 mAbs and laminarin 
did not affect the viability of the cells during our experiments. Remarkably, the cytokine response of 
neutrophils and macrophages towards Macrogard was very low compared to the other β-glucans.  
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A 
 
 
 
B 
 
 
 
Figure 6. Role of dectin-1 and CR3 in the β-glucan-mediated cytokine response in porcine innate immune 
cells. 
(A) Neutrophils (2 x 10
5
 cells) were pre-incubated (1h) with 1 mg/ml laminarin, 3 µg/ml αCD11R3 or 3 µg/ml 
isotype control. β-glucans (200 µg/ml) were then added to the cells, and after 16 hours the supernatants was 
collected. Cytokine secretion (TNFα, IL-8 or IL-1β) was assessed by ELISA. (B) Monocyte-derived marcophages 
(2 x 10
5
 cells) were pre-incubated (1h) with 1 mg/ml laminarin, 15 µg/ml αCD11R3 or 15 µg/ml isotype control. 
β-glucans (200 µg/ml) were then added to the cells, and after 16 hours the supernatants was collected. 
Cytokine secretion (IL-8, TNFα or IL-1β) was assessed by ELISA. The results illustrate the mean cytokine 
concentration ± SEM of four pigs. Values of the negative control have been subtracted from the values 
represented on the graph. Medium control values were below 22 pg/ml for TNFα, 85 pg/ml for IL-1β and 208 
pg/ml for IL-8 secretion by neutrophils, while they were below 148 pg/ml for TNFα, 128 pg/ml for IL-1β and 
4500 pg/ml for IL-8 secretion by macrophages. *: p < 0.05; **: p < 0.01. 
 
3.4.5 Dectin-1 silencing in porcine macrophages does not interfere with the β-glucan-mediated 
cytokine secretion  
To exclude the possible inability of laminarin to block porcine dectin-1, dectin-1 expression was 
reduced with 60.74% (± 6.03) compared to basal expression levels in primary macrophages by siRNA 
transfection. Furthermore, the CR3 expression (Figure 7A) and viability (Figure 7B) of the 
macrophages was unaffected by this siRNA transfection. However, dectin-1 knock down did not 
interfere with the β-glucan-induced cytokine secretion in porcine macrophages (Figure 7C), implying 
that other receptors may play a role in β-glucan signalling. Indeed, macrophages have several other 
β-glucan receptors, such as CD36 and SCARF1, which may be involved in β-glucan recognition and 
signalling.134 
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A   B   C 
 
 
 
 
 
 
 
 
Figure 7. Dectin-1 is not involved in the β-glucan-mediated cytokine response in porcine monocyte-derived 
macrophages. 
Monocyte-derived macrophages (2 x 10
5
 cells) were transfected with 50 nM dectin-1 siRNA or control siRNA for 
48h prior β-glucan stimulation (200 µg/ml). (A) Dectin-1 expression was silenced to 48.56% ± 5.39 as compared 
to basal expression levels in primary macrophages. (B) The viability of macrophages appeared unaffected by 
this siRNA transfection. (C) Cell supernatants were analysed for TNFα and IL-1β by ELISA and lysates were 
subjected to qPCR. Data represent mean cytokine concentration ± SEM of three pigs. Values of negative control 
have been subtracted from the values represented on the graph.  
 
3.4.6 The FAK signalling pathway is critically involved in the β-glucan-induced signalling in 
neutrophils and macrophages 
Engagement of integrin receptors phosphorylates FAK, while ligation of dectin-1 activates Syk.97 In 
order to define the role of Syk and FAK signalling in the β-glucan-induced signalling in porcine 
neutrophils and monocyte-derived macrophages, these two pathways were blocked by Syk and FAK 
specific inhibitors. The inhibitors did not influence CR3 expression or viability of neutrophils during 
our experiments. Remarkably, blocking the FAK signalling pathway significantly reduced the β-glucan-
induced ROS production in neutrophils and macrophages, whereas blocking the Syk signalling 
pathway only marginally reduced ROS production in both cell types (Figure 8A and B). The latter did 
not result from species-specific differences in the capacity of R406 to block Syk, as this inhibitor 
significantly inhibited the immune complex-mediated ROS production (Figure 8C), ruling out species-
specific differences in R406’s ability to inhibit Syk signalling. Furthermore, the PMA-induced ROS 
production in neutrophils was unaffected by R406 and PF 573228 treatment, while other FAK (FAK 
inhibitor 14) or Syk (piceatannol) inhibitors did interfere with the ROS production in neutrophils (data 
not shown). 
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C     D 
 
 
Figure 8. Focal adhesion kinase (FAK) is critically involved in the β-glucan signalling by porcine neutrophils 
and monocyte-derived macrophages. 
Neutrophils (2 x 10
5
 cells) (A) or monocyte-derived marcophages (2 x 10
5
 cells) (B) were pre-incubated for 1h 
with Syk (R406) or FAK (PF-573 228) inhibitors at the indicated concentrations. 200 µg/ml β-glucans 
(Macrogard, zymosan or Euglena gracilis) were then added and ROS production was measured by a 
chemiluminescence assay. The results are presented as mean relative percentage inhibition ± SEM (% 
inhibition) of at least four pigs. Values of the negative control have been subtracted from the values 
represented on the graph. (C) The efficacy of the Syk inhibitor (R406) was assessed by stimulating neutrophils 
with immune complexes in the presence of R406. The results show the mean relative percentage inhibition ± 
SEM of four pigs. *: p < 0.05; **: p < 0.01; ***: p < 0.001. (D) Neutrophils (2 x 10
5
 cells) were pre-incubated (1h) 
with the indicated concentrations of Syk (R406) or FAK (PF-573 228) inhibitors. Subsequently, the cells were 
stimulated with (depleted) zymosan. ROS production was measured by a chemiluminescence assay and the 
results are presented as mean relative percentage inhibition ± SEM (% inhibition) of four pigs.  
 
Zymosan, a crude extract consisting of β-glucans, mannans and proteins, triggers not only β-glucan-
mediated signalling pathways, but also TLR2 signalling.71, 190, 387 As such we have evaluated the 
oxidative burst towards depleted zymosan, a hot alkali treated preparation of zymosan with no TLR-
stimulating properties, by porcine neutrophils. Zymosan and depleted zymosan displayed an identical 
ROS production (Figure 7D), suggesting that only the binding of β-glucans to CR3 triggers the FAK 
signalling pathway in neutrophils, leading to an oxidative burst response. 
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3.4.7 β-glucan-induced FAK signalling controls cytokine secretion by neutrophils and 
macrophages 
In the previous cytokine assay, we could not detect a role for CR3 or dectin-1 in the β-glucan-
mediated cytokine response in neutrophils. Conversely, blocking FAK resulted in a strongly reduced 
secretion of IL-8 and IL-1β in neutrophils upon zymosan and Euglena gracilis stimulation, while this 
effect was less pronounced for TNFα secretion (Figure 9A). Interestingly, inhibition of Syk signalling 
only reduced IL-1β secretion in Euglena gracilis stimulated neutrophils. In macrophages a similar 
response was observed (Figure 9B). Both TNFα and IL-1β secretion was significantly reduced upon 
blocking of FAK signalling in zymosan- and Euglena gracilis stimulated macrophages. Similar to 
neutrophils, inhibition of Syk signalling also reduced IL-1β secretion by Euglena gracilis stimulated 
macrophages. These results are not due to an increased cell death, as the FAK inhibitor PF 573228 
did not affect the viability of the cells during our experiments, while the Syk inhibitor R406 only 
reduced cell viability by 30% in neutrophils.  
A 
 
 
B 
 
 
 
 
Figure 9. Focal adhesion kinase (FAK) is significantly involved in the β-glucan-mediated cytokine secretion in 
porcine neutrophils and monocyte-derived macrophages. 
 (A) Neutrophils (2 x 10
5
 cells) were pre-incubated for 1h with 100 µM Syk (R406) or 5 µM FAK (PF-573 228) 
inhibitors. 200 µg/ml β-glucans (Macrogard, zymosan or Euglena gracilis) were then added and after 16h cell 
supernatants were analysed for TNFα, IL-1β and IL-8 by ELISA. The results are presented as mean cytokine 
concentration ± SEM of four pigs. Values of the negative control have been subtracted from the values 
represented on the graph. (B) Monocyte-derived macrophages (2 x 10
5
 cells) were pre-incubated for 1h with 5 
µM Syk (R406) or 5 µM FAK (PF-573 228) inhibitors. 200 µg/ml β-glucans (Macrogard, zymosan or Euglena 
gracilis) were then added and after 16h cell supernatants was analysed for TNFα and IL-1β by ELISA. The results 
are presented as mean cytokine concentration ± SEM of six pigs. Values of the negative control have been 
subtracted from the values represented on the graph. *: p < 0.05; **: p < 0.01. 
 
Chapter 3 - β-glucan recognition and signalling in porcine innate immune cells 
 
72 
 
3.5 Discussion 
Different β-glucans induce oxidative burst responses and cytokine secretion in porcine innate 
immune cells,380 however, little is yet known about the differential contribution of the β-glucan 
receptors CR3 and dectin-1 to induce these biological activities. Several studies in mice have 
established that dectin-1 is the most efficient β-glucan receptor on immune cells,75, 81, 125, 148, 149 while 
recent studies in man have reported that CR3 is more important in these responses.156, 372 Domestic 
pigs as translational model have much to offer, since recent genome wide studies indicate that pigs 
are immunologically far closer to man than mice.253, 388 Here, we used pigs to investigate the specific 
role of two β-glucan receptors, dectin-1 and CR3, in the response of innate immune cells towards 
different particulate β-glucans. Recent studies in humans clearly showed that phagocytosis of and 
ROS production mediated by zymosan as well as whole yeast by neutrophils was completely 
dependent on CR3,372 while in monocytes distinct receptors are involved in the β-glucan-mediated 
oxidative burst.156 This implies that the recognition of β-glucans is cell type-specific. Indeed, similar to 
their human counterparts, our present study shows that the β-glucan-mediated ROS production and 
phagocytosis in porcine neutrophils is CR3-dependent, while in macrophages different receptors are 
responsible for the cellular responses towards β-glucans. In contrast with these findings in humans 
and pigs, Li et al. (2011) demonstrated in mice that both dectin-1 and CR3 are crucial for β-glucan-
induced responses in neutrophils, whereas dectin-1 alone serves as a β-glucan receptor in 
macrophages. Furthermore, they demonstrated that in neutrophils dectin-1 activates CR3 in a vav 
protein-dependent manner to recognise and phagocytose β-glucans, while vav-proteins have no 
significant role in the phagocytosis of zymosan in macrophages.125 Conversely, our results point out 
that CR3 alone serves as a β-glucan receptor in porcine neutrophils, while dectin-1 could assist CR3 
to respond towards β-glucans by vav proteins in macrophages. The similarity between our data (pig) 
and human studies and the dissimilarity with those of mice studies may be due to species-
differences, indicating that the pig is a more valuable model than the mouse to study the β-glucan-
mediated effects on innate immunity. 
We further investigated the role of dectin-1 and CR3 in β-glucan-mediated responses by inhibiting 
their signalling pathway. The CR3-downstream signalling kinase FAK is critically involved in both ROS 
and cytokine production by porcine neutrophils and macrophages stimulated with all three β-
glucans, while blocking Syk (dectin-1 signalling pathway) could only partially affect these responses. 
This observation was not consistent with previously published results in mice,98, 125 where it was 
shown that Syk is critically involved in the β-glucan-induced dectin-1 activation in murine neutrophils 
and a subpopulation of macrophages. Similar to our study, a recent human study demonstrated that 
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Syk is not involved in the antimicrobial response towards particulate β-glucans in monocytes.156 
However, Bose et al.156 could not detect a reduced ROS production in human monocytes when 
blocking FAK upon stimulation with particulate β-glucans. Regardless, we report for the first time 
that porcine neutrophils and macrophages signal via FAK, which serves as a master switch regulating 
responses towards particular β-glucan in both cell types. The partial contribution of Syk in the 
response towards β-glucans could be explained by the activation of Syk through integrin 
engagement. Indeed, ligation of CR3 will activate Src kinases, which in turn can phosphorylate ITAM-
containing adaptor proteins, leading to docking sites for Syk kinases.130, 131 However, this signalling 
pathway is not crucial for β-glucan-mediated responses, since cytokine secretion is only slightly 
affected in the absence of Syk. 
Taken together, we propose that β-glucans are recognised by the αM subunit of CR3 in porcine innate 
immune cells. In pigs, two candidate receptors for the αM subunit of CR3, namely CD11R1 and 
CD11R3, were described.124 Here, we report that detection of β-glucans by CR3 requires only 
CD11R3. CD11R3 possess clearly equivalent functionality as the αM subunit of human CR3, however, 
whether this receptor is involved in complement function as well has not been investigated. 
Furthermore, we suggest that binding of β-glucans to CD11R3 will activate Src kinases, which will 
induce several downstream signalling events, such as activation of FAK and Syk, the latter activating 
FAK as well. Besides this CR3 signalling pathway, we believe that in porcine macrophages dectin-1 
and other putative β-glucan receptors, such as the scavenger receptors CD36 and SCARF1, are 
responsible for β-glucan recognition as well. 
It is interesting to note that the minimal structural differences between zymosan, Macrogard and 
Euglena gracilis affect biological outcomes such as phagocytosis, ROS production and cytokine 
secretion. We detected only a marginal cytokine response by porcine neutrophils and macrophages 
upon stimulation with Macrogard (200 µg/ml), while zymosan and Euglena gracilis were able to 
trigger cytokine secretion in both neutrophils and macrophages. As Macrogard is able to induce 
cytokine secretion in innate immune cells at lower concentrations,380 we suggest that Macrogard has 
a dose-dependent immunomodulatory effect. Macrogard has a β(1,3)-linked backbone with β(1,6)-
linked branches, thus we suspect that the large β(1,3)(1,6)-linked glucans stereochemically interfere 
with each other and as a result less receptors become bound. Indeed, β-glucans derived from 
Euglena gracilis do not have branches, and zymosan has non-uniform branches, indicating that 
differences in branch frequencies are important for their immune stimulating properties.  
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3.6 Conclusions 
In conclusion, porcine neutrophils detect β-glucans via CR3, while porcine macrophages use multiple 
receptors to detect and respond to β-glucans. However, in both cell types FAK serves as a master 
regulator in β-glucan-mediated responses. Furthermore, this study supports the use of pigs as a 
valuable model to evaluate the effects of β-glucans on innate immunity, since these results are more 
related to the results of human studies than mice studies. Thus, further studies in pigs can reveal the 
mechanism of β-glucan recognition and immune activation in pigs and humans. A better 
understanding of this mechanism could lead to a rationale-based decision process to improve health 
and as in-feed additives in livestock species and to optimise β-glucans as nutraceuticals in humans. 
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4.1 Abstract 
Designing efficient recombinant mucosal vaccines against enteric diseases is still a major challenge. 
Mucosal delivery of recombinant vaccines requires the encapsulation in potent immunostimulatory 
particles to induce an efficient immune response. This article evaluates the capacity of β-glucan 
microparticles (GPs) as antigen vehicle and characterises their immune-stimulatory effects. The 
relevant infectious antigen FedF was chosen to be loaded inside the microparticles. The 
incorporation of FedF inside the particles was highly efficient (84.53%) and occured without antigen 
degradation. In addition, these β-glucan microparticles have immunostimulatory effects as well, 
demonstrated by the strong reactive oxygen species (ROS) production by porcine neutrophils upon 
their recognition. Although antigen-loaded GPs still induce ROS production, antigen loading 
decreases this production by neutrophils for reasons yet unknown. However, these antigen-loaded β-
glucan microparticles are still able to bind their specific β-glucan receptor, demonstrated by blocking 
complement receptor 3, which is the major β-glucan receptor on porcine neutrophils. The dual 
character of these particles is confirmed in a T cell proliferation assay. FedF-loaded particles induce a 
significantly higher FedF-specific T cell proliferation than soluble FedF. Taken together, these results 
show that β-glucan microparticles are efficient antigen carriers with immune-stimulatory properties. 
 
4.2 Introduction 
Mucosal vaccination is the most efficient way to protect man and animals against enteric infections. 
However, the development of effective mucosal subunits vaccines encounters multiple challenges, 
such as antigen degradation and limited immunogenicity.33-36 The encapsulation of antigens in 
microparticles is a promising approach to overcome these problems, as they can protect the antigens 
against degradation as well as carry potent adjuvants or immune modulators to enhance the 
immunogenicity.313-315 Frequently used particle system are those based on poly(lactic-co-glycolic acid) 
(PLGA), however, low antigen encapsulation efficiency and antigen degradation during their 
formation limits their use in commercial vaccines.389 On the contrary, β-glucan microparticles (GP) 
are emerging microparticles known for their safety, immunogenicity and high antigen encapsulation 
efficiency.21-29, 328 These promising antigen-carriers are derived from the cell wall of Saccharomyces 
cerevisiae (Baker’s yeast) and are composed of >85% β-1,3-D-glucan polymers (β-glucans), ~2% chitin 
and <1% lipids and proteins, with the rest being mostly ash and moisture.26 The main component of 
these particles, the β-glucans, is a ‘microbe-associated molecular pattern’ (MAMP), which is very 
interesting in vaccine development for their immunostimulating characteristics.183, 187 We have 
previously reported that particulate β-glucans are mainly recognised by complement receptor 3 
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(CR3) on porcine innate immune cells and require the signalling molecule FAK to perform their 
immunostimulatory responses.390 However, which receptor is involved in the immunostimulating 
characteristics of GPs is not yet known. Many articles have described the strong potency of these β-
glucan microparticles to elicit durable immune responses in mice.21, 22, 25, 32, 165 Incubation of mouse 
bone marrow derived dendritic cells (BMDCs) with ovalbumin (OVA) loaded GPs resulted in 
phagocytosis, upregulation of maturation markers, rapid proteolysis of ovalbumin and proliferation 
of OVA-reactive transgenic CD8+ OT-I and CD4+ OT-II T cells.25 However, the immunological effect of 
these particles on porcine innate immune cells has not been investigated yet.  
Moreover, besides the incorporation of model antigens, no clinically relevant antigens were 
incorporated in these β-glucan microparticles. We have incorporated FedF, the tipadhesin of F18 
fimbriae, inside the particles, since this antigen is one of the most important virulence factors of F18+ 
Escherichia coli. E. coli carrying the F18 fimbriae colonise the small intestine of pigs and cause post-
weaning diarrhoea and edema disease in pigs, resulting in economic losses to the pig production 
industry.391 One of the most important virulence factors of these infections are the fimbriae, by 
which the pathogen adhere to the intestinal epithelial cells and colonise the intestine. There are two 
closely related antigenic variants of F18, namely F18ab and F18ac. In general, post-weaning 
diarrhoea (ETEC infections) is caused by the F18ac variant whereas F18ab is more related to oedema 
disease (STEC infections).9 Porcine ETEC strains can produce 5 fimbrial types (F4, F18, F41, F5, F6) of 
which F4 and F18 are most frequently associated with ETEC-induced diarrhea.9 The F18 fimbriae are 
polymeric proteins composed of several subunits: FedA is the structural subunit,392 FedB the outer 
membrane usher, FedC the periplasmic chaperone, FedE the minor pilin and FedF the adhesin, which 
is essential for fimbrial adhesion (Figure 1).393, 394 These subunits also regulate the length of the F18 
fimbriae, which are normally 1-2 µm in length.395 The FedF subunit of F18 fimbriae is located in a 
dedicated single copy adhesin at the distal tip of the fimbriae.396 Tipadhesins are usually composed of 
two immunoglobulin (Ig)-like domains: an N-terminal lectin or receptor binding module and a C-
terminal pilin. As it needs a complementary β-strand from the FedE subunit, using donor strand 
complementation is necessary to achieve a stable recombinant expression of FedF.393 To protect pigs 
against F18+ ETEC infections, local intestinal immunity is required. However, oral immunisation with 
F18 fimbriae does not elicit protection in a piglet model, probably due to the presence of 
immunodominant epitopes in the FedA subunit397 or release of FedF from the fimbriae.398 We 
reasoned that oral immunisation of piglets with purified FedF subunit would enable induction of 
protective immunity, but only if FedF is encapsulated inside microparticles in order to deliver higher 
amounts of antigens to the gut-associated lymphoid tissue (GALT) and to induce strong immune 
responses by mimicking pathogen dimensions.  
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We have incorporated FedF inside β-glucan microparticles for oral administration 
to induce intestinal FedF-specific antibody responses. In this article, we 
investigated the capacity of these β-glucan microparticles as both antigen vehicle 
and immunostimulants. Porcine immune cells were used as translational model, 
because β-glucan recognition and signalling in porcine innate immune cells is 
closer related to humans than murine cells.253, 388, 390 
 
Figure 1. Schematic representation of F18 fimbriae. 
The main component of F18 fimbriae is FedA (green). Adhesin subunits of F18 (FedF) are in grey. Periplasmic 
chaperones and outer membrane ushers are in purple and blue, respectively. Structural subunits are in red.  
 
4.3 Materials and Methods 
4.3.1 Generation of FedF 
FedF was generated using the method of De Kerpel et al. (2006).399 Briefly, the fedF15-165 gene from 
F18 E. coli 107/86 strain was cloned in the pDEST14 vector under a T7 promotor. The gene was C-
terminal truncated and then transformed into E. coli strain C43 (DE3). The C43 (DE3) cells were 
grown, induced with 1 mM IPTG and incubated for 2h. Cells were subjected to osmotic shock and the 
periplasmic extract was loaded onto a Source 3S column (Amersham, Bucks, UK) for cation exchange 
in 20 mM Tris pH 7.5. Proteins were eluted at 140 mM NaCl and further purified using gel filtration 
on a Superdex-75HR column in 10 mM HEPES pH 7.0 and 150 mM NaCl. Finally, the protein was 
dialysed against 0.9% saline. 
 
4.3.2 Development of β-glucan microparticles and protein encapsulation 
Hollow β-glucan microparticles (GPs) were prepared from Saccharomyces cerevisiae using a series of 
alkaline and acidic extraction steps and loaded with FedF as previously described.25, 26 Therefore, 10 
mg of dry GPs were swollen with 5 mg FedF dissolved in 0.9% saline for 2h at 4°C, followed by 
lyophilisation. These dry GP-FedF preparations were reswollen with 300 µl aqua dest to maximise 
FedF diffusion into the GPs. Upon relyophilisation, FedF was trapped inside the GPs by adding 350 µl 
of 25 mg/ml tRNA (derived from torula yeast) in TEN buffer (50 mM Tris HCl with 2 mM EDTA and 
0.15 M NaCl, pH 8.2) for 30 minutes at 50°C. To complete the complexation reaction, another 500 µl 
of 10 mg/ml tRNA was added to the particles. The suspension was centrifuged, washed four times in 
0.9% saline and stored at -20°C (2.5 mg/ml).25 To calculate the amount of FedF trapped inside the 
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GPs, the unbound FedF protein in the wash fractions was measured by BCA against a BSA standard 
(0.05-1 mg/ml). 
 
4.3.3 Western blot 
Incorporation of FedF inside the particles was confirmed using a protein gel electrophoresis after 
digesting the β-glucan microparticles with β-1,3-D-glucanase from Helix pomatia (Sigma). FedF-
loaded β-glucan microparticles were first incubated in β-glucanases (1 mg/ml) diluted in 150 mM 
sodium acetate buffer (Sigma, Diegem, Belgium) for 24h at 37°C. Proteins, released in the 
supernatants, were separated via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) consisting of a 12% separating gel and a 4% stacking gel. The gels were prepared by dissolving 
30% acrylamide in Tris (pH 8.8), 10% SDS, 10% APS and TEMED. To load the samples, the proteins 
were mixed in equal volume ratios with loading buffer containing β-mercaptoethanol and heated at 
100°C for 5 minutes. Electrophoresis was performed at 28 mA for 1h. After separating, the proteins 
were transferred to a 0.45 µm PVDF membrane (GE Healthcare, Diegem, Belgium) at 40 V for 2h. 
Next, the membrane was blocked (1h at room temperature) with 5% milk powder diluted in PBS + 
0.1% Tween®20 to prevent antibodies from non-specifically binding to the membrane. Monoclonal 
anti-mouse FedF-specific antibodies (10 µg) were added overnight to the blot, followed by 
horseradish peroxidase conjugated rabbit anti-mouse IgG (1/2000; Dako, Heverlee, Belgium) for 1 
hour at room temperature. The bands were visualised using ECL western blotting substrate (Pierce, 
Merelbeke, Belgium) and ChemiDOCTM MP imaging system (Biorad, Temse, Belgium). 
 
4.3.4 Oxidative burst by porcine neutrophils 
All animal experiments were approved by the animal care and ethics committee of the Faculty of 
Veterinary Medicine, Ghent University (EC2013/62). Piglets (between 4 and 20 weeks old) were 
housed under standard conditions as blood donors. Peripheral blood was collected on heparin from 
the jugular vein of four pigs. Subsequently, neutrophils were isolated by density gradient 
centrifugation on a discontinuous Percoll gradient (68% and 75%) (GE healthcare) as described 
previously.380 To examine the immunostimulating characteristics of the particles, the ability of the β-
glucan microparticles to induce an oxidative burst response by porcine neutrophils was investigated. 
The production of reactive oxygen species (ROS) was measured by a chemiluminescence assay 
described by Donne et al. (2005) with some modifications.381 Neutrophils were seeded in a 96-well 
plate at 2.0 x 105 cells/well in RPMI without phenol-red. The plates were incubated at 37°C for 2h in a 
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humidified atmosphere with 5% CO2 to allow the cells to adhere to the plastic surface. Subsequently, 
the supernatant was replaced by 175 µl luminol (0.5 mM). After 5 minutes of background 
measurement at 37°C, 25 µl of the indicated β-glucan microparticles (400, 200 or 100 µg/ml) were 
added. Stimulation of the cells with phorbol myristate acetate (PMA; 50 µg/ml) was used as a 
positive control. ROS production was then measured during 120 min in the integration mode. All 
stimulations were performed in duplicate. The ROS production is expressed as relative light units 
(RLU). 
 
4.3.5 Determination of the β-glucan receptor in porcine neutrophils 
To analyse the role of dectin-1 and CR3 in the immunostimulating characteristics of these β-glucan 
microparticles, the production of reactive oxygen species (ROS) by neutrophils was measured using a 
chemiluminescence assay as described above with some modifications. Neutrophils were seeded in a 
96-well plate at 2.0 x 105 cells/well. The plates were incubated at 37°C for 2h in a humidified 
atmosphere with 5% CO2 to allow the cells to adhere to the plastic surface. Then, the cells were pre-
treated with the β-glucan receptor inhibitors for 1 hour at 37°C. To inhibit dectin-1, laminarin (1 
mg/ml) was added to the cells. To inhibit CR3-mediated responses, monoclonal antibodies (mAbs; 
mouse IgG1 isotypes) against CD18 (5 µg/ml) and CD11R3 (15 µg/ml) (AbD Serotec, Kidlington, UK) 
were added. These antibodies were dialysed against PBS to remove sodium azide. An isotype-
matched mAb control (IgG1) was added to the cells to measure background inhibition. Subsequently, 
luminol was added to the cells (0.5 mM diluted in HBSS + Ca2+ Mg2+) and, after 5 minutes of 
background measurement at 37°C, 25 µl of the β-glucan microparticles (200 µg/ml) were added. 
Stimulation of the cells with phorbol myristate acetate (PMA; 50 µg/ml) was used as a positive 
control. ROS production was then measured during 120 min in the integration mode. All stimulations 
were performed in duplicate. ROS production is expressed as relative light units (RLU). 
 
4.3.6 Generation of monocyte-derived dendritic cells (MoDCs) 
Peripheral blood monomorphonuclear cells (PBMCs) were isolated by density gradient centrifugation 
on Lymphoprep (NYCOMED Pharma AS, Life Technologies, Merelbeke, Belgium). Furthermore, 
monocytes were enriched from the PBMCs to a purity of >95% by positive immunomagnetic bead 
selection (MACS; Miltenyi Biotec, Leiden, The Netherlands) using the anti-SIRPα monoclonal antibody 
(clone 74-12-15a400). These cells were seeded in a 24-well plate at a density of 0.5 x 106 cells/ml in 
MoDC medium (DMEM supplemented with 10% FCS, 1% P/S, recombinant porcine 1/200 GM-CSF401 
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and 5 ng/ml IL-4). After three days incubation at 37°C in a humidified atmosphere at 5% CO2, we 
added fresh medium supplemented with GM-CSF and IL-4 at the same concentration to cells to 
generate monocyte-derived dendritic cells as previously described.402 
 
4.3.7 Antigen presentation assay  
To investigate whether incorporation of FedF inside the particles is necessary to induce FedF-specific 
cellular immune responses, a coculture of MoDCs and CD6+ T cells was set up. Therefore, T cells 
isolated from pigs immunised intramuscularly with 250 µg purified FedF in incomplete Freund’s 
adjuvant were used [35]. CD6+ T cells were enriched from PBMCs to a purity of > 95% by positive 
immunomagnetic selection with the α-CD6 mAb (IgG1, clone a38b2; [36]) and goat anti-mouse 
microbeads (MACS). MoDCs were stimulated with 8 µg FedF or FedF-loaded GPs (8 µg FedF 
encapsulated) for 24 h or left untreated (control). These stimulated MoDCs were subsequently co-
cultured at titrated numbers with 1.0 x 105 autologous CD6+ T cells for 5 days and the 3Hmethyl-
thymidine (1 Ci/well; Amersham ICN, Bucks, UK) incorporation (18h) was measured using a -
scintillation counter (Perkin-Elmer). 
 
4.3.8 Statistics 
Data are presented as the mean ± SEM. Data were analysed with GraphPad Prism 5 using the paired 
t-test for comparison of two data and using a repeated measures ANOVA (Post hoc: Tukey) for 
comparison of multiple data sets. Data were considered significant at p < 0.05. 
 
4.4 Results and Discussion 
4.4.1 Efficient loading of FedF inside β-glucan microparticles 
To assess if loading of FedF into GPs affects the antigenicity, we performed Western blotting. We first 
confirmed the high loading capacity of GPs, as FedF was incorporated inside the β-glucan 
microparticles with a loading efficiency of 84.53% ± 2.89 (Figure 2A). Furthermore, we examined by 
gel electrophoresis the correct incorporation of FedF inside the particles. Therefore, we first 
destroyed the β-glucan particles by β-glucanases, whereafter the supernatants with the released 
antigens were loaded on a protein gel electrophoresis and detected by monoclonal FedF-specific 
antibodies (clone IMM04398). Figure 2B illustrates the protein FedF in lane 1 and the FedF released 
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from the digested GPs in lane 2. As shown, both FedF and the released FedF migrate near the 
expected MW of 18 kDa. No degradation is visible indicating the correct incorporation of FedF inside 
the particles. Based on these results we conclude that FedF is efficiently incorporated inside the 
particles.  
 
A      B 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. FedF was efficiently incorporated inside β-glucan microparticles. 
(A) The loading efficiency of FedF inside GPs was determined by BCA. The unbound FedF protein in the wash 
fractions was measured by BCA against a BSA standard (0.05-1 mg/ml). (B) FedF incorporation inside the GPs 
was analysed by Western blotting after digesting the particles with β-glucanases. FedF was detected with 
specific monoclonal antibodies against FedF. Lane 1 illustrates FedF, while the FedF released from the GPs 
upon digestion is shown in lane 2. 
 
4.4.2 FedF-loaded β-glucan microparticles still possess immune-stimulatory effects 
To assess the effect of antigen loading on the inherent immunostimulating characteristics of the GP, 
we determined the oxygen radical production of porcine neutrophils after stimulation with antigen-
loaded particles. Figure 3 demonstrates that FedF-loaded GPs possess immune-stimulatory effects. 
Interestingly, hollow β-glucan microparticles could stimulate ROS production by neutrophils more 
than antigen-loaded particles, indicating that antigen loading partially masks the β-glucans of the 
particles from recognition by their receptors, dectin-1 and complement receptor 3 (CR3). 390 
However, using confocal microscopy we failed to detect any FedF associated with the surface of the 
particles (data not shown). 
 
Figure 3. FedF-loaded β-glucan microparticles still 
possess their adjuvant function. 
Neutrophils (2 x 10
5
 cells) were stimulated with 
GPs at the indicated concentrations. ROS 
production was determined via 
chemiluminescence. Data are shown as the mean 
relative light units (RLU) ± SEM of four pigs. **: p < 
0.01. Values of the negative control have been 
subtracted from the values represented on the 
graph. 
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4.4.3 The immune-modulatory effects of β-glucan microparticles are mainly mediated by 
binding to the α subunit of complement receptor 3 (CR3)  
We further investigated which β-glucan receptor is involved in the particle-induced activation of 
porcine neutrophils. As shown in Figure 4, the β-glucan microparticles-induced ROS production by 
neutrophils was significantly inhibited in the presence of anti-CD11R3 as compared to its isotype-
matched control. In contrast to the α subunit of CR3, the ability of CD18-specific mAbs to block ROS 
production by porcine neutrophils was negligible (β subunit of CR3). Interestingly, blocking dectin-1 
by laminarin decreased the ROS production as well, albeit not as much as CD11R3-specific mAbs. 
Although incorporation of antigens inside the particles seems to influence the recognition of GPs by 
dectin-1, CD11R3 is still the most important receptor for the GP-induced ROS production in porcine 
neutrophils. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. CR11R3 is involved in the recognition of β-glucan microparticles by neutrophils.  
Neutrophils (2 x 10
5
 cells) were incubated with laminarin (1 mg/ml), aCD18 (5 µg/ml), aCD11R3 (15 µg/ml) or 
isotype control (IgG1; 15 µg/ml). Subsequently, the cells were stimulated with 200 µg/ml of the indicated β-
glucan microparticles. ROS production was determined via chemiluminescence. Values shown are mean 
relative light units (RLU) ± SEM of four pigs. Values of the negative control have been subtracted from the 
values represented on the graph. *: p < 0.05; **: p < 0.01. 
 
4.4.4 T cell proliferation is significantly increased when FedF is incorporated inside GPs 
To assess whether β-glucan microparticles could serve as an immune stimulatory antigen delivery 
system, we investigated the FedF-specific T cell proliferation after stimulation of MoDCs with FedF-
GPs. As illustrated in Figure 5, FedF-loaded GPs promoted the antigen presentation capacity of 
MoDCs to porcine CD6+ T cells as compared to immature and FedF-stimulated MoDCs, clearly 
indicating that encapsulation of FedF inside immunostimulatory particles is necessary to induce T cell 
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proliferation. Interestingly, FedF stimulation of dendritic cells did not influence T cell proliferation, 
suggesting that FedF has an inhibitory effect on MoDCs. 
 
 
 
 
 
Figure 5. T cell proliferation is significantly increased when FedF is incorporated inside GPs. 
Encapsulation of FedF in β-glucan microparticles promotes antigen presentation to T cells. Autologous CD6
+
 T 
cells were co-cultured for 5 days with immature, FedF (8 µg) or FedF-loaded GPs (8 µg FedF encapsulated) 
stimulated MoDCs. The data represent the mean cpm ± SEM (n = 4). The spontaneous proliferation of the CD6+ 
responder cells equalled 78.25 ± 14.15 cpm, while for ConA-stimulated cells the proliferation amounted to 
15203 ± 5622.9 cpm. Control: immature MoDCs. The asteriks indicates a significant difference between 
stimulated and immature MoDCs. *, p < 0.05. 
 
4.5 Conclusions 
β-glucan microparticles are emerging particles known for their high antigen loading capacity and 
safety. In the current study, we have evaluated the incorporation of a clinically relevant infectious 
disease antigen FedF, the tipadhesin of F18 fimbriae, inside these particles. The results clearly 
demonstrate that FedF is incorporated intact inside the particles with a high loading efficiency 
(84.5%). Besides antigen carrier, these particles are able to stimulate the innate immune system by 
binding to the α subunit of complement receptor 3 (CR3). To confirm the duality of these particles, 
we have demonstrated in a T cell proliferation assay that FedF inside the particles is processed by 
MoDCs and subsequently presented to T cells, resulting in their activation and proliferation. Taken 
together, FedF-loaded β-glucan microparticles are promising vaccine candidates in the protection of 
pigs against F18+ ETEC and STEC infections and this study motivates exploring this vaccine in vivo. 
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5.1 Abstract 
Enteric diseases still have a devastating impact on global health. Oral vaccination is crucial to prevent 
intestinal infections, since only vaccines delivered to the intestinal tract elicit potent immune 
responses at the site of pathogen entry. However, oral vaccines encounter multiple barriers, 
including poor uptake and tolerance mechanisms, preventing the immune system to react to 
innocuous environmental antigens. Antigen delivery systems combined with selective targeting seem 
a promising strategy to overcome these obstacles. The current study evaluates the capacity of 
aminopeptidase N (APN)-targeted β-glucan microparticles (GPs) as antigen delivery system. 
Antibodies against APN, an intestinal epithelial receptor, are conjugated oriented efficiently to GPs 
via the biolinker protein G. The resultant microparticles were analysed for their antigen load, 
adjuvanticity and interaction with enterocytes and dendritic cells (DCs). Functionalisation of GPs with 
antibodies neither impedes antigen load nor adjuvanticity. In addition, targeting to APN increases the 
uptake of microparticles by enterocytes and DCs, leading to an enhanced maturation of the latter as 
evidenced by an upregulation of maturation markers and a strong pro-inflammatory cytokine 
response. Finally, oral administration of APN-targeted antigen-loaded particles to piglets elicits 
higher serum antigen-specific antibody responses as compared to control particles. Taken together, 
these data support the use of APN-targeted GPs for oral delivery of antigens. 
 
5.2 Introduction 
Gastrointestinal infections are still the main cause of enteric morbidity and mortality in man and 
animals. Since parenteral vaccines are unable to elicit potent immune response at the intestinal 
mucosa, the oral route seems to be the most favourable way to prevent intestinal infections. 
However, the few current oral vaccines, consisting of live-attenuated or inactivated organisms, often 
do not completely prevent infection and have a high safety risk profile.403 Therefore, several subunit 
vaccines with recombinant or purified antigens are currently being explored to avoid these problems. 
Until now no oral subunit vaccine affording protection against intestinal infections has been 
commercialised as their development encounters multiple challenges, such as instability and limited 
immunogenicity.33-36 Antigen encapsulation in nano/microparticles is a promising approach to 
overcome these problems, as it can protect the antigens against degradation as well as carry potent 
adjuvants or immune modulators to enhance their immunogenicity.313-315 Great advances have been 
made in the development of microparticle systems, of which particles based on poly(lactic-co-glycolic 
acid) (PLGA) are the most used one. However, low antigen encapsulation efficiency and the necessity 
to dissolve antigens in organic solvents limits their use in commercial vaccines.389 
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β-glucan microparticles (GPs) represent an alternative antigen particle system for oral delivery. These 
hollow and porous GP are known for their safety, immunogenicity and high antigen encapsulation 
efficiency.21-29, 328 These promising antigen carriers are derived from the cell wall of Saccharomyces 
cerevisiae (Baker’s yeast) and are mainly composed of β-1,3-D-glucans, ‘microbe-associated 
molecular patterns’ (MAMPs) with adjuvant ability.26, 183, 187 β-glucan microparticles display a strong 
potency to elicit durable immune responses.21, 22, 25, 32, 165 For instance, subcutaneous immunisation of 
mice with GP-OVA induced strong humoral and Th1- and Th17-biased CD4+ T cell responses,25 while 
oral administration of GP-OVA resulted in a Th17-biased response and the production of OVA-specific 
secretory IgA in intestinal fluids.32 This local immune response is obtained following transepithelial 
transport of GPs by Peyer’s patch M cells,22, 32, 404 resulting in the accumulation of GPs in CD11c+ 
phagocytes situated in the Peyer’s patch sub-epithelial dome (SED) regions.22 However, M cells 
represent only a minor cell population in the intestinal tract and a huge amount of particles is 
necessary to induce immunity. Villous enterocytes vastly outnumber M cells and possess a 
transcytotic capability for macromolecules and inert particles, making them interesting target cells.337 
Selective targeting of these microparticles to a transcytotic receptor present on the apical surface of 
both intestinal villous cells and M cells may further enhance their passage through the epithelial 
barrier.  
Although many approaches have been reported, selective targeting is still a challenge. A classical 
approach for selective targeting is mediated by recognition of the target via capture molecules, such 
as antibodies.337, 355 However, conventional methods to conjugate antibodies to particles often result 
in a loss of binding activity due to the random orientation and structural or conformational 
disruption of the antibodies.365 Here, we took advantage of the antibody-binding properties of the 
biolinker protein G, which binds the Fc region of the antibody (IgG), to conjugate monoclonal 
antibodies in a proper orientation to the surface of β-glucan microparticles. To demonstrate the 
feasibility of this design to functionalise microparticles, aminopeptidase N (APN, CD13) was selected 
as a target. APN is a conserved membrane glycoprotein expressed by many cell types, including small 
intestinal enterocytes and dendritic cells. APN is mainly known to regulate the biological activity of 
various peptides by proteolysis, however, APN displays many other functions as well, such as 
signalling molecule and receptor for some viruses/bacteria and cholesterol.405 Indeed, 
aminopeptidase N as signalling molecule is known to mediate angiogenesis and metastasis of 
different human tumor cells and is suggested as a suitable target for anti-cancerous therapy.405 
Furthermore, aminopeptides N (APN) is utilised as receptor for viruses and bacteria, such as group I 
coronaviruses347 and transmissible gastroenteritis virus (TGEV).348 Recently, our lab identified porcine 
APN as an endocytotic receptor for F4 enterotoxigenic Escherichia coli (ETEC) in pigs.260 Moreover, it 
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has been demonstrated that intestinal APN-targeting results in a strong IgA, IgG and IgM immune 
response, indicating that APN may represent a promising target for oral delivery of antigens across 
the epithelial barrier.260 In addition, crosslinking CD13, expressed on immune cells, positively 
modulates phagocytosis,352 making APN an attractive target for both transcytosis and immune 
stimulation. 
The present study aimed to evaluate APN-targeted GPs as candidate antigen delivery system for oral 
vaccination. We report on the characteristics and adjuvanticity of these microparticles and their 
functional surface decoration with anti-APN-specific antibodies. The interaction between APN-
targeted GPs and intestinal epithelial cells was explored as well. Furthermore, we report on the 
intracellular uptake of the particles by porcine monocyte-derived dendritic cells (MoDCs) and their 
capacity to induce DC maturation. Finally, we loaded FedF, a clinically relevant antigen, inside the 
particles. FedF is the tipadhesin of F18 fimbriae, which are colonization factors of a porcine-specific 
enterotoxigenic E. coli strain. These strains cause diarrhea in infected animals upon FedF-mediated 
binding of the bacteria to small intestinal epithelial fucosylated glycosphingolipids.396, 406 These APN-
targeted FedF-loaded GPs were orally administered to piglets to investigate their capacity to trigger 
FedF-specific systemic immunity. 
 
5.3 Materials and Methods 
5.3.1 Reagents 
Protein G, 2-(N-morpholino)ethanesulfonic acid (MES), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (sulfo-NHS), O-(2-
aminoethyl)polyethylene glycol (PEG-NH2), glycine, sodium borate, dimethyl pimelimidate (DMP), 
triethanolamine, ethanolamine, luminol, accutase, sheep anti-mouse IgG/FITC, N-acetyl-L-cysteine, 
cholera toxin (CT) and 3,3’,5,5’-tetramethylbenzidine liquid substrate for membranes (TMB) were 
obtained from Sigma (Diegem, Belgium). Goat anti-mouse IgG-AlexaFluor647 antibody was 
purchased from Abd Serotec (Kidlington, UK). Percoll gradient was purchased from GE healthcare 
(Diegem, Belgium). Lymphoprep, latex beads, Sytox red, Phalloïdin-Texas Red, isotype-matched 
irrelevant antibodies and secondary fluorescent antibodies were purchased from Life Technologies 
(Merelbeke, Belgium). Cell culture products and reagents, unless mentioned otherwise, were 
purchased from GIBCO (Life Technologies). Immunomagnetic beads (MACS) were purchased from 
Miltenyi Biotec (Leiden, The Netherlands). Phorbol myristate acetate (PMA) was obtained from Enzo 
Life Sciences (Antwerpen, Belgium). Sterile biopsy foam pads were obtained from Simport (Beloeil, 
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Canada). Human CTLA4-muIgG2a fusion protein was purchased from Ancell (Bayport, USA). Porcine 
IL-4 and ELISA kits were purchased from R&D systems (Abingdon, UK). Colistin, ProMycine® Pulvis, 
was obtained from VMD (Arendonk, Belgium). Pariet® was purchased from Janssen-Cilag (Tilburg, 
The Netherlands). Anti-pig-Ig (H+L), IgA/HRP and HRP-conjugated anti-mouse IgG antibodies were 
obtained from Bethyl Laboratories (Antwerpen, Belgium). 
 
5.3.2 Preparation of protein-loaded β-glucan microparticles 
Hollow β-glucan microparticles (GPs) were prepared from Saccharomyces cerevisiae using a series of 
alkaline and acidic extraction steps and loaded with BSA-FITC as an antigen model as previously 
described.25, 26 The resulting BSA-FITC-loaded GPs were washed four times in 0.9% saline and stored 
at -20°C (2.5 mg/ml). To calculate the amount of BSA-FITC trapped inside the GPs, the unbound BSA-
FITC protein in the wash fractions was measured by fluorimetry against a BSA-FITC standard (3.125 – 
1000 µg/ml). The incorporation of BSA-FITC into the GPs was 96.89% ± 0.31 (data not shown). 
 
5.3.3 Functionalisation of β-glucan microparticles 
β-glucan microparticles were targeted to aminopeptidase N (APN) by surface decorating the GPs with 
an in-house produced monoclonal antibody (mAb) against porcine APN (IMM013). An overview of all 
required steps to synthesize these antibody functionalised GPs is given in Figure 1. First, protein G 
was conjugated to the particles via carbodiimide crosslinker chemistry.28, 407, 408 Briefly, BSA-FITC GPs 
(500 µg/ml) were centrifuged (500 g, 5 min) and resuspended in 1 ml 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (0.1 M MES; pH 6.0). To avoid aggregation, GPs were 
sonicated for 2 minutes (230V, 50Hz). N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC, 1 mM) and N-hydroxysuccinimide (sulfo-NHS, 2.5 mM) were added to activate 
the surface carboxyl groups (15 minutes incubation, RT). Subsequently, the particles were 
centrifugated and resuspended in 1 ml PBS (pH 7.2). After another sonication period of 5 minutes 
(230V, 50Hz), 62.5 µg protein G was added to the GPs and incubated overnight on a shaker at 4°C. To 
block the remaining activated carboxyl groups, the particles were PEGylated by mixing with O-(2-
aminoethyl)polyethylene glycol (10 mg, 3000 MW) for 30 minutes, followed by 0.1 M glycine (30 
minutes).  
Next, these protein G-decorated particles were functionalised with APN-specific mAbs. The particles 
were first washed twice and resuspended in antibody binding buffer (50 mM sodium borate, pH 8.2). 
After sonication for 2 minutes, mAbs against APN (250 µg/ml; IgG1) or irrelevant isotype-matched 
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control mAbs (250 µg/ml; IgG1) were added and gently rocked for 45 minutes at room temperature. 
Subsequently, the antibodies were crosslinked to the GPs by adding 20 mM dimethyl pimelimidate 
(DMP) dissolved in crosslinking buffer (0.2 M triethanolamine, pH 8.2). To block the remaining 
antibody binding spots, 0.1 M ethanolamine (pH 8.2) was added to the particles for 10 minutes. The 
particles were stored at -20°C in PBS at a concentration of 0.5 mg/ml.  
The conjugation efficiency was determined by flow cytometry and confocal microscopy. Goat anti-
mouse IgG-Alexa647 antibody (1/250) was added to the uncoated or coated β-glucan microparticles 
(2.5 µg) and incubated for 30 minutes. These particles were examined by flow cytometry (FACSCanto, 
BD Biosciences) to determine the percentage of conjugated particles and by confocal microscopy 
(Leica DMI6000 B inverted microscope attached to an Andor DSD2 confocal scanner) to determine 
the position of the antibodies on the particles. FACS analysis was performed on 20,000 events within 
the FITC+ gate with FACSDiva software 6.1.3. Confocal images were processed with Imaris software. 
 
5.3.4 Microparticle characterisation 
The surface and internal morphology of the coated and uncoated particles was examined on an 
atomic force microscope (AFM) and on a FACSCanto, respectively. To investigate antigen loss during 
coating, the fluorescence intensity of the uncoated and coated GPs was measured by flow cytometry 
(20,000 events within the GP gate). In addition, we determined the concentration of BSA-FITC in the 
supernatant collected during the coating protocol via fluorimetry against a BSA-FITC standard (2.5 – 
30 µg/ml). To determine antigen capture and the particle size, BSA-FITC-loaded, APN-targeted GPs 
were investigated by confocal microscopy. Image analysis was performed by Imaris software (3D 
visualisation) and ImageJ (diameter calculation). To calculate the mean size distribution, analysis on 
at least 350 particles was performed. The zeta potential of coated and uncoated particles was 
measured in 0.9% saline using a Malvern Zetasizer NS. Both coated and uncoated particles were 
neutrally charged as indicated by the low zeta-potential (-4.85 ± 3.10 mV for coated particles and -
7.22 ± 4.43 mV for uncoated particles). 
 
5.3.5 Primary cell culture 
All animal experiments were approved by the animal care and ethics committee of the Faculty of 
Veterinary Medicine, Ghent University (EC2013/62). Piglets (between 4 and 20 weeks old) were 
housed under standard conditions as blood donors. Peripheral blood was collected on heparin from 
the jugular vein of four pigs. Neutrophils were isolated by density gradient centrifugation on a 
β-glucan microparticles targeted to APN as oral antigen delivery system - Chapter 5 
 
91 
 
discontinuous Percoll gradient (68% and 75%) as described previously.380 Peripheral blood 
monomorphonuclear cells (PBMCs) were isolated by density gradient centrifugation on Lymphoprep 
and monocytes were further enriched from the PBMCs by positive immunomagnetic bead selection 
(MACS). Monocyte-derived dendritic cells (MoDCs) were generated as previously described.402 
 
5.3.6 Oxidative burst assay 
The production of reactive oxygen species (ROS) was measured by a chemiluminescence assay 
described by Donne et al. (2005) with some modifications.381 Neutrophils were seeded in a 96-well 
plate at 2.0 x 105 cells/well in RPMI without phenol-red. The plates were incubated at 37°C for 2 h in 
a humidified atmosphere with 5% CO2 to allow the cells to adhere to the plastic surface. 
Subsequently, the supernatant was replaced by 175 µl luminol (0.5 mM). After 5 minutes of 
background measurement at 37°C, 25 µl of the indicated β-glucan microparticles (0.5 mg/ml) or 1 µm 
latex beads (100 µg/ml) were added. Stimulation of the cells with phorbol myristate acetate (PMA; 
50 µg/ml) was used as a positive control. ROS production was then measured during 120 min in the 
integration mode. Each stimulation was performed in duplicate. The ROS production is expressed as 
relative light units (RLU). 
 
5.3.7 Cell line 
The porcine intestinal epithelial cell line IPEC-J2 was stably transfected with pAPN.260 Cell cultures 
were maintained in Dulbecco's modified Eagle's (DMEM)/F12 supplemented with 10% fetal calf 
serum (FCS, Integro), 1% recombinant human insulin, transferrin and sodium selenite (ITS, Sigma), 
100 U/ml penicillin, 100 µg/ml streptomycin (P/S), 2% L-glutamine, 5 ng/ml epidermal growth factor 
(EGF; Invitrogen) and 1.5 mg/ml geneticin® (G418; Life Technologies) at 37°C and 5% CO2. 
 
5.3.8 Targeting effect assay by flow cytometry 
IPEC-J2 cells were seeded in 24-well plates at a cell density of 1 x 105 cells/well and cultured for 24h 
until a confluent monolayer was achieved. The cells were stimulated with medium, different 
concentration of BSA-FITC loaded β-glucan microparticles (BSA-FITC-GP) conjugated with anti-APN or 
with irrelevant control monoclonal antibodies (100, 25 or 1.25 µg/ml). The particles were incubated 
for 3h at 37°C. After this incubation period, the cells were detached by accutase and analysed by flow 
cytometry (FacsCanto). Dead cells were excluded from the analysis by Sytox red staining (5 nM). Ten 
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thousand viable cells were analysed by FACSDiva software. To determine the expression of APN on 
the surface of these cells, IPEC-J2 cells (105 cells) were stained with an anti-APN mAb (IMM013; 1 µg) 
or an isotype-matched control mAb (IgG1; 1 µg) for 20 minutes on ice, followed by the addition of 
sheep anti-mouse IgG/FITC (1/500) (20 minutes on ice). Cells were analysed by flow cytometry 
(10,000 viable cells). 
 
5.3.9 Fluorescent confocal imaging 
IPEC-J2 cells were cultured on glass coverslips in a 24 well-plate (1 x 105 cells/well). Upon reaching 
confluence, GPs (6.25, 25 or 100 µg/ml) were added to the cell monolayer for 3h. Subsequently, the 
cells were washed and fixed in 3% paraformaldehyde (PFA). Cells were counter-stained with 10 
µg/ml Hoechst and the actin cytoskeleton was visualised by Phalloïdin-Texas Red (1/100) (1h at RT). 
The confocal images were taken by Leica TCS SPE confocal microscope and processed with Imaris 
software. 
 
5.3.10  Porcine small intestinal explants 
Fresh porcine intestinal tissue from the jejunum (with or without Peyer’s patches) and the ileum 
(Peyer’s patches) was obtained from euthanized pigs (6-10 weeks old). The serosa was removed and 
the intestine was first washed with ice cold PBS + 1% P/S, followed by washing with DMEM 
supplemented with 1% P/S and 1% kanamycine for 10 minutes at room temperature (2 times). The 
intestine was cut into sections by a biopsy punch (0.8 cm diameter) in a sterile hood and placed on 
sterile biopsy foam pads, which, in turn, were placed inside six-well plates (one section per well). 
Porcine intestinal explants were cultured at the air-medium interface with the apical side facing 
upward. Culture medium (2.25 ml per well) was poured carefully inside the wells, and was composed 
of DMEM with 5% FCS (Integro), 1% P/S, 20 mM HEPES (Sigma), 1% NE-AA and 1% kanamycine. The 
explants were then placed inside a humidified incubator at 37°C, 5% CO2 for 1 h followed by the 
addition of fresh medium, supplemented with 7.5 mM N-acetyl-L-cysteine.22 Fifteen minutes later, 40 
µg antibodies (anti-APN or isotype control) or 5 µg APN-targeted GPs were added to the explants for 
1h. Then, explants were washed with PBS, placed in methocel and snap-frozen in liquid nitrogen. 
Cryosections (14 µm) were cut by a cryotome (Leica CM3050 S), placed on APES-coated glass slides 
and fixed in aceton for 10 minutes at -20°C. To quantify uptake of particles by intestinal explants (5 
µg GPs, 5 min incubation), cryosections (18 µm) were cut every 500 µm (duplicates per pig, three pigs 
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in total) and the particles within or underneath the epithelial layer were counted. The mean particle 
uptake of 12 different sections per explant (in duplicate) was calculated. 
 
5.3.11  Immunohistochemistry 
Cryosections were washed with PBS and blocked with 10% normal goat serum (diluted in PBS), 
followed by incubation with a mix of sheep anti-mouse IgG-FITC (1/500) with Phalloïdine-Texas Red 
(1/100) or only with Phalloïdine-Texas Red (1/100) at 37°C (60 minutes) in a humidified chamber. 
Slides were then washed with PBS, counterstained with Hoechst (10 µg/ml) for 30 minutes at 37°C 
and mounted with DABCO. Images were acquired with a confocal microscope. 
 
5.3.12 Uptake by MoDCs 
MoDCs were stimulated with medium, 100 µg/ml uncoated BSA-FITC-loaded GPs or coated with anti-
APN mAb or with irrelevant control mAb. The particles were incubated for 1h at 37°C. MoDCs were 
detached by accutase and analysed by flow cytometry (10,000 viable cells). Dead cells were excluded 
from the analysis by Sytox red staining. To investigate the expression of APN on MoDCs, cells were 
stained with an APN-specific mAb (IMM013) or an isotype-matched control, followed by the 
incubation with sheep anti-mouse-IgG FITC antibodies (1/500). Sytox red was used to exclude dead 
cells. To confirm the uptake of the particles by MoDCs, cells were cultured on glass coverslips and 
visualised by confocal microscopy. Therefore, cells were first fixed in 3% PFA and then stained with 
anti-SIRPα mAbs, followed by the incubation with goat anti-mouse IgG AlexaFluor594 antibodies (1h 
at RT). Cells were counterstained with 10 µg/ml Hoechst. Confocal images were processed with 
Imaris software. 
 
5.3.13 Maturation of MoDCs 
The cell surface expression of DC activation markers after stimulation of MoDCs (24h, 37°C) with 
medium, 100 µg/ml uncoated BSA-FITC-loaded GPs or coated with anti-APN or with irrelevant 
control mAb was assessed by flow cytometry using mAbs against MHCII (MSA3, IgG2a409), CD40 (G28-
5, IgG1, anti-human410), CD25 (K231.3B2, IgG1411) and a human CTLA4-muIgG2a fusion protein 
respectively, followed by R-phycoerythrin and AlexaFluor-647 conjugated anti-mouse isotype-specific 
secondary antibodies. Briefly, MoDCs were harvested with accutase, whereafter the cells were 
incubated with pre-titrated saturating concentrations of the primary Abs (20 min, 4°C). Cells stained 
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with isotype-matched irrelevant mAbs were used as negative controls. After washing, the cells were 
stained with the secondary Abs (20 min at 4°C). Next, the cells were washed and data were acquired 
and analysed as described above. 
 
5.3.14 Cytokine secretion profile 
MoDCs were stimulated with the different GPs as mentioned above. After 24h cell-free culture 
supernatant was collected and the porcine TNFα, IL-1β, IL-12p40, IL-8, IL-6, IL-10 and cytokine 
concentrations were determined with commercially available ELISA kits according to the 
manufacturer’s instructions. Briefly, microtiter plates were coated overnight at room temperature 
with capture Ab specific for the analysed cytokines. The plates were washed, blocked and samples 
and standards were analysed in duplicate with the detection Ab and the streptavidin-HRP system. 
Optical densities were measured with an ELISA plate reader at 450 nm. The cytokine concentrations 
were calculated using DeltaSOFT JV 2.1.2 software (BioMetallics, Princeton, NJ, USA) with a 5-
parameter curve-fitting algorithm applied for standard curve calculations. 
 
5.3.15 Oral immunisation model 
Piglets (3-4 weeks old) were screened for the presence of FedF-specific serum antibodies and 
negative animals were further tested for the presence of the F18-receptor (F18R) by detection of a 
polymorphism in the FUT1 gene.412 Twelve F18R+ FedF seronegative piglets were selected and 
transported to isolation units with water and feed ad libitum. To prevent E. coli infections, animals 
were treated orally with colistin for four consecutive days (150 000 U/kg body weight/day; 
ProMycine® Pulvis) until one day before the immunisation. Experimental and animal management 
procedures were approved by the animal care and ethics committee of the Faculty of Veterinary 
Medicine (EC2014/114). Piglets received oral doses of either 50 µg cholera toxin (CT) in 0.9% saline, 
soluble FedF (1 mg) with CT (50 µg), FedF-GP (2.5 mg) with CT (50 µg) or anti-APN FedF-GP (2.5 mg) 
with CT (50 µg) in 0.9% saline. FedF was loaded inside the β-glucan microparticles with an efficiency 
of 84.53% ± 2.89. Booster doses were given on day 14. One day before the immunisations, 20 mg 
Pariet® was given and feed but not water was withheld overnight. On day 28, blood was collected to 
analyse total FedF-specific Ig and IgA antibody responses in sera via ELISA. Briefly, microtiter plates 
were coated overnight at room temperature with FedF (5 µg/ml). The plates were washed, blocked 
(PBS supplemented with 0.2% Tween80 and 3% BSA) and serum (1/15) was analysed in duplicate 
with anti-pig-Ig (H+L) or IgA/HRP (1:5000). Optical densities were measured with an ELISA plate 
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reader at 405 nm and data are expressed as corrected optical densities (ODd28 - ODd0). The optical 
density cut-off points (corrected ODd28 of control group + 3 x SD) were 0.0887 for serum FedF-specific 
Ig and 0.0209 for serum FedF-specific IgA. At day 28, 14 days after the booster immunisation, 
peripheral blood mononuclear cells (PBMCs) were isolated from heparinised blood to detect 
circulating FedF-specific antibody secreting cells (ASC) by ELIspot as previously described.413 Briefly, a 
96-well microtiter plate (Maxisorp™ Thermo Scientific) was coated with FedF (5 µg/ml). 
Subsequently, the plates were blocked (RPMI + 10% FCS) and 5.0 x 105 PBMCs in 100 µl RPMI 
complete (RPMI containing 1% kanamycin, 1% P/S, 5% FCS, 1% glutamine, 1% NE-AA, 1% sodium-
pyruvate) were added overnight at 37°C in a humidified 5% CO2 atmosphere. After removing the 
cells, FedF-specific IgG ASC were detected with monoclonal anti-porcine IgG or IgA (1 h, 37°C) 
followed by an incubation for 1 h at 37°C with HRP-conjugated anti-mouse IgG antibody (1:1000). To 
visualise spots, 50 µl 3,3’,5,5’-tetramethylbenzidine liquid substrate for membranes (TMB) was 
applied for 15 min at room temperature. The resulting spots were scanned with an Immuno-Spot® 
analyser (CTL-Europe GmbH, Germany). For each condition spots in 7 wells (0.5 × 106 cells/well) were 
counted to obtain the number of FedF-specific IgG and IgA ASCs per 3.5 × 106 PBMCs. 
 
5.3.16 Statistical analysis 
All statistical analyses of the experiments were conducted by GraphPad Prism using a t-test to 
compare two conditions or a one-way analysis of variance (ANOVA) test (post hoc: Tukey) to 
compare more than two conditions. A P-value of <0.05 was considered significant.  
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5.4 Results and Discussion 
5.4.1 Oriented conjugation of monoclonal antibodies to β-glucan microparticles 
To allow oriented conjugation of antibodies to BSA-FITC-loaded β-glucan microparticles (BSA*GPs), a 
key feature to achieve optimal targeting potential, the GPs were first conjugated with protein G. This 
protein is well-known for binding Fc fragments of mouse IgG1 antibodies. Noteworthy, protein G has 
several Fc binding domains making oriented conjugation less critical. A carbodiimide linker was 
chosen to perform this conjugation, since these GPs contain carboxyl groups on their surface, due to 
the residual proteins present in the cell wall, available for linkage to NH2 groups of protein G.
28 Next, 
the protein G-conjugated GPs were functionalised with mouse monoclonal antibodies (mAbs) against 
APN (IgG1) (APN-BSA*GPs) (Figure 1). The conjugation efficiency of three independent procedures 
was determined by flow cytometry (Figure 2A) and confocal microscopy (Figure 2B). Figure 2A 
depicts a representative dotplot of the uncoated and coated particles. The mean conjugation 
efficiency was 96.9% ± 3, illustrating a highly efficient conjugation of the mAbs to the particles. 
Confocal imaging demonstrated the position of these antibodies on the particles (Figure 2B). The 
monoclonal antibodies (red) clearly cover the particles (green) (Figure 2B2) as compared to uncoated 
particles (Figure 2B1), demonstrating the equal distribution of the mAbs on the GP surface, despite 
its low protein content. 
 
 
 
 
 
 
 
Figure 1. Development of APN-targeted β-glucan microparticles.  
Schematic representation of the synthesis of antibody-conjugated β-glucan microparticles. Empty porous β-
glucan microparticles were loaded with BSA-FITC (green) and coated with protein G (purple) via EDC-NHS 
chemistry. The unbound amino-reactive spots were blocked with PEG. Monoclonal antibodies were crosslinked 
to protein G. 
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Figure 2. Coating efficiency of antibodies to β-glucan microparticles.  
(A) Coating efficiency was determined by flow-cytometric quadrant statistics using a secondary anti-mouse IgG 
AlexaFluor 647 antibody. FITC
+
 and AlexaFluor647
+
 GPs were defined and compared to uncoated particles. 
Histogram showing the distribution of AlexaFluor647
+
 particles. (B) Confocal images of uncoated BSA-FITC 
loaded GPs (B1) and BSA*GPs coated with anti-APN mAbs (B2). Representative data of three independent 
batches are shown.  
 
5.4.2 β-glucan microparticle characteristics 
When analysing the conjugation efficiency, we observed an increase in the side scatter (SSC) value of 
the mAb-conjugated BSA*GPs as compared to uncoated particles (Figure 3A2). This was unexpected 
as SSC values usually reflect the internal complexity of particles and the GP surface modification 
should not affect the particle’s interior. To further look into this, conjugated and unconjugated 
particles were analysed with atomic force microscopy (AFM). As illustrated by Figure 3A1 uncoated 
GPs exhibit a smooth surface (Figure 3A1a), while conjugated GPs have a rougher surface (Figure 
3A1b), probably due to the EDC/NHS-chemistry used to conjugate protein G. These findings also 
indicate that measuring SSC by flow cytometry, a high throughput technology, can inform on changes 
in surface morphology during microparticle fabrication. Analysis of the BSA*GPs by confocal 
microscopy revealed aggregation of the microparticles (Figure 3B1), a feature which could hamper its 
application in oral vaccination. This aggregation was reduced by the introduction of a PEGylation step 
during production of the mAb-conjugated BSA*GPs (Figure 3B2). To address whether conjugation 
affected the size of the particles, we determined the size distribution upon exclusion of aggregates. 
As shown in Figure 3C, the size distribution of the uncoated and coated particles was similar, just as 
their mean diameter (uncoated particles: 3.246 ± 0.871 µm; coated particles: 3.272 ± 0.709 µm).  
Yeast-derived β-glucan microparticles combine antigen delivery and adjuvant activity.25 Importantly, 
conjugation of these particles with antibodies did not interfere with these properties, as reflected by 
a similar antigen load and respiratory burst response by neutrophils. Indeed, we could not detect a 
difference in the fluorescence intensity between the uncoated GPs and anti-APN mAb-conjugated 
GPs (Figure 3D) and we were unable to detect BSA-FITC in the supernatant, collected during the 
A 
B1 
B2 
    BSA-FITC        Antibody          Merge 
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conjugation protocol, by a fluorimeter (data not shown), demonstrating that BSA-FITC is strongly 
incorporated inside the GPs. Furthermore, 3D images (Figure 3E) clearly show a similar distribution of 
the antigens inside the coated GPs. Besides their high encapsulation efficiency, GPs contain β-
glucans, which are well-known to trigger antimicrobial activity of neutrophils.380 To investigate 
whether mAb conjugation to GPs resulted in masking of β-glucans, and thus in masking their 
adjuvanticity, the production of reactive oxygen species (ROS) by neutrophils incubated with GPs was 
examined. As compared to inert latex beads (1 µm), both uncoated and coated GPs triggered ROS 
production by neutrophils, while mAb conjugation slightly decreased this response compared to 
uncoated GPs (Figure 3F). Since porcine neutrophils are APN-negative (data not shown), this ROS 
production results from the β-glucans, which are clearly still exposed after conjugating the particles 
with antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Characterisation of APN-targeted β-glucan microparticles.  
(A) Atomic force microscopic (AFM) images of uncoated (A1a) or APN-coated (A1b) GPs. Side scatter (SSC) 
analysis of uncoated and coated particles. Data is presented as the mean SSC ± SEM of three batches (A2). (B) 
Confocal images of uncoated (B1) or coated (B2) BSA-FITC loaded GPs. (C) Size distribution histograms of 
uncoated and coated GPs. Aggregates were excluded from the results. (D) Determination of antigen (BSA-FITC) 
loss after coating by measuring the fluorescence intensity (FI) of uncoated and coated GPs by flow cytometry. 
Data are presented as the mean FI ± SD of three batches. (E) A 3D image of APN-BSA-FITC loaded particles. (F) 
Neutrophils (2 x 10
5
 cells) were stimulated with 100 µg/ml of the indicated GPs. ROS production was 
determined via chemiluminescence. Data are shown as the mean relative light units (RLU) ± SEM of five pigs. 
Values of the negative control have been subtracted from the values represented on the graph. 
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5.4.3 Uptake by intestinal epithelial cells 
One of the most important features of potential oral vaccine delivery systems is their efficient 
transcytosis through intestinal epithelial cells. Although the size of these β-glucan microparticles is 
ideal for internalisation by M cells in Peyer’s patches, reaching villous enterocytes may promote the 
efficacy of oral vaccines. Targeting enterocytes as well as M cells could result in a higher 
bioavailability, thus lowering vaccine dosage and reducing the high cost of subunit vaccines. As an 
endocytotic receptor on the apical surface of enterocytes, aminopeptidase N (APN) is an appealing 
target to promote antigen delivery across the epithelial barrier. We recently reported that polyclonal 
antibody-mediated targeting to APN resulted in antigen uptake and in robust immune responses.260 
To further expand these findings to antibody-mediated uptake of microparticles, we targeted β-
glucan microparticles (GP) to APN and explored GP uptake by the porcine intestinal epithelial cell line 
IPEC-J2414 and by intestinal explants. This cell line was transfected to increase APN surface levels 
(Figure 4A). To investigate if conjugation of the anti-APN mAb to GPs resulted in an increased 
internalisation of GPs, we measured the endocytosis of anti-APN mAb-conjugated GPs and GPs 
conjugated with an irrelevant control mAb by flow cytometry. GPs targeted to APN were taken up 
significantly more than isotype-conjugated GPs (Figure 4B). Even at a 16-fold lower concentration, 
APN-targeted GPs are still ten times more internalised by IPEC-J2 cells as compared to control GPs. 
The viability of the cells was not reduced even at the highest GP concentration (data not shown). To 
discriminate between membrane-associated GPs and internalised GPs, we performed confocal 
microscopy. Figure 4C clearly demonstrates the presence of the APN-BSA*GPs particles inside the 
cells, indicating that the functionalisation of the β-glucan microparticles with APN-specific antibodies 
was highly efficient, resulting in an increased uptake of the targeted GPs by enterocytes. 
In a next effort we evaluated internalisation of these GPs by intestinal explants. Figure 5B 1, 2 and 3 
clearly show the uptake of APN-specific mAbs by intestinal epithelial cells located in the jejunum 
without Peyer’s patches and the jejunum and ileum with Peyer’s patches, respectively, while the 
irrelevant control mAb failed to bind to or be taken up by the intestinal epithelial cell layer in all 
compartments (Figure 5A). This indicates that antibodies against APN are promising ligands to target 
intestinal epithelial cells. Indeed, Figure 5C clearly shows that APN-targeted GPs are transcytosed 
through the epithelial barrier in the jejunum and ileum. Even in the jejunum without Peyer’s patches, 
internalisation of APN-BSA*GPs was observed. Interestingly, when we quantified particles in the 
lamina propria (LP), APN targeting resulted in a significantly higher uptake as compared to control 
particles (Figure 5D). As expected, in the ileal Peyer’s patches the uptake of the particles was higher 
than for the lamina propria (Figure 5D), however, no significant difference in uptake between the 
different particles was detected.  
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These results demonstrate the efficient functionalisation of β-glucan microparticles with anti-APN 
monoclonal antibodies via protein G-mediated oriented conjugation. Moreover, APN targeting 
clearly resulted in a higher uptake of the GPs by intestinal epithelial cells located in the jejunal lamina 
propria than uncoated particles. Since the lamina propria constitutes the largest surface area in the 
intestine, these results imply that more APN-targeted GPs may reach the intestinal mucosa upon oral 
administration than control particles, which may allow for a lower vaccine dosage. 
 
 
 
 
 
 
 
Figure 4. Endocytosis of APN-targeted GPs by IPEC-J2 cells. 
(A) Binding of anti-APN to APN-IPEC-J2 cells was quantified by flow cytometry. Data are presented as the mean 
percentage FITC-positive cells (mean ± SD) of three independent experiments. (B) In vitro microparticle uptake 
by the porcine intestinal epithelial cell line APN-IPEC-J2. IPEC-J2 cells were incubated with BSA-FITC-loaded GPs 
coated with anti-APN or irrelevant control mAb at particle concentration of 100, 25 or 6.25 µg/ml for 3h. Data 
represent the percentage FITC-positive cells (mean ± SD) of three independent experiments. **: p < 0.01; ***: 
p < 0.001. (C) Confocal image of APN-IPEC-J2 cells following incubation with BSA-FITC loaded GPs coated with 
anti-APN mAb (green). The actin cytoskeleton was visualised with phalloidine-TR (red), while the nucleus was 
counterstained with Hoechst (blue). 
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Figure 5. Endocytosis of APN-targeted GPs by intestinal explants. 
Confocal images of porcine intestinal tissue following incubation (1h, 37°C) with an isotype control (A) or 
monoclonal antibodies against APN (B). Binding or endocytosis of this antibody was determined in explants 
obtained from the jejunum without PP (LP) (1), the jejunum with PP (2) and the ileum PP (3). The monoclonal 
antibody was visualised with anti-mouse IgG-FITC (green), the plasma membrane with Phalloidine-TR (red) and 
the nucleus with Hoechst (blue). (C) Confocal images of porcine intestinal tissue following incubation with APN-
BSA*GPs (green). Endocytosis was determined in explants obtained from the jejunum without PP (LP) (1), the 
jejunum with PP (2) and the ileum PP (3). The plasma membrane was visualised with Phalloidine-TR (red) and 
the nucleus with Hoechst (blue). The white arrows indicate engulfed particles surrounded by actin, indicative of 
endocytosis. (D) The uptake of particles by porcine intestinal explants (jejunum without PP (LP) and the ileal 
PP) was quantified via fluorescence microscopy. The mean particle uptake of 12 different sections per explant 
(in duplicate) was calculated (mean ± SEM, n = 3).*: p<0.05. 
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5.4.4 APN-targeted GPs promote DC maturation 
Once the GPs are transcytosed through the epithelial barrier, they have to trigger antigen presenting 
cells (APCs) to activate the innate and adaptive immune system. One of the most potent APCs are 
dendritic cells (DCs), which bridge innate and adaptive immunity.415 To assess whether the 
conjugated particles can be taken up by DCs, monocyte-derived dendritic cells (MoDCs) were 
cultured in the presence of GPs and their uptake was evaluated by flow cytometry and confocal 
microscopy. Although only a subset of porcine MoDCs (~30%) express APN (Figure 6A1), most MoDCs 
have taken up the particles irrespective of mAb conjugation (Figure 6A2). Interestingly, dendritic cells 
stimulated with APN-targeted GPs showed a significantly higher antigen load than MoDCs stimulated 
with uncoated particles, while the endocytosis of isotype control conjugated particles was 
approximately the same as the anti-APN conjugated particles (Figure 6A2). This indicates that the 
decoration of GPs with antibodies can promote a more efficient internalisation by DCs. Next, 
confocal microscopy was used to distinguish between internalised and cell membrane bound APN-
targeted GPs. As shown in Figure 6A3, a huge amount of APN-targeted BSA*GPs were taken up by 
the MoDCs. A key feature of DCs is their maturation, a process culminating in the enhanced ability to 
activate T cells via the upregulated expression of membrane proteins, involved in antigen 
presentation and T cell interaction, and the secretion of cytokines.415 In an effort to determine the 
maturation of these GP-stimulated DCs, the cell surface expression of MHCII, CD40, CD80/86 and 
CD25 was analysed (Figure 6B).416 In comparison with control MoDCs, APN-targeted GPs resulted in 
an upregulated cell surface expression of CD40 and CD25 on the MoDCs, while MHCII and CD80/86 
levels were less affected. DC maturation is accompanied by elevated cytokine secretion levels, which 
drive the differentiation and polarisation of T cells. To assess the effect of GPs on the MoDCs 
cytokine secretion profile, we analysed the secretion of TNFα, IL-1β, IL-12p40, IL-8, IL-6 and IL-10 
(Figure 6C). As compared to control MoDCs, IL-10 and TNFα secretion was significantly increased for 
all conditions. Interestingly, APN-targeted GPs significantly triggered higher TNFα secretion levels 
than uncoated GPs. Moreover, APN-targeted GPs significantly upregulated the IL-1β and IL-12p40 
secretion levels, while these cytokine levels were less elevated by DCs stimulated with control GPs. 
Intriguingly, in all these experiments no significant difference between the anti-APN and isotype 
control coated GPs was observed. Presumably, the Fc domains of the conjugated mAbs can still 
interact with the Fcγ receptors located on dendritic cells. Indeed, multiple IgG molecules within an 
immune complex can bind activating Fc receptors (FcγRs) present on monocyte-derived DCs.417 
Altogether, these findings demonstrate that APN-targeted GPs promote DC maturation, probably 
due to the synergistic effect of APN-targeting, Fc receptor engagement and β-glucan recognition. 
Indeed, crosslinking of APN positively influences phagocytosis by immune cells and β-glucans are 
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known as immune stimulators,187, 352 suggesting that APN-targeted GPs possess a dual function: 
promoting the transcytosis through the epithelial barrier and DC maturation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Immune stimulation by APN-targeted β-glucan microparticles. 
(A1) Binding of anti-APN to MoDCs was quantified by flow cytometry. Data are presented as the mean 
percentage FITC-positive cells (mean ± SEM) of four animals in duplicate. (A2) MoDCs (5 x 10
5
 cells) were 
cultured for 5 days followed by incubation with β-glucan microparticles (100 µg/ml). After 1 hour the cells were 
collected and analysed by flow cytometry. Data are represented as percentage FITC-positive cells (mean ± SD) 
or mean fluorescence intensity (MFI ± SD) of four animals in duplicate. (A3) Confocal image of MoDCs following 
incubation with APN-targeted particles (green). Nucleus was visualised with Hoechst (blue) and the plasma 
membrane with SIRPα-Alexa594 (red). (B) Analysis of DC activation marker expression. Stimulated MoDCs were 
analysed for the expression of the cell surface markers MHCII, CD40, CD25 and CD80/86 by flow cytometry. The 
data represent the mean ± SEM of four pigs. Values of the isotype control have been subtracted from the 
values represented on the graph. (C) Cytokine secretion levels of activated MoDCs. Immature MoDCs were 
stimulated with the indicated agents for 24h. Cell-free supernatant was collected and the concentration of 
TNFα, IL-1β, IL-12p40, IL-8, IL-6 and IL-10 was quantified by ELISA. Data are represented as means ± SEM (n = 5 
individual blood donors). 
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5.4.5  Increased systemic antibody responses upon oral immunisation with APN-targeted FedF-
GPs 
Because of the promising in vitro and ex vivo characteristics of the APN-targeted GP delivery 
platform, i.e. efficient antigen encapsulation, highly efficient internalisation by porcine intestinal 
epithelial cells and MoDC maturation in vitro, we used these targeted particles in an oral 
immunisation experiment. We aimed to determine if oral immunisation with APN-targeted FedF-GPs 
could deliver encapsulated antigens (FedF) to the immune system and induce systemic antigen-
specific antibody responses. As illustrated in Figure 7, piglets orally received either CT, soluble FedF 
and FedF-GPs coated with or without APN-specific antibodies (Figure 7A). Booster doses were given 
on day 14. After 28 days, the FedF-specific Ig and IgA levels in serum were not increased in the FedF-
treated pigs as compared to the control group (Figure 7B). Although FedF is a weak antigen,418 
loading of FedF into GPs (FedF-GP group) triggered FedF-specific antibodies as compared to the 
control group, although the significance level was not reached (Figure 7B). These results are 
comparable with previous results where no significant antigen-specific immune responses could be 
detected in serum of mice orally immunised with uncoated OVA-GPs.32 In contrast to FedF-GPs, 
targeting of FedF-GPs to APN elicited significantly higher FedF-specific antibody responses. In 
addition, FedF-specific IgA antibodies were only detected in the APN-FedF-GP group (Figure 7B). A 
similar result was seen for the FedF-specific IgG ASC. Only APN-targeted FedF-GP induced a 
significant higher number of FedF-specific IgG ASC as compared to the control group (Figure 7C). 
Likewise, the highest FedF-specific IgA ASC were observed in the APN-FedF-GP group (Figure 7C). We 
conclude that oral administration of APN-targeted FedF-GP particles to piglets triggers a higher FedF-
specific systemic antibody response as compared to non-targeted particles. The production of IgA 
antibodies is important for protection against mucosal pathogens. Indeed, secretory IgA antibodies 
are known to neutralise pathogens and their enterotoxins in the lumen of the gut. Mucosal intestinal 
IgA responses were analysed as well, however, these data were not useful due to the high 
background immune responses in the control group. Further research should focus on the enteric 
protection triggered by oral administration of these particles. 
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Figure 7. Systemic antibody responses upon oral immunisation of piglets. 
(A) Oral administration protocol. (B) FedF-specific serum immunoglobulin (Ig and IgA) levels on d28 as 
measured by ELISA are expressed as corrected optical density (OD) (mean ± SEM, n = 3). (C) FedF-specific IgG 
and IgA ASCs on d28 as measured by ELIspot are expressed as spots per 3.5 x 10
6
 cells (mean ± SEM, n = 3). *: p 
< 0.05. 
 
5.5 Conclusions 
In conclusion, by protein G conjugation we have developed a novel β-glucan microparticle (GP)-based 
antigen delivery platform to achieve selective targeting towards intestinal epithelial cells. 
Functionalisation of these β-glucan microparticles with monoclonal antibodies was highly efficient, 
and this conjugation did neither interfere with the antigen load nor the inherent adjuvanticity of the 
β-glucans. Furthermore, targeting to APN is a promising way to deliver antigens to the intestinal 
mucosa, since these microparticles are internalised by intestinal epithelial cells and trigger the 
maturation of dendritic cells, both crucial events in the induction of protective immunity. In addition, 
oral immunisation of piglets with APN-targeted FedF-GPs elicits systemic antigen-specific antibody 
responses. These findings might be crucial to assist the design of an oral subunit vaccine against 
enteric pathogens. 
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CHAPTER 6: General Discussion 
6.1 Introduction 
To control post-weaning diarrhoea (PWD) in pigs antibiotics are commonly used.9, 10 The long term 
and extensive use of antibiotics, both as therapeutic and as growth-promoting agent, has resulted in 
antibiotic resistance.419 Therefore, since 2006, the use of antibiotic growth promoters for prevention 
of diarrhoeal diseases in piglets has been completely banned in the European Union. However, this 
caused a reduced performance and increased morbidity in post-weaning pigs and consequently, the 
development of alternative strategies, such as feed supplements or vaccination, is required to sustain 
animal health and performance.11 Non-digestible carbohydrates have been tested as effective 
alternatives for antimicrobial growth promoters to help post-weaning piglets to cope with feed 
transition and stress during this period.12, 13 Dietary β-glucans have the capacity to act as 
immunostimulants and are thus of particular interest as alternative nutritional additives. The 
immunostimulatory effects of β-glucans are well-known, however, the contribution of the different 
β-glucan receptors to the β-glucan mediated effects is still a matter of debate. In this dissertation, we 
examined the role of the β-glucan receptors dectin-1 and complement receptor 3 (CR3) and their 
signalling pathways in the β-glucan-mediated activation of porcine innate immune cells. Besides feed 
additives, oral vaccination could alleviate PWD. Oral vaccines are superior to parenteral vaccines due 
to their ability to trigger both systemic and local antibody responses and their socio-economic 
advantages. Current commercial oral vaccines mainly use live-attenuated microorganisms replicating 
in the gut.38 However, live vaccines have potential risks and therefore, vaccine design also focuses on 
creating non-replicating oral vaccines. Thus, the development of an oral vaccine is challenging since 
the gastrointestinal tract is a very hostile environment, the passage through the epithelial barrier is 
difficult and orally administered antigens generally induce oral tolerance.33-37 Therefore, strategies to 
surmount these obstacles, e.g. encapsulation, adding adjuvants and selective targeting, are required 
to develop oral vaccines. Here, we took advantage of the immunostimulatory potential of particulate 
β-glucans to create an oral vaccine. β-glucan microparticles (GPs) are already described as promising 
antigen vehicle systems with a high antigen encapsulation efficiency and safety.21-32 In addition, we 
further improved these particles by enhancing their uptake across the epithelial barrier.  
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6.2 β-glucans and their receptor usage 
Since no data are available on the β-glucan receptor usage and the β-glucan signalling pathway in 
porcine neutrophils and macrophages, chapter 3 investigated the involvement of dectin-1 and 
complement receptor 3 (CR3) in the β-glucan-mediated responses by porcine innate immune cells. 
For this purpose, dectin-1 and CR3 were blocked and the β-glucan-mediated reactive oxygen species 
(ROS) production by porcine neutrophils was measured. Laminarin was used to inhibit dectin-1, since 
blocking monoclonal antibodies against porcine dectin-1 are not available and the human and murine 
dectin-1 mAbs do not crossreact with porcine dectin-1. Laminarin has been shown to be one of the 
most effective inhibitors of dectin-1.420 Similar to the results in human neutrophils, dectin-1 does not 
seem to play a role in the ROS production by porcine neutrophils towards β-glucans, while CR3 is 
indispensable in these responses. Interestingly, we have strong indications that CD11R3 is the α 
subunit of CR3 in pigs, since this receptor is involved in the β-glucan mediated immune responses in 
porcine neutrophils. In contrast, CD11R1, which is recognised by cross-reactive human CD11b-
specific mAbs, is not involved in these responses. Furthermore, as the FAK inhibitor is able to 
completely inhibit the β-glucan-mediated responses, we propose that the signal molecule FAK is 
indispensable for the β-glucan-mediated responses (ROS and cytokine production) in porcine 
neutrophils. As a role for dectin-1 is lacking, but there is a minor role for Syk in β-glucan signalling, we 
believe that recruitment of Syk is mainly triggered by phosphorylation of the adaptor molecules FcRγ 
or DAP12 by Src kinases (Figure 1a). It has already been described that integrin ligation could induce 
phosphorylation of the ITAM-bearing adaptor molecules FcRγ or DAP12, which creates docking sites 
for Syk and contributes to the activation of FAK.130 
On the contrary, the contribution of dectin-1 and complement receptor 3 in the β-glucan-mediated 
responses is less clear for porcine macrophages. Dectin-1 seems to be involved in the phagocytosis of 
zymosan. Unlike the results obtained in porcine neutrophils, complement receptor 3 does not play a 
role in zymosan phagocytosis by macrophages, however, CD11R3 seems to be involved in the 
cytokine secretion mediated by different particulate β-glucans, including zymosan. Conversely, 
dectin-1 is not involved in this β-glucan-mediated response, not even for zymosan, indicating the 
complex mechanism of β-glucan recognition and signalling in porcine macrophages. The most 
interesting revelation is that FAK acts as a crucial regulator in the β-glucan-mediated responses, 
whereas Syk is only partially involved. Interestingly, in the Euglena gracilis-mediated cytokine 
responses Syk’s role seems to be as important as FAK. Therefore, we propose that the β-glucan 
structure determines which receptor they bind. Indeed, complement receptor 3 (CR3) seems to play 
a minor role for Euglena gracilis-mediated responses in macrophages, whereas this receptor is 
significantly involved in the zymosan- and Macrogard-mediated cytokine responses. Since both 
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zymosan and Macrogard have a β(1,3)-linked backbone with β(1,6)-linked branches, while Euglena 
gracilis is unbranched, we suspect that branches are crucial for recognition by CR3 on porcine 
macrophages. Other receptors, such as scavenger receptors or lactosylceramide, are probably 
involved in the β-glucan-mediated responses as well (Figure 1b). We propose that macrophages can 
switch between different β-glucan receptors, however, one receptor will dominate over the other 
and will direct the immune response (Figure 1b).421 This hypothesis correlates with the host response 
to infection being reliant on the cellular heterogeneity. It is likely that different receptors contribute 
to β-glucan recognition, and it would be interesting to determine which receptors could substitute 
for dectin-1 and CR3.153 CD36 and SCARF1 are potential β-glucan receptors expressed on porcine 
macrophages (Supplemental Figure 1) and are probably involved in β-glucan recognition. However, 
experiments have to be performed to confirm this hypothesis. 
Besides the difference in receptor recognition, the β-glucan structure is also responsible for their 
biological activity, probably attributed to the dominant β-glucan receptor binding capacity. 
Macrogard (200 µg/ml) could only induce marginal cytokine responses by neutrophils and 
macrophages, while zymosan and Euglena gracilis were able to trigger higher cytokine secretions. 
Conversely, at the same concentration, Macrogard and Euglena gracilis were able to induce strong 
ROS production by neutrophils, while this response towards zymosan was significantly lower. This 
indicates that differences in branches are important for their receptor recognition and subsequent 
immunomodulating properties. However, a cautious approach must be adopted to the interpretation 
of these data, since β-glucan preparations, such as zymosan, are often impure, which could influence 
receptor binding or cellular responses. 
Altogether, the observed results in pigs correlate with the receptor usage described in human innate 
immune cells, while they differ with the rodent system. In porcine and human neutrophils, CR3 
seems to be the most important β-glucan receptor,150, 151 which contrasts with what has been 
published for murine neutrophils.125, 148, 153 On the contrary, the importance of receptor 
heterogeneity in β-glucan recognition by monocytes/macrophages seems to be important in all three 
species. These interesting results could contribute to the implementation of β-glucans as feed 
additives or as alternatives for antibiotics in pigs. Indeed, knowledge about β-glucan receptor binding 
and signalling by porcine neutrophils could be used to steer specific immune responses in vivo.  
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Figure 1. β-glucan recognition and signalling in porcine neutrophils and macrophages. 
(A) β-glucan recognition and signalling in porcine neutrophils. Particulate β-glucans bind the α subunit of CR3 
(CD11R3), which results in the activation of focal adhesion kinase (FAK) and Src kinases, followed by ROS 
production, phagocytosis and cytokine production. Phosphorylated Src kinases can also induce phosphorylation 
of ITAM-containing adaptor molecules, such as DAP12 and FcRγ. This results in docking sites for Syk kinases, 
which will activate FAK as well. (B) β-glucan recognition and signalling in porcine macrophages. Particulate β-
glucans activate the Src-family kinases (Src) by binding dectin-1. Syk is recruited to these phosphorylated 
ITAMs, which results in cytokine production and FAK-mediated ROS production. These β-glucan-mediated 
responses can also be induced by binding to complement receptor 3 (CR3), which induces FAK/Src 
phosphorylation. Phosphorylated Src kinases can also induce phosphorylation of ITAM-containing adaptor 
molecules, such as DAP12 and FcRγ. This results in docking sites for Syk kinases, which will activate FAK as well. 
Other receptors can bind particulate β-glucans in the absence of dectin-1 and CR3, which induces the activation 
of different signalling pathways. 
 
In normal homeostasis, neutrophils are present in blood. Interestingly, it has been described that 
orally administered β-glucan particles are found in the blood of rats,422 indicating the possibility to be 
phagocytosed by blood neutrophils. However, neutrophils are also found at the intestinal mucosa 
and in the gut lumen. Indeed, during intestinal inflammation neutrophils are the first line of defence. 
Tissue-resident macrophages contribute to the recruitment of neutrophils to the lamina propria or 
the intestinal lumen through production of chemokines.423 424 Intestinal neutrophils release anti-
microbial molecules, reactive oxygen intermediates and monocyte chemoattractants. Oral 
administration of β-glucans can modulate these neutrophil responses. Furthermore, shortly after 
arrival of neutrophils to the mucosa, macrophages are recruited for a second-wave inflammatory 
response that ensues for the next several days.423 Although our experiments were performed on 
monocyte-derived macrophages from porcine blood, the results from our studies give an indication 
about the complex mechanism of β-glucan recognition and signalling in porcine macrophages. 
Different β-glucans will trigger distinct immunological responses. A better understanding of this 
complex interplay might provide new avenues for manipulating macrophage function. Besides the 
recruitment of neutrophils and macrophages during inflammation, resident macrophages are also 
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present in the gut. Thus, β-glucans can bind intestinal macrophages under normal homeostasis as 
well. Interestingly, it is well established that the epithelium works in coordination with microflora 
and immune cells to maintain this intestinal homeostasis.425 Thus, the influence of β-glucans on the 
microflora or intestinal epithelial cells84 could affect neutrophil or macrophage recruitment to the 
intestinal mucosa. Understanding the interaction of β-glucans with the microflora, intestinal 
epithelial cells and immune cells could result in a better decision process for the selection of β-
glucans as feed additive or growth promoters. 
 
6.3 Functionalised β-glucan microparticles as a versatile oral vaccine platform 
Since particulate β-glucans are well-known for their immune-stimulating character (chapter 3), using 
these polysaccharides as adjuvants for oral vaccination seems very interesting. In particular, β-
glucans derived from the major cell wall component of yeast (zymosan and Macrogard) have DC 
immunostimulating properties,53 suggesting that β-glucan-rich yeast shells have the potential to be 
exploited as an oral antigen delivery system. Saccharomyces cerevisiae-derived β-glucan 
microparticles (GPs) are already described as hollow and porous particles primarily composed of β-
1,3-D-glucan polymers (β-glucans) with a high antigen loading efficiency.26 The immunostimulating 
properties of these particles have been demonstrated as well. Indeed, β-glucan microparticles 
induces TNFα responses by dendritic cells (DCs) in vitro31 and Th17 responses in mice after oral 
administration.32  
Besides mucosal adjuvants, oral vaccines require the protection of their antigens against the hostile 
environment of the gastro-intestinal tract. Incorporation of antigens in microparticles is helpful to 
protect them against degradation in the stomach. Moreover, the encapsulation in microparticles is a 
promising way to deliver a sufficient amount of antigens to the intestinal mucosa in order to elicit 
sufficient immune responses against the orally administered soluble antigens. Interestingly, β-glucan 
particles have a dual function: these polysaccharides serve as both adjuvant and antigen carrier. 
Indeed, hollow β-glucan particles are known to be easily loaded with antigens, which can protect the 
antigens against enzymatic degradation in the gastrointestinal tract. The high antigen loading 
capacity was confirmed in our experiments. Previous studies only loaded albumin (BSA, OVA), while 
we successfully loaded a clinically relevant infectious antigen (FedF) inside the GPs. Antigen-loaded 
GPs have immunostimulatory responses, however, these responses were lower in comparison with 
hollow particles for reasons yet unknown. Perhaps the β-glucan structure changes after antigen 
loading. An extra hollow GP control, which undergoes the same protocol without antigen loading, 
would give us more information whether the decreased ROS production is caused by the antigen or 
the used protocol. However, the antigen-loaded particles still exert antimicrobial activity on porcine 
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neutrophils by binding to CR3, indicating the immunestimulating potential of the β-glucans in this GP-
based oral vaccine.  
Besides their immunostimulatory properties and their ability to carry a large amount of soluble 
antigens, these particles can be functionalised with targeting antibodies, making these particles very 
promising as oral antigen delivery vehicle. The most difficult task for conjugation of antibodies to 
particles is their oriented conjugation. The antigen binding site (Fab fragment) has to face outwards 
from the particle surface in order to detect their ligand. We used protein G as linker molecule to 
properly conjugate antibodies to the particles. In this thesis (chapter 5), aminopeptidase N (APN) was 
selected as a target to increase the uptake of particles by the epithelial barrier. The correct 
functionalisation of the particles with APN-specific mAbs was demonstrated by the significant higher 
uptake of the APN-targeted GPs by APN-IPEC-J2 cells and by intestinal epithelial cells located in the 
jejunal lamina propria. Since the lamina propria constitutes the largest surface area in the intestine, 
these results suggest that the targeted particles will be transcytosed more in vivo than control 
particles. Indeed, preliminary data in ligated loops indicate that APN-targeted particles are 
endocytosed more than uncoated particles (Supplemental Figure 2). Interestingly, besides the 
efficient targeting to intestinal epithelial cells, aggregation of the APN-targeted particles was 
minimised due to coating with the near neutrally-charged PEG (polyethylene glycol).322 This is 
another reason why we believe that targeted particles will reach the intestinal mucosa more in vivo 
than not-targeted particles. However, to serve as antigen delivery vehicle, it is also necessary that the 
antigens encapsulated within the microparticles are efficiently internalised and subsequently 
processed by antigen-presenting cells (APCs), such as dendritic cells (DCs). DCs are the most potent 
APCs, which orchestrate innate and adaptive immune responses and have the unique capacity to 
activate naïve T cells.426 Uncoated β-glucan microparticles are highly engulfed by dendritic cells, 
which leads to maturation of the dendritic cells (chapter 5) and subsequent antigen presentation to T 
cells (chapter 4). In chapter 5, we demonstrated that targeted particles are more efficiently 
internalised and induce increased maturation compared to uncoated particles. This observation can 
be explained by the synergistic effect of β-glucan recognition by different β-glucan receptors and 
APN targeting. Further experiments are needed to assess this proposed synergistic effect. The 
promising in vitro results incited us to investigate for the first time the efficacy of this APN-targeted 
FedF-loaded GP-based vaccine as oral delivery system in a large animal model. The results clearly 
demonstrate a higher systemic FedF-specific immune response in the group receiving APN-targeted 
particles than in the control group. Although these levels were only significant for total Ig in serum 
and IgG antibody-secreting cells (ASC) in blood, we also observed an increased IgA immune response 
in the APN-targeted group. These results indicate that APN-targeted FedF GPs are a promising oral 
antigen delivery system to combat F18+ E. coli infection. However, whether this vaccine induces a 
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local immune response and could provide protection against a subsequent F18+ E. coli infection has 
not been investigated yet. A schematic representation of these targeted β-glucan microparticles and 
their biofunctionality is given in Figure 2. 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of the effectiveness of APN-targeted β-glucan microparticles.  
Soluble antigens are encapsulated in β-glucan microparticles. Subsequently, these particles are coated with 
protein G, followed by the addition of antibodies against APN. APN-targeted β-glucan microparticles are 
efficiently endocytosed by intestinal epithelial cells by binding to its target protein APN. Furthermore, targeted 
particles induce MoDC maturation and cytokine production significantly more than uncoated particles. 
 
6.4 Main conclusions and future perspectives 
β-glucans use different receptors on innate immune cells to evoke their specific immunomodulatory 
responses. Interestingly, their receptor usage seems to be cell-type specific and species-dependent. 
Indeed, in both human and porcine neutrophils, complement receptor 3 (CR3) and its signalling 
molecule FAK seem to be indispensable for the β-glucan-mediated effects. On the contrary, the 
heterogeneity of receptors is more important to recognise β-glucans in macrophages or monocytes. 
The results obtained in pigs are more similar to the results in man than in mice, where dectin-1 
dominates β-glucan recognition in both neutrophils as macrophages. Since the results from pigs can 
be extrapolated to man, we propose that pigs are a better translational model for β-glucan research 
than mice. Transferring this knowledge to commercial β-glucans developed as in-feed alternatives for 
antibiotics or as immunostimulants might protect both pigs as humans against enteric infections.  
To predict the immunological outcome, the cooperation of different β-glucan receptors and their 
signalling pathways upon stimulation with multiple β-glucans in intestinal resident immune cells 
could be unravelled. Moreover, in order to select more immunostimulatory β-glucans, further 
research could focus on the physiology of different β-glucans and their interaction with the 
microbiota, intestinal epithelial cells (IEC) and the immune system in pigs. β-glucans are already 
known to induce secretion of the pro-inflammatory chemokines IL-8 and CCL2 by human IEC cell lines 
(HT-29 and SW480) via dectin-1 and Syk signalling. These findings highlight the importance of β-
  General Discussion 
 
115 
 
glucan and IEC interactions in intestinal inflammation.84 Investigating the interaction of β-glucans 
with porcine intestinal epithelial cells could be used to redirect the intestinal immune response.  
Furthermore, microbiota are important for gut health and play an important role in immune 
enhancing effect of orally administered β-glucans. This could be attributed to 1) the effect of β-
glucans on microbiota population dynamics (β-glucans have been shown to change the composition 
of the microbiota)214, 427 or to 2) the fermentation of β-glucans by the microbiota into short-chain 
fatty acids (SCFA), such as butyrate, which has multiple beneficial effect on gut health.212 
Unfortunately, the influence of the microbiota on the fate of the β-glucans and the modulation of the 
immune system is not investigated yet in pigs. To address this issue, we could orally administer β-
glucans to gnotobiotic pigs, localise the β-glucans and study the cytokine responses by intestinal 
immune cells. Furthermore, intestinal loop experiment in pigs could be used to evaluate the 
physicochemical behaviour (structural modification, digestibility,..) of different β-glucans. In addition, 
transcriptomic profiling can be assessed for cytokine production and by the pig intestinal micro-array 
as described earlier.428 As such, the most effective β-glucan could be selected as feed-additive as well 
as for designing β-glucan-based oral subunit vaccines, where they can serve as both adjuvant and 
antigen vehicle.  
Until today, only β-glucans derived from Saccharomyces cerevisiae are used as antigen vehicle 
system. Orally delivered yeast-derived β-glucan microparticles are already known to trigger innate 
and adaptive (Th1 and Th17) immune responses and have a high antigen encapsulation efficiency. 
However, β-glucans derived from other sources or from certain mutant strains429 could trigger 
different immune responses. Multiple yeast deletion mutants, carrying a null mutation in a gene 
involved in cell wall synthesis, have been developed to evaluate their immunostimulatory 
characteristics in invertebrates.429 For instance, the Mnn9 yeast mutant, which has less cell-wall 
bound mannoproteins and more glucan and chitin, seems to completely protect Artemia against the 
pathogen Vibrio campbellii.429 Likewise, our preliminary results demonstrate a higher ROS production 
by porcine neutrophils when stimulated with Mnn9 in comparison with the wild-type yeast cells (WT) 
(Supplemental Figure 3).429 However, more research has to be performed to assess the 
immunostimulatory capacity of these yeast mutants. Selection of the most effective β-glucan 
preparation for the desired purpose is important to direct the immune system.  
In this thesis, we have used yeast-derived β-glucan microparticles as antigen carrier for oral 
administration, since its high loading efficiency and immunostimulatory characteristics were already 
thoroughly described. We have incorporated for the first time a clinically relevant antigen, FedF, 
inside these particles. Since the loading of FedF inside the particles was less efficient than for the 
model antigens albumin, optimalisation of the antigen concentration could lead to a higher antigen 
load. However, FedF-loaded GPs were able to induce FedF-specific T cell proliferation and FedF-
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specific antibody responses after oral administration, indicating the successful incorporation of FedF 
inside the particles.  
Furthermore, besides their role as immunostimulants and antigen vehicle, these particles can be 
functionalised with targeting antibodies to direct them towards specific cell types and/or help them 
crossing the epithelial barrier. Aminopeptidase N (APN) was selected as target for the oral GP-based 
vaccine, since APN targeting results in an efficient transcytosis of the particles inside intestinal 
epithelial cells and this protein is also expressed on immune cells. Up till now, the in vivo 
performance and fate of these APN-targeted particles upon oral administration in pigs remain 
unanswered. Are these particles able to cross the epithelial barrier? Although we observed 
transcytosis of the particles in porcine intestinal explants and intestinal loops, the kinetics and 
physiology of the in vivo uptake by enterocytes after oral administration awaits in-depth research. 
Furthermore, it would be interesting to investigate which immune cells phagocytose GPs upon 
crossing the epithelial barrier. Are these immune cells activated and what kind of immune response 
do they elicit? An additional loop experiment is necessary to answer these questions.  
Interestingly, our oral immunisation experiment has demonstrated that APN-targeted FedF-loaded 
particles in combination with cholera toxin (CT) induce FedF-specific serum antibody responses in 
vaccinated pigs, indicating the immune-stimulating capacity of these particles in vivo. Despite these 
promising results, other in vivo experiments should be performed to investigate whether local FedF-
specific SIgA responses are triggered and if these are adequate to protect piglets against an F18+ 
ETEC infection. Since cholera toxin was used as adjuvant immunising piglets with APN-targeted GPs, 
it would be of interest to study the effect of these particles without adjuvant. De Smet et al.32 and De 
Jesus et al.22 already reported that unconjugated microspheres without adjuvant were efficiently 
transcytosed through M cells in the murine gut in vivo and are excellent inducers of both innate and 
T cell responses. However, whether these APN-targeted particle formulations without adjuvant are 
able to overcome oral tolerance in larger animals is not known yet. To address this issue, we could 
investigate whether intestinal APCs will trigger pro-inflammatory cytokine responses upon GP 
uptake. As such, we could predict whether the APN-targeted particles will induce effector T cell or 
regulatory T cell (Treg) responses, thus if this leads to a state of immunological hyporesponsiveness 
towards the administered antigen or not. If these particles are not able to induce protective immune 
responses, modification of the particles with other targeting molecules or adjuvants might direct the 
immune response towards protection. Since the conjugation of protein G creates a platform which 
allows easy switching of the targeting moiety, a combination of targeting ligands could be used to 
functionalise the particles, such as APN to get through the epithelial barrier and TLR5 to target DCs. 
In mice, the ability of TLR5 signalling by DCs to induce mucosal production of IL-17 and IL-22 has been 
demonstrated.430 Since recent studies highlighted the contribution of IL-17 and IL-22 to defensive 
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reactions within the mucosa,431-433 targeting TLR5 could differentiate lymphocytes into T helper 17 
(Th17) cells, which could results in protective immune responses. In addition, TLR5 is also expressed 
on lamina propria DCs in pigs and stimulating these DCs results in functional maturation.434 
Furthermore, the double mutant heat-labile enterotoxin (dmLT) is an attractive adjuvant for inclusion 
in mucosal vaccines. Indeed, dmLT was not only found to be safe and well tolerated in a clinical 
trial,304 this adjuvant also induces cytokine secretion (IL-17, IFN-γ, tumor necrosis factor (TNF)), 
antigen-specific mucosal IgA and cellular immune responses when mucosally administered in 
combination with a pathogenic antigen in mice.435 In addition, further optimising the number of 
antibodies on the surface of the particles, optimising the vaccination dose and encapsulation in an 
enteric coating could result in an efficient immune response towards the pathogenic antigen 
incorporated inside the particles, and consequently, result in a lower vaccination dose. 
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SUPPLEMENTAL FIGURES 
 
 
 
 
 
 
 
Suppl Figure 1. Expression of CD36 and SCARF1 on porcine neutrophils and macrophages. 
The relative expression of CD36 and SCARF1 on porcine neutrophils and macrophages was 
determined by qPCR in relation to the reference gene GAPDH. The relative CT values are presented in 
the graphic. CD36 is highly expressed on porcine macrophages.  
 
 
 
 
 
 
 
 
 
 
 
Suppl. Figure 2. Uptake of APN-targeted GPs in the lamina propria of porcine intestinal loops. 
Pigs were anesthetised under intramuscular anesthesia after an overnight fast as described by Loos 
et al.436 Isolated loops of about 15 mm in length were prepared in situ from the jejunum without 
PP.404, 437 Approximately 500 µl of the GP-suspension was injected into the lumen of the loop. The gut 
was returned to the abdominal cavity, the abdomen was closed and general anaesthesia was 
maintained. After 15 minutes, loops were removed and immediately frozen in methocel. 
Cryosections (18 µm) were cut by a cryotome (Leica CM3050 S), placed on APES-coated glass slides 
and fixed in aceton for 10 minutes at -20°C. (A) Fluorescence image of APN-targeted particles (green) 
in the jejunal lamina propria is given (B) The mean fluorescence intensity of 4 different sections was 
calculated (mean ± SD, n = 1).***: p<0.001. 
 
 
A                   B 
 
 
 
 
 
 
Suppl. Figure 3. ROS production by neutrophils stimulated with yeast (mutants). 
Neutrophils (2 x 105 cells) were stimulated with the living wild type yeast cell (WT1) or the Mnn9 
yeast mutant (A) or hollow yeast particles (B). ROS production was determined via 
chemiluminescence. Data are shown as the mean relative light units (RLU) of four pigs.  
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Postweaning diarrhoea (PWD) is one of the most frequent causes of heavy economic losses in swine 
husbandry due to growth retardation, increased drug use and elevated mortality. Escherichia coli are 
most common causative agent. In order to cope with this problem, antibiotics have been used to 
sustain animal health and performance. However, almost 75% of the piglets in Flanders carry 
resistant E. coli, caused by the excessive use of antibiotics. As these resistant bacteria can also be 
transmitted to humans via the faeces, a serious risk for human health exists. Thus, an alternative 
strategy is necessary to control PWD.  
Immunomodulators, such as β-glucans, have potential to increase the functionality of the immune 
system. The immunostimulating mechanism of β-glucans is, however, still a matter of debate. Dectin-
1 is considered as the main β-glucan receptor in mice, while studies in man show that complement 
receptor 3 (CR3) is more important in β-glucan-mediated responses. In pigs, no data are available on 
the β-glucan receptor usage and the β-glucan signalling pathway in innate immune cells. Elucidating 
which receptor contributes to the response of innate immune cells towards particulate β-glucans in 
pigs has been investigated in this thesis. 
Besides the use of immunomodulators, active oral vaccination against ETEC infections is another 
strategy to prevent PWD in piglets. Current oral vaccines, based on attenuated or killed pathogens, 
have safety risks or elicit an inefficient immune response. Subunit vaccines are a safe alternative, 
however, are less efficacious and require adjuvants. Different strategies exist to increase the 
immunogenicity of these vaccines, such as encapsulation in particles. Designing a subunit oral 
vaccine platform based on particulate β-glucans is another aim of this thesis.  
In the first chapter a brief introduction is given on the molecular structure of different β-glucans, 
their receptors and signalling pathways. Furthermore, the current knowledge on the biological 
effects of orally administered β-glucans is reviewed. 
In chapter 2 a short introduction on the intestinal immune system is given. Furthermore, we 
summarised current registered human and porcine oral vaccines and gave an overview of different 
oral vaccine design strategies, focussing on the use of β-glucan microparticles and different targeting 
strategies. 
Chapter 3 presents our findings on the use of β-glucan receptors and signalling pathways in porcine 
innate immune cells. The cell-type specific recognition of particulate β-glucans in porcine neutrophils 
and macrophages was partially elucidated. Indeed, our results clearly demonstrated an important 
role of CR3 in β-glucan recognition, as blocking this receptor strongly reduced the phagocytosis of β-
glucans and the β-glucan-induced reactive oxygen species (ROS) production by porcine neutrophils. 
Conversely, dectin-1 does not seem to play a major role in β-glucan recognition in neutrophils. In 
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porcine macrophages, however, both dectin-1 and CR3 are involved in the β-glucan-mediated 
responses. In addition, we assume that other receptors, such as scavenger receptors or 
lactosylceramide, are involved in these responses towards β-glucans by macrophages as well. 
Interestingly, we have strong indications that CD11R3 is the α subunit of CR3 in pigs, since this 
receptor is involved in the β-glucan mediated immune responses in porcine neutrophils. In contrast, 
CD11R1, which cross-reacts with the human CD11b mAbs, is not involved in these responses. 
Furthermore, we have demonstrated that CR3 signalling through focal adhesion kinase (FAK) was 
indispensable for β-glucan-mediated ROS production and cytokine production in both neutrophils 
and macrophages, while the Syk-dependent pathway was only partly involved in these responses. 
We conclude that CR3 plays a cardinal role in β-glucan signalling in porcine neutrophils, while 
macrophages use a more diverse receptor array to detect and respond towards β-glucans. 
Nonetheless, FAK acts as a master switch that regulates β-glucan-mediated responses in neutrophils 
as well as macrophages. These results in pigs correlate with the receptor usage described in human 
innate immune cells, while they differ with the rodent system. Therefore, this study supports the use 
of pigs as a valuable model to evaluate the effects of β-glucans on innate immunity. 
Chapter 4 and 5 focus on the design of an oral subunit vaccine platform. β-glucan microparticles 
(GPs) are promising antigen delivery systems for oral vaccination, because of their dual character as 
both antigen vehicle and immunostimulants. We first investigated the loading capacity of these 
particles by incorporating the clinically relevant antigen FedF inside GPs. The incorporation of FedF 
inside the particles was highly efficient and occurred without antigen degradation. Furthermore, GPs 
still retain immune-stimulatory properties upon antigen loading, although ROS responses were 
diminished for reasons yet unknown. In addition, the dual character of these particles was confirmed 
in a T cell proliferation assay. Indeed, FedF-loaded particles induced a significant higher FedF-specific 
T cell proliferation than soluble FedF. These results encourage the use of β-glucan microparticles as 
antigen delivery system for oral vaccination. However, multiple barriers need to be overcome to 
design oral vaccines, including the poor uptake by the epithelial barrier. Selective targeting to 
intestinal epithelial cells seems a promising strategy to surmount this obstacle. Chapter 5 evaluated 
the capacity of aminopeptidase N (APN)-targeted β-glucan microparticles (GPs) as oral antigen 
delivery system. APN is expressed on the apical surface of intestinal epithelial cells and is strongly 
conserved in multiple species. Antibodies against APN were efficiently conjugated to GPs in a correct 
orientation via the biolinker protein G. The resultant microparticles were analysed for their antigen 
load, adjuvanticity and interaction with enterocytes and dendritic cells (DCs). Functionalisation of 
GPs with antibodies neither impedes antigen load nor adjuvanticity. In addition, targeting to APN 
increased the uptake of microparticles by enterocytes and DCs, leading to an enhanced maturation 
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of the latter as evidenced by an upregulation of maturation markers and a strong pro-inflammatory 
cytokine response (TNFα, IL-1β, IL-12p40). Finally, oral administration of APN-targeted antigen-
loaded particles to piglets elicited higher serum antigen-specific antibody responses as compared to 
control particles. Taken together, these data support the use of APN-targeted GPs for oral delivery of 
antigens. 
The final chapter (chapter 6) presents the general discussion and future perspectives and 
applications of the findings. 
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Speendiarree is één van de belangrijkste oorzaken van zware economische verliezen voor 
varkenshouderij als gevolg van groeivertraging, een verhoogd gebruik van geneesmiddelen en 
sterfte. Escherichia coli is de belangrijkste bacterie die deze ziekte veroorzaakt bij biggen. Om dit 
probleem te bestrijden werden antibiotica gebruikt om de gezondheid en prestatie van het dier te 
behouden. Overvloedig en langdurig gebruik van antibiotica werken echter het ontstaan van 
antibiotica resistente bacteriën in de hand. Recent werd aangetoond dat ongeveer 75% van de jonge 
biggen in Vlaanderen resistente E. coli bacteriën dragen.419 Deze resistente bacteriën kunnen 
overgedragen worden naar de mens via besmette groenten, wat een risico inhoudt voor de humane 
gezondheid. Er is dus nood aan alternatieve strategieën om gespeende biggen te beschermen tegen 
E. coli infecties. 
Immunomodulatoren, zoals β-glucanen, kunnen dienen als alternatieven voor antibiotica en zijn 
gericht op het versterken van het immuunsysteem. De immunostimulerende werking van deze β-
glucanen is echter nog steeds omstreden. In muizen wordt dectin-1 beschreven als de voornaamste 
β-glucaan receptor, terwijl bij de mens complement receptor 3 (CR3) belangrijker is in de β-glucaan 
gemedieerde responsen. Bij varkens is er nog geen data beschikbaar over β-glucaan receptor binding 
and hun signalisatie wegen. In deze thesis werd er onderzocht welke receptor betrokken is bij de β-
glucaan gemedieerde immuunresponsen van aangeboren immuuncellen bij varkens. 
Naast het gebruik van immunomodulatoren kan de toediening van een oraal vaccin biggen 
beschermen tegen speendiarree. De hedendaagse orale vaccins, gebaseerd op verzwakte of dode 
pathogenen, vertonen echter veiligheidsrisico’s of induceren inefficiënte immuunresponsen. 
Subéénheid vaccines, daarentegen, zijn een veiliger alternatief, maar de werkzaamheid van deze 
vaccins is echter zwakker en eisen vaak adjuvantia. De immunogeniciteit van deze vaccins kan 
verhoogd worden door deze in te kapselen in partikels. Het doel van dit deel van de thesis is het 
ontwikkelen van een subéénheid oraal vaccin platform gebaseerd op partikelvormige β-glucanen. 
Hoofdstuk 1 geeft een korte inleiding over de moleculaire structuur van de verschillende β-glucanen, 
hun receptoren en signalisatie wegen. Daarnaast wordt de huidige kennis over de biologische 
effecten van oraal toegediende β-glucanen beschreven. 
Een korte inleiding over het intestinaal immuunsysteem wordt gegeven in hoofdstuk 2. We geven 
een overzicht over de hedendaagse geregistreerde humane en varkens orale vaccins en de 
verschillende orale vaccin strategieën, waarbij de nadruk gelegd werd op het gebruik van β-glucaan 
partikels en verschillende strategieën om vaccins doelgericht af te leveren. 
Hoofdstuk 3 geeft het experimenteel werk weer over de belangrijkste β-glucaan receptor en 
signalisatie wegen in varkens immuuncellen. In dit onderzoek hebben we de celtype afhankelijke 
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herkenning van β-glucanen in varkens neutrofielen en macrofagen gedeeltelijk ontrafeld. Onze 
resultaten tonen duidelijk een belangrijke rol in β-glucaan herkenning voor complement receptor 3 
(CR3) aan, aangezien het blokkeren van deze receptor de fagocytose van β-glucanen sterk 
vermindert alsook de β-glucaan geïnduceerde zuurstofradicaal productie door varkens neutrofielen. 
Dectine-1 daarentegen speelt geen rol in de β-glucaan herkenning in neutrofielen. In varkens 
macrofagen zijn zowel dectine-1 als CR3 betrokken in de β-glucaan gemedieerde responsen. 
Bovendien vermoeden we dat andere receptoren, zoals scavenger receptoren of lactosylceramide, 
ook betrokken zijn in deze reacties tegenover β-glucanen in macrofagen. Bij varkens is het nog steeds 
omstreden welke receptor de α subunit van CR3 vormt. Aangezien CD11R3 betrokken is in de β-
glucaan gemedieerde immuunresponsen in varkens neutrofielen, hebben we sterke vermoedens dat 
CD11R3 de α subunit van CR3 vormt. CD11R1 is daarentegen niet betrokken in deze responsen. 
Daarenboven hebben we aangetoond dat CR3-signalisatie via ‘focal adhesion kinase’ (FAK) 
onontbeerlijk is voor de β-glucaan gemedieerde zuurstofradicaal productie en cytokine productie in 
neutrofielen en macrofagen, terwijl de Syk-afhankelijke pathway gedeeltelijk betrokken was in deze 
responsen. We kunnen dus besluiten dat CR3 een essentiële rol speelt in de β-glucaan signalering in 
varkens neutrofielen, terwijl macrofagen meerdere receptoren gebruiken om β-glucanen te 
detecteren. Desalniettemin gedraagt FAK zich als de belangrijkste signaalmolecule om β-glucaan 
gemedieerde responsen in neutrofielen en macrofagen te reguleren. Deze resultaten met betrekking 
tot de belangrijkste β-glucaanreceptor bij varkens correleren met wat beschreven is in humane 
studies, maar verschillen met de resultaten bij knaagdieren. Daarom is het gebruik van varkens een 
waardevol model om de effecten van β-glucanen op het aangeboren immuunsysteem te evalueren. 
Hoofdstuk 4 en 5 leggen de nadruk op het ontwerp van een oraal subéénheid vaccin platform. Het 
gebruik van β-glucaan micropartikels (GPs) als antigeen afleversysteem is veelbelovend, aangezien 
deze partikels een duaal karakter bezitten als antigeen vervoersmiddel en immunostimulants. Eerst 
hebben we de ladingscapaciteit van deze partikels onderzocht door het klinisch relevante antigeen 
FedF te incorporeren in de partikels. Het laden van FedF in de partikels was zeer efficiënt en 
gebeurde zonder antigeen degradatie. Daarenboven behouden de gistpartikels hun 
immunostimulerende eigenschappen na antigeen lading, alhoewel de zuurstofradicaal responsen 
verminderd waren door nog onbekende redenen. Het duale karakter van deze partikels werd 
bevestigd in een T cel proliferatie experiment, waarbij we aangetoond hebben dat FedF-geladen 
partikels een significant hogere FedF-specifieke T cel proliferatie opwekten dan oplosbare FedF. Deze 
gunstige resultaten moedigen het gebruik van β-glucaan partikels als antigeen afleversysteem voor 
orale vaccinatie aan. Bij de ontwikkeling van een oraal vaccin moeten er echter enkele barrières 
overwonnen worden, zoals de zwakke opname van antigenen ter hoogte van de epitheliale barrière. 
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Het selectief richten van de partikels naar intestinale epitheelcellen is een veelbelovende strategie 
om dit obstakel te overwinnen. Hoofdstuk 5 evalueerde de capaciteit van aminopeptidase N (APN)-
gerichte β-glucaan micropartikels als oraal antigeen afleversysteem. APN wordt geëxpresseerd op de 
apicale zijde van intestinale epitheelcellen en is sterk geconserveerd bij verschillende species. 
Antilichamen tegen APN werden efficiënt en in een correcte oriëntatie geconjugeerd aan GPs via de 
biolinker proteïne G. De resulterende micropartikels werden geanalyseerd voor hun antigeen lading, 
adjuvanticiteit en interactie met enterocyten en dendritische cellen (DCs). Functionalisatie van GPs 
met antilichamen beïnvloedde de antigeen lading of adjuvanticiteit van de partikels niet. Het richten 
van de partikels naar APN leidde bovendien tot een verhoogde opname van de micropartikels door 
enteroyten en DCs. Opname van de partikels door DCs resulteerde in een verhoogde opregulatie van 
de maturatie merkers en een sterke pro-inflammatoire cytokine respons (TNFα, IL-1β, IL-12p40). Ten 
slotte wekte orale toediening van APN-gerichte antigeen-geladen partikels aan biggen hogere serum 
antigeen-specifieke antilichaam responsen op in vergelijking met controle partikels. Deze data 
ondersteunen dus het gebruik van APN-gerichte GPs voor de orale aflevering van antigenen. 
Het laatste hoofdstuk (hoofdstuk 6) stelt de algemene discussie voor en de potentiële 
toekomstperspectieven en toepassingen van onze bevindingen. 
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Daarnaast wil ik ook de laboranten Griet, Simon, Hanne, Charlotte en Cliff bedanken. Dank jullie wel 
voor alle praktische hulp bij de experimenten. De aangename werksfeer werd grotendeels door jullie 
gebracht. Griet, bedankt voor alle hulp met de β-glucanen en het meten van de ROS-productie. 
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koppigheid en al was het soms met wat gemor , heb je nooit geweigerd om mij te helpen, 
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alle frustraties van ons af te kloppen. Ook jij succes met het einde van je doctoraat! 
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Ten slotte wil ik mijn familie bedanken. Papa, enorm bedankt om me de kans te geven om 
universitaire studies aan te vatten, zonder uw steun zou ik hier nooit geraakt zijn. Martine, bedankt 
voor alle steun en om er altijd te zijn. Last but not least, wil ik mijn zusjes bedanken! Els, enorm 
bedankt voor al uw goede raad. Zonder uw tips bij het solliciteren had ik waarschijnlijk nooit aan dit 
doctoraat kunnen beginnen. Ook de laatste maanden van mijn doctoraat stond je door 
omstandigheden dicht bij mij en heb je mij steeds trachten te kalmeren als ik enorm gestresseerd 
thuis rondliep. En als laatste wil ik Ann bedanken, die steeds geluisterd heeft naar alles wat er misliep 
tijdens mijn doctoraat, mij altijd gesteund heeft, mij de dingen heeft kunnen doen relativeren en er 
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